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1 Introduction
Understanding the behavior of genes as a response to external influences, such as radiation or
chemicals, on a fundamental level is one of the great challenges of modern biology. In specific,
the investigation of chemically-induced toxicity is of major importance since it is crucial for
the identification of biomarkers and the development of drugs. One approach to accomplish
this objective utilizes toxicogenomics which is based upon the combination of toxicology and
the analysis of genome-wide gene expression data. This research field uses the technology of
microarrays which allows the simultaneous measurement of the expression of tens of thousands
of genes. Nowadays, toxicogenomics has evolved to an established practice in the still emerging
field of chemical hazard identification. It comprises the analysis of large-scale gene expression
data in order to identify and characterize different modes of action associated with certain
expression changes. Such deregulations, which occur as a response to chemical exposure,
provide initial evidence of the involved toxic mechanisms. Based upon it, the key aspect is to
detect those genes which improve the understanding of molecular mechanisms on a protein level.
It is this particular understanding of the linkage between the entirety of all genes, transcriptome,
proteome and eventually metabolome which qualifies for the assessment of biological processes
within the human organism. Hence, especially the pharmaceutical sector applies the methods
used within toxicogenomics for the research on drugs and, here, particularly the correct dosage
is of vital importance.
Often, concentrations that cause gene alterations are associated with adverse effects. According
to the saying ”The dose makes the poison” (Latin: ”sola dosis facit venenum”) which goes
back to Paracelsus (founder of toxicology), who said ”All things are poison and nothing is
without poison; only the dose makes a thing not a poison”, the dosis is decisive for the effect of a
compound. The principle is based on the finding that all substances can cause toxic effects if
consumed in high (excessive) quantities. For instance, a high salt consumption can lead to renal
insufficiency. Still, sodium chloride is not considered as a toxic substance since it is commonly
consumed in moderate amounts. In general, most chemicals, especially in forms of drugs, cause
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only toxic reactions when overdosed extremely. To ensure the desired effect, the right dosage is
essential. Because of this, dose finding and dose selection are ubiquitous topics in many fields,
such as pharmacology, pharmacokinetics, toxicology or clinical research. Methods for modeling
dose-response relationships are used to measure the effectiveness and toxicity of a compound.
Often, dose-response studies are conducted to determine the lowest effective concentration at
which first signs of cytotoxicity become detectable. In this context, Jiang (2013) has proposed
to estimate the Absolute Lowest Effective Concentration (ALEC), which is the concentration
at which a fixed and pre-specified effect level is reached exactly (point estimate), by fitting a
log-logistic model to the data.
In the framework of this thesis, the model-based approach is applied to gene expression data
to detect concentrations with critical changes in gene expression. Typically, only measured
concentrations are considered as potential candidates for alert concentrations. Based on the
assumption that the response dependency of the dose can be described by a sigmoidal function, a
four-parameter log-logistic (4pLL) model is fitted to the data. Two alert concentrations referring
to critical compound concentrations are estimated from the fitted average trend and compared
with those of the classical naïve approach where for each measured concentration separately it is
tested if the critical effect level is exceeded. The results are evaluated in a simulation study and
in a real dose-response study.
Modeling gene expression data is only one topic of the thesis. Besides this, the work deals with
two further issues that often arise in the context of gene expression analysis: The identification
and characterization of genes associated with certain modes of action and the detection of
biomarker candidates in the in vitro system for the prediction of toxicity in vivo. To better
understand the key principles of transcriptome changes, a genome-wide gene expression analysis
is performed. Special attention is drawn to statistical challenges arising from working with large
data sets. Besides the curse of dimensionality (many more variables than observations) and the
small number of replicates, the statistical analysis is faced with additional complexity including
batch effects and implausible concentration progressions. To address this issue in a general
manner, a pipeline involving several curation steps and a systematic strategy for the identification
of consensus genes is proposed.
Thus, the main objective of this thesis is to gain a better understanding to whether a model-
based approach yields more accurate results in terms of predicting critical concentrations than
the classical one which is used in this work for the analysis of large-scale toxicogenomics data
sets.
3The structure of the thesis is as follows: In Chapter 2 the biological basics relevant to the
understanding of the gene reactions investigated later in this work are presented. In the context
of gene expression analysis, the Affymetrix GeneChip Technology and the RMA+ algorithm for
pre-processing Affymetrix microarray data are described. In addition, a thorough description of
the used data is given.
In Chapter 3 the statistical methods applied for data analysis within this work are described.
This includes methods of descriptive analysis for large-scale gene expression data sets as well as
methods for analyzing concentration-dependent expression progressions in the context of dose-
finding studies. In the context of differential expression analysis the Limma t-test is outlined.
Within a model-based approach for detecting critical expression changes, the (absolute) lowest
effective concentration (A)LEC, derived from a dose-response model, is introduced. Methods for
constructing confidence intervals for the (A)LEC and the effect level are presented. Moreover, the
t4pLL-test for the detection of critical expression changes in dose-response analysis is introduced.
All methods are based on the application of the four-parameter log-logistic (4pLL) model.
The data is analyzed within the Chapters 4-6 using the aforementioned methods. In Chapter 4
and Chapter 5 the data of human and rat hepatocytes (in vitro) and rat liver cells (in vivo) is
evaluated. Chapter 6 deals with simulated and real dose-response data. The thesis finishes with a
comprehensive conclusion and an outlook on further research in Chapter 7.
2 Biological background
This chapter serves as an introduction to microarray analysis, beginning with the fundamentals
of molecular genetics and ending with the generation of gene expression data. Section 2.1
gives a brief insight into the biological basics. Herein, the central dogma of molecular genetics
according to which the genetic information is transferred from DNA to RNA to protein, is
explained. High density oligonucleotide array technologies allow the simultaneous measurement
of the expression of tens of thousands of genes. The Affymetrix GeneChip Technology is one of
the most commonly applied methods for generating gene expression data. Section 2.2 describes
the Affymetrix GeneChip array design and elucidates the principles of the photolithographic
process for synthesizing DNA on microarray. The Affymetrix microarray data has to be pre-
processed before it can be used for statistical analysis. There exist a number of pre-processing
algoritms among which RMA is the most widely used pre-processing method for Affymetrix
microarray data. Section 2.3 introduces an extended version of the RMA algorithm, the RMA+
algorithm, which is used for the normalization of the Affymetrix gene expression arrays analyzed
within this work. The data sets used for analysis are introduced in Section 2.4.
2.1 Central dogma of molecular genetics
The deoxyribonucleic acid (DNA) is a nucleic acid that contains the genetic information which
is essential for the development of all organisms. The DNA contains the genetic instructions
that are necessary for the production of ribonucleic acid molecules whose essential function
are the implementation of the information into proteins. The segments of the DNA that carry
this information are called genes. The other sequences of the DNA, the non-coding segments,
are either responsible for the regulation of the functional processes or just sequences with so
far unknown functions. Within cells, DNA is organized in long structures called chromosomes.
A chromosome is a single piece of coiled DNA containing many genes, regulatory elements
and other nucleotide sequences. Humans have a diploid set of homologous chromosomes
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consisting of 22 autosomes and one set of haploid chromosomes consisting of two gonosomes,
one chromosome from each parent. The combination of all gene variants, i.e. the whole set of
genes, is known as genotype.
The DNA consists of two strands which are spirally wrapped around one another forming
the structure of a double helix. The so-called nucleotides form the molecular backbone of a
DNA strand. They consist of a sugar molecule (desoxyribose), a phosphate group and one
of four organic bases: Guanine (G), adenine (A), thymine (T) and cytidine (C). The two
strands are connected via hydrogen bonds which are formed during the binding process of
two complementary bases, A↔ T and C↔ G. The ribonucleic acid (RNA) differs from the
deoxyribonucleic acid in its sugar molecule (ribose). The base thymine is replaced by uracil as
complementary base to adenine. With the help of the RNA the genetic information is decoded
and translated into proteins. The process in which the genotype is realized into its phenotype is
known as gene expression. In Figure 2.1 the DNA and RNA strands are shown.
Figure 2.1: Illustration of the DNA and RNA structure. The deoxyribonucleic acid (DNA, right
panel) consists of two long strands which are coiled around one another in a double helix.
The molecular backbone of each single strand is composed of deoxyribonucleotides. The
nucleotides are differentiated by four bases: Adenine (A)↔ thymine (T) and cytosine
(C)↔ guanine (G). The ribonucleic acid (RNA, left panel) is, in contrast, to the DNA
single-stranded, contains ribose instead of deoxyribose and replaces the base thymine by
uracil (BK101, 2017).
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The array of a base sequence defines the sequence of an amino acid which in turn defines the
structure of a protein. Proteins are chains that are linked together by amino acids which differ in
their length and array. They are synthesized according to their base order in the DNA. One of 20
possible amino acids is encoded by a base triplet (codon). The assignment of the base triplet to
its respective amino acid is specified by the genetic code, see Figure 2.2. Some amino acids are
encoded by more than one codon.
The protein biosynthese is one of the most important life processes in cells of living organisms.
It consists of two subprocesses, the transcription and translation process (see Figure 2.3).
During the transcription process the DNA sequence is transcribed into complementary mRNA.
In contrast to the double-stranded DNA, the RNA is single-stranded. As the DNA consists of
coding and non-coding sequences, the exons and introns, the transcribed non-coding sequences
are excised from the pre-mRNA (preliminary messengerRNA) while the exons are retained. This
process, known as splicing, plays a decisive role in regulating gene expression. However, due the
accidental deletion of single exons during the splicing process, mRNA molecules of the same
pre-mRNA may differ from one another. The variations resulting from the different composition
of the exons in the mRNA might alter the protein structure. Thus, the splicing permits a wide
variation of possible nucleotide combinations in the mRNA. These slightly modified proteins are
called isoformes. Although isoformes are encoded by the same gene, they might execute different
functions. The structural differences can either prevent the gene from functioning properly or
just result in silent mutations, that means meaningless protein variants. Splicing is the reason
why the human genome consists of much more proteins than genes. Moreover, allelic differences
in mRNA splicing are often associated with genetic disease susceptibility.
Once the mRNA chain is generated, the synthesis of proteins can start. This process, known
as translation, is the key process of the protein biosynthesis. The base sequence of the mRNA is
translated sequentially into the corresponding amino acid sequence. Amino acids are bonded
together by peptide bonds. Two amino acids join together to form dipeptides, more than ten
amino acids form polypeptides, and more than 100 amino acids build proteins.
2.2 Affymetrix GeneChip Technology
Microarray technologies belong to the group of high throughput technologies which are used to
generate expression data of tens of thousands of genes simultaneously. In the early 1990s, the US
company Affymetrix developed the world’s first commercial high-density chip for the analysis of
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Figure 2.2: The genetic code: The wheel is read from the inside out with each triplet coding for one
particular amino acid. The sequence AUG encodes the start codon and the sequences
UAA, UAG, and UGA encode the stop codons (Lobanov et al., 2010).
gene expression data, the so-called GeneChip. Since then, microarrays are increasingly applied
in the field of biomedical research. In practice, two kinds of microarrays are used, one based
on cDNA (complementary DNA) and one based on oligonucleotides. They mainly differ in the
way how the base sequences are synthesized on the chip. Affymetrix makes use of the latter
method which synthesizes the single-stranded oligonucleotides on the chip base by base by
a photolythographic procedure. Technologies using cDNA chips, in contrast, synthesize the
complementary DNA sequence as a whole. The latter type of technologies are not part of this
work and are therefore not discussed any further. Within this work, only Affymetrix microarray
data is used for analysis. Thus, only their GeneChip technology is described in detail.
DNA microarrays allow to capture gene specific sequences in a cell. Conclusions on the
phenotype can be drawn by means of sequential composition. Tens of thousands of such RNA
transcripts can be captured and measured simultaneously using the Affymetrix’s GeneChip.
Depending on the analyzed organism, different GeneChips are used for transcription. The
Human Genome U133 Plus 2.0 GeneChip, for example, is used for transcribing the human
genome. The chip covers over 50 000 transcripts coding for more than 20 000 genes. Data from
rat cells can be analyzed using the Rat Expression Set 230 Array GeneChip or its extended
version 230 2.0, each comprising more than 15 000 and 30 000 transcripts and variants from
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Figure 2.3: From DNA to protein: The DNA sequence is transcribed into the corresponding RNA
sequence by transcribing the base sequence of the gene into its complementary RNA
nucleotide sequence. A base triplett encodes for a particular amino acid and the chain of
amino acids defines the structure of a protein (oerpub/epubjs-demo book, 2017).
over 10 000 and 13 000 genes, respectively. All those chips consist of hundreds of thousands
of microscopically small probe cells, each containing millions of copies of a base sequence
artificially synthesized of 25 nucleotides. This oligonucleotide sequence is complementary to the
base sequence of the target mRNA. 11-20 of such oligonucleotide probes represent one specific
transcript. To detect non-specific hybridizations, and to ensure high accuracy and reproducibility
of the data, Affymetrix makes use of a paired design to match and mismatch transcripts (see
Figure 2.4). The first probe is referred to as a perfect match (PM) probe and perfectly matches the
target sequence, i.e. it is completely complementary to the target mRNA. Each PM is paired with
a mismatch probe (MM) that is created by replacing the middle (13th) base by its complement.
Thus, at this position it should come to no or a substantially weaker binding. The oligonucleotide
probes referring to one probe set differ from one another in terms of their base sequences, such
that 11-20 different exon regions of a gene are covered. To avoid spatial effects, the probe pairs
of a particular probe set are spread all over the chip.
First of all mRNA is extracted from the tissue of interest. Then it is reverse transcribed into
complementary DNA (cDNA). This newly created cDNA serves as template for the amplification
of the mRNA. The resulting cRNA molecules are fragmented, labeled with a fluorescent dye and
are fixed onto the array such that they can hybridize with their complementary probes on the array.
The more the probes on the array coincide with the cRNA molecule, the higher the required
temperature to disconnect the match. With a temperature increase non-specific hybridizations
can be reduced. It is not uncommon that cRNA fragments hybridize with probes they are not
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Figure 2.4: GeneChip expression array design. Structure of a probe set with 16 probe pairs. One
probe pair consists of a perfect-match (PM) and a mismatch (MM) of which each consists
of 21 oligonucleotides. Both sequences are identical except for the 13th base which
is replaced by the corresponding complementary base. The PM probe is completely
complementary to the base sequence of the target mRNA, whereas the MM probes serve
as control. A probe set is represented by multiple probe pairs (PBworks, 2016).
intended to hybridize. The MM probes serves as controls for measuring background signals. In
the case that only sub-sequences of the cRNA are complementary to the probes, less hydrogen
bonds are formed during the binding process such that this kind of bindings can be released
easier than the intended ones. As soon as the fluorescently stained cRNAs have interacted with
their complementary oligonucleotides a light signal is provided. The unbound cRNA fragments
are washed out and the hybridization pattern can be read off from the light distribution. A high
definition laser scanner scans the intensity of the fluorescent signals which is used as a measure
for the quantity of hybridized target RNA. The intensity values are combined into one raw
expression value per probe set and stored as CEL files (see Figure 2.5 for procedure overview).
2.3 Data Preprocessing
As previously described, multiple probe pairs quantify one probe set which represents a gene.
A gene in turn can be encoded by multiple probe sets. The step, in which the scanned data is
reduced from probe level to gene level, is referred to as pre-processing. There exist a number of
pre-processing algorithms which all summarize single probe set intensities to one representative
expression value. Robust Multiarray Analysis (RMA) proposed by Irizarry et al. (2003a) is
one of the most commonly used pre-processing algorithms for Affymetrix microarray data. In
a three-stage process the data is background-corrected, normalized and finally summerized to
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Figure 2.5: Affymetrix microarrays: Photolithographic synthesis of oligonucleotides on microarrays.
A chip consists of hundreds of thousands of microscopically small probe cells. Each
cell contains millions of copies of oligonucleotide sequences which serve as template
for the hybridization of the probes with their fluorescently labeled mRNA targets. The
fluorescent signals are read by a high definition laser scanner and are combined into one
raw expression value per probe set (Affymetrix, 2017).
one value. However, the simultaneous analysis of data requires the simultaneous pre-processing
of the respective microarrays. This interdependency of multiple microarrays has one obvious
disadvantage: The inclusion of new microarrays implicate the re-pre-processing of the original
data set which has to be pre-processed together with the new microarrays, and this process
changes again the gene expressions of the original data. Thus, separate pre-processed data
sets are not comparable. To ensure the comparability of results across different arrays wihtout
changing the expression values of previously pre-processed microarrays Harbron et al. (2007)
propose an extended version of the RMA algorithm, which they refer to as RMA+ algorithm.
The idea is based on the calculation of reference parameters estimated from a reference set of
microarrays which are stored and used for the normalization process of future microarrays. In
this manner, the key properties of the RMA algorithm are maintained and new microarrays can
be normalized in addition to the already pre-processed ones without re-estimating the reference
parameters. This extension of the RMA algorithm allows the joint analysis of arrays analyzed in
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different batches. The RMA+ algorithm is being implemented in the package RefPlus for the
open source statistical software R (Chang et al., 2016).
The RMA+ algorithm makes use of the Extrapolation Strategy which splits the data into two
sets of microarrays: One set is used as the reference set and the other one as the future set.
The reference parameters are estimated from the reference set and are applied to the future set.
They are obtained from fitting an RMA model to the reference set. This is accomplished by
the aforementioned three-step procedure. Background correction is performed on each array
individually and is therefore not discussed here. The reader is referred to Irizarry et al. (2003b)
for a detailed explanation of the background correction procedure. After the intensity values have
been background-corrected, a normalization step is required to achieve comparability across
all arrays. As the slightest differences in the test execution, be it in the target preparation or in
the hybridization procedure, might lead to a wide dispersion of the intensity values between
arrays, RMA uses quantile normalization to normalize the probe intensities to a common set of
quantiles, such that the intensities of all arrays have the same distribution. In the last step, the
background-corrected and normalized probe set intensities are summarized to one expression
value.
Let i denote the microarray and j the probe of a probe set, then the log2 background-corrected
and normalized intensity Nij of probe j on array i is given by:
Nij = Pj + Ii + ij, (2.1)
where P is the effect of the jth probe, I is the expression of the probe set on array i and ij
indicates the error term. The expression value is estimated for each probe set separately by using
Tukey’s median polish which is an algorithm for calculating a robust average over all probes and
arrays.
The probe set intensities of the reference set are stored together with their estimated quantiles
and probe effects. The future microarrays undergo the same three-step procedure as the reference
set: Background-correction, quantile normalization and aggregation to one expression value. But
this time the microarrays are normalized to the reference quantiles. Assuming that the probe
effects of the future set equal those of the reference set, the probe set intensity I˜f of a future
array f is estimated from the model in (2.1) and given by
I˜f = medianj∈Probes(Nfj − Pj),
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where Nfj indicates the background-corrected and normalized intensity of probe j on array f
and Pj represents the effect of the jth reference probe.
Figure 2.6 compares the RMA algorithm with its extended version, the RMA+ algorithm.
Figure 2.6: Illustration of the RMA and RMA+ algorithm. Both algorithms uses background cor-
rection, quantile normalization and a linear model fit to the normalized data to obtain
an intensity value for each probe set. In contrast to the RMA algorithm which uses
the information of the complete microarray set the RMA+ algorithm makes use of the
extrapolation strategy which splits the data into two sets of microarrays, the reference-
and the future set. The reference set is used for the estimation of the reference parameters
which are stored and used for the future set. The reference parameter are obtained from
fitting a RMA model to the reference set. (Slightly modified version of a figure provided
by Harbron et al. (2007)).
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2.4 Data sets
Within the scope of this work, several data sets were used for analysis. All analyses were
performed on the basis of Affymetrix gene expression data. For the normalization of the
arrays, the Robust Multi-Array Average (RMA+) algorithm was applied. As reference, different
normalization parameters were used which depended on the used model organism. The respective
parameters were obtained from fitting a RMA model to previously analyzed data of the same
GeneChip. The estimated parameters were stored and applied to the currently analyzed arrays.
After normalization, the difference in gene expression between treated- and corresponding
untreated samples was calculated for each test condition separately. The subtraction procedure
was based on averaged replicate values. As gene expression data is measured on a log2-scale, the
difference between logarithmized average values corresponds to the logarithmized fold change
FCi of gene i:
log (FCi) = log
(
x¯Expi
x¯Ctrli
)
= log
√√√√ n∏
j=1
xExpij
− log
√√√√ n∏
j=1
xCtrlij

= log
[(
xExpi1 · . . . · xExpin
) 1
n
]
− log
[(
xCtrli1 · . . . · xCtrlin
) 1
n
]
=
1
n
[
n∑
j=1
log
(
xExpij
)]
− 1
n
[
n∑
j=1
log
(
xCtrlij
)]
,
where xExpij denotes the gene expression for gene i, i = 1, . . . , nPS, and array j, j = 1, . . . , n,
and xCtrlij the corresponding control value. The terms x¯
Exp
i and x¯
Ctrl
i indicate the geometric mean
of the exposed samples and the controls, respectively. The fold change is used as a measure for
the exposure-related effect of a compound. All analyses base on the fold change values of a gene.
However, the term gene expression is used in that context. Table 2.1 provides an overview of the
data sets used for analysis.
2.4.1 TG-GATEs database
TGP (The Toxicogenomics Project) is a project funded by both the Japanese government and
the private sector. The National Institute of Biomedical Innovation (NIBIO, 2017), the National
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Institute of Health Sciences (NIHS, 2017) as well as the pharmaceutical industry contributed to its
establishment. Between 2002 and 2006, gene array data was generated within the project testing
≈ 150 compounds, including hepatotoxic and non-hepatotoxic ones, in primary human and rat
hepatocytes as well as rat liver and kidney cells in vivo. That data was used to generate a large-
scale toxicogenomic database. The TG-GATEs (ToxicoGenomics Project-Genomics Assisted
Toxicity Evaluation System) database was then finally created by integrating further options into
the existing database system. The extended database offered possibilities of performing targeted
analyses for the prediction of toxicity of the test compounds. TGP2 (The Toxicogenomics
Informatics Project 2) was a follow-up project of TGP that was initiated in 2007 by the same
founder. In the period from 2007 to 2011 30 safety biomarkes were detected within the framework
of this project by using the TG-GATEs database. The new data gained by TGP2 was included
into TG-GATEs. Open TG-GATEs is a publicly available database for the use of non-profit
purposes. The raw microarray data (CEL files) for all analyzed compounds and conditions can be
downloaded from the Open TG-GATEs website (http://toxico.nibiohn.go.jp/english/index.html).
The portal has been developed to give scientists the opportunity to use the research results of
TGP and TGP2. The user is free to use the data for both scientific and private purposes, including
the publication of results and the disclosure of the information to third parties. The database
compiles Affymetrix HG U133 Plus 2.0 gene expression microarray data on 170 compounds.
The search for data is enabled via compound name or pathological findings by organ. Access to
phenotype data is provided as well. The documents contain information about the experimental
setup, the histopathological findings and the research results of the TGP project which are
supplied as PDF file and can be viewed directly or downloaded from the homepage. Currently,
the documents are only available in Japanese (NIBIOHN, 2017).
Table 2.1: Overview of the data sets used in the analyses.
Database Data Test system
Primary human hepatocytes in vitro
Primary rat hepatocytes in vitroTG-GATEs
Rat liver hepatocytes in vivo
Primary rat hepatocytes in vitro
NRW
Rat liver hepatocytes in vivo
UKN1 Human embryonic stem cells in vitro
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Primary human hepatocytes
The primary human hepatocytes were treated with different test compounds using three con-
centrations (Low, Middle, High) and three incubation periods (2h, 8h, and 24h). For cytotoxic
compounds the highest tested concentration was chosen such that it represented approximately
the EC10 (the concentration that produces 10% reduction of the maximal effect). Each concen-
tration was assessed using two replicate experiments. Table 2.2 provides an overview of the
experimental design. A subset of compounds was tested under all conditions (n=52), while
most of the compounds were tested only under some of the conditions. The compounds were
tested either for only one or two exposure periods, or with only two concentrations, as shown in
Table B.1 in the Appendix. Experiments without replication, as well as experiments including
cytokines and LPS (lipopolysaccharide), were excluded from the analyses. Cytokines are proteins
involved in the regulation of proliferation and differentiation processes in cells. Seven of the
tested compounds were cytokines and due to their molecular functionality excluded. Table 2.2
shows the number of compounds tested under the indicated condition with and without cytokines
in brackets.
Table 2.2: Matrix of the compounds tested in primary human hepatocytes. The table provides the
numbers of compounds tested under the indicated condition, for each combination of
concentration and exposure period, before and after (in brackets) excluding cytokines and
LPS (lipopolysaccharide) from the analyses.
2h 8h 24h Overlap
Low 53 (48) 82 (75) 81 (75) 52 (48)
Middle 53 (48) 153 (146) 157 (151) 52 (48)
High 53 (48) 153 (146) 153 (148) 52 (48)
Overlap 53 (48) 82 (75) 77 (72) 52 (48)
Primary rat hepatocytes
The cultured rat hepatocytes were tested in duplicates with the indicated compounds using a low,
middle and high concentration for the incubation periods 2h, 8h, 24h. For a detailed overview of
the data the reader is referred to Table B.2 in the Appendix. The highest tested concentration
was again chosen close to cytotoxic levels. Table 2.3 shows the number of compounds tested at
the indicated concentration and time sets. The same exclusion criteria as those for the human
hepatocytes were applied to the data from the rat model, for both the in vitro and in vivo test
system.
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Table 2.3: Matrix of the compounds tested in primary rat hepatocytes. The table provides the
numbers of compounds tested under the indicated conditions for each combination of
concentration and exposure period, before and after (in brackets) excluding cytokines and
LPS (lipopolysaccharide) from the analyses.
2h 8h 24h Overlap
Low 140 (138) 140 (138) 145 (143) 140 (138)
Middle 140 (138) 140 (138) 140 (138) 140 (138)
High 138 (137) 139 (138) 138 (137) 138 (137)
Overlap 138 (138) 139 (137) 138 (138) 52 (48)
Rat liver hepatocytes
Rat liver samples were treated with the compounds listed in Tables B.3 and B.4 which are
given in the Appendix. Each compound was tested at three concentrations (Low, Middle, High)
and sacrificed at different time periods after exposure. This time eight incubation times (3h,
6h, 9h, 24h, 4 days, 8 days, 15 days, 29 days) were investigated, using three replicates in
each experiment. Table 2.4 summarizes the compounds with available data with respect to the
indicated test condition.
Table 2.4: Matrix of the compounds tested in rat liver cells. The tables provide the numbers of
compounds tested under the indicated conditions for each combination of concentra-
tion and exposure period, before and after (in brackets) excluding cytokines and LPS
(lipopolysaccharide) from the analyses.
3h 6h 9h 24h Overlap
Low 153 (151) 153 (151) 153 (151) 157 (155) 153 (151)
Middle 152 (150) 153 (151) 153 (151) 157 (155) 152 (150)
High 151 (149) 151 (149) 151 (149) 153 (151) 150 (148)
Overlap 150 (148) 150 (148) 150 (148) 152 (150) 149 (147)
4 days 8 days 15 days 29 days Overlap
Low 141 (141) 141 (141) 141 (141) 141 (141) 141 (141)
Middle 141 (141) 141 (141) 141 (141) 141 (141) 141 (141)
High 143 (143) 143 (143) 139 (139) 127 (127) 127 (127)
Overlap 141 (141) 141 (141) 138 (138) 126 (126) 126 (126)
The reader is referred to the Tables B.1-B.4 in the Appendix which provide a detailed
compound-specific summary for the three model organisms. The tables give full and abbrevi-
ated compound names as well as the concentration in µM (µg/mL, µg/kg) and the number of
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independent replicates of gene array data available after incubation with a low, middle and high
concentration for the indicated exposure period.
2.4.2 UKN1 test system
Embryonic stem cell (ESC)-based systems have been developed to recapitulate in vitro the
differentiation of stem cells into neuronal cells. Stem cells have the property of pluripotency,
i.e. the ability to differentiate into all types of cells. During the differentiation process different
mechanisms such as cell proliferation, migration and apoptosis are induced. Cultures of differen-
tiating human embryonic stem cells (hESC) offer the opportunity to observe, study and control
the early steps of human development. External stimulus influences, such as drug exposure, can
interfere with early developmental stages. In that context, different human ESC (hESC)-based in
vitro systems have been developed to recapitulate the different phases of early tissue specification
and neural development. The UKN1 test system is one of them and was developed to model the
stage of differentiation of neuroepithelial precursor cells (NEP) from hESC. Figure 2.7 visualizes
the test system’s treatment protocol. In that system the cells were exposed to the test compounds
within 6 days. In the present study two compounds, valproic acid (VPA) and methylmercury
(MeHg), were tested to detect chemically-induced gene expression alterations. VPA is used as an
anti-epileptic drug and known to cause neural tube defects, just as MeHg. Earlier analyses have
shown that exposure-related effects strongly depend on the concentration of the test compound.
Therefore, the compounds were tested with different concentrations covering non-toxic to toxic
concentrations. The highest concentration was chosen according to a benchmark concentration
representing the EC10. For more details on the test systems the reader is referred to Krug et al.
(2013).
VPA chronic concentration study
The VPA concentration study was conducted to investigate the development of human embryonic
stem cells (hESC) to neuroectoderm. The cells were treated in vitro with valproic acid (VPA)
using eight different concentrations (25-1000 µM). Each concentration was assessed using three
replicate experiments (see Table 2.5). The compound was exposed to the cells during the entire
differentiation process. In addition, six untreated measurements were available. Replicates of
controls were averaged before subtracting from corresponding exposed samples (paired design).
The study was carried out within the framework of the European Commission-funded research
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consortium (ESNATS) which targets the prediction of toxicity of drug candidates for the use of
embryonic stem cell-based novel alternative tests.
Figure 2.7: Overview of the UKN1 test system’s treatment protocol. The test system recapitulates
the differentiation process of human embryonic stem cells (hESC) to neuroepithelial
precursor cells (NEP). The cells were treated with valproic acid (VPA). The bars below
the test system provide information on replating, medium change, toxicant exposure and
day of array analysis, as indicated in the legend to the right (Krug et al., 2013).
Table 2.5: Overview of the number of replicates used in the VPA chronic concentration study.
Concentration in µM
0 25 150 350 450 550 650 800 1000
6 3 3 3 3 3 3 3 3
2.4.3 NRW database
The NRW data set comprises 30 compounds that have been tested in rats in vivo (Ellinger-
Ziegelbauer et al., 2008) and 29 compounds that have been tested in cultivated rat hepatocytes
(Schug, 2011). With the exception of one compound (Phenobarbital) that was only exposed to rat
cells in vivo, the other 29 test compounds were the same. Male Wistar rats were used as model
organism for both test systems.
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In vivo rat cell culture
Primary rat hepatocytes with in vivo rat liver data were treated with each compound in 3 replicates
and sacrificed after 6h, 12h, 24h, 48h, 3 days, 7 days and 14 days after exposure. Incubation peri-
ods of 6h, 12h and 48h were not considered any further as only one compound (Acetaminophen)
was tested for these time periods. Table B.5 in the Appendix contains an overview of the
number of replicates used in the in vivo experiments. The rat liver cells were obtained from
five animals treated daily with each compound. The treatment of animals was performed in
different experimental series. Therefore, ’experimental series’- and ’exposure period’-matched
controls were subtracted from the corresponding treated samples. The concentrations used for
the individual compounds during the entire incubation period are indicated in Table B.5 as
well. For transcriptional analysis the rae230a array was used which comprises 15 923 probe
sets, corresponding to approximately 10 045 annotated genes. As no reference parameters are
provided for this chip, the arrays of the treated samples were normalized to the complete set
of control arrays. The study was originally conducted to predict the toxicity class of unknown
compounds. A classifier that separated genotoxic from non-genotoxic carcinogens was built from
a set of training compounds (n=13) and applied to an independent set of validation compounds
(n=16). The training and validation sets together form the database for the in vivo analyses. The
classification into the annotated categories is given in the Appendix in Table B.5.
In vitro rat cell culture
Cultured rat hepatocytes were also tested with three replicates using three concentrations (Low,
Middle and High) and one incubation period (24h). The highest concentration represents the
EC20. Similar to the in vivo experiments, not all concentration- and time sets are complete. Some
of the compounds were tested only for two conditions as shown in Table B.6 in the Appendix.
The experiments were organised in 6-well-dishes. Per concentration, 3-wells were incubated with
the test compound and 3-wells were used as controls. According to that test design, the controls
were 6-well dish- matched subtracted from the corresponding exposed samples. Transcriptional
analysis was performed by using the rat2302-GeneChip 31 099 probe sets encoding 13 685
genes. For comparability reasons, the analyses was restricted to those transcripts that have
been measured on the rae230a-GeneChip which was used for the in vivo experiments. For
the normalization of the entire set of expression arrays the RMA+ algorithm was used which
provided reference parameters for future data sets, such as the TG-GATEs rat data sets.
3 Statistical methods
This chapter provides an overview of the statistical methods used for data analysis in this
thesis. First, multivariate methods for pattern recognition are introduced. The basic principle
of principal component analysis is explained and the heatmap is introduced as a visualization
method for high-dimensional data. In Section 3.3 the Limma t-test, which is used for the
analysis of high-dimensional gene expression data, is outlined. In the context of dose-finding
studies, several indices for the description of concentration-dependent progressions are presented
(Section 3.4). Section 3.5 deals with the theory of dose-response models. Within this section,
the four-parameter-log-logistic model (4pLL) together with its estimate for the Absolute Lowest
Effective Concentration (ALEC) is presented. Moreover, it is elucidated how to construct
confidence intervals for the effect level (response) and to how calculate the lowest effective
concentration (LEC) by means of hypothesis testing.
3.1 Principal component analysis
Principal component analysis (PCA) is a multivariate procedure for the detection of structures in
large data sets. The method targets to reduce the dimensionality of data by projecting the data into
a lower-dimensional space while aiming for preservation of information. The approach implies
the construction of uncorrelated linear combinations representing the principal components which
are sorted according to the proportion of their explained variance in descending order. Thereby
the total variance serves as a measure for the information content. LetX> = [X1, . . . , Xp] be
a p-dimensional vector of an n× p data matrix with n observations and p variables. The idea
is to transform the coordinate system that is spanned by the random variables X1, . . . , Xp by
rotation into a new coordinate system, the vector subspace Rk (k < p). The objective is to find a
set of linearly uncorrelated components that are orthogonal to each other and sorted in order of
their magnitude, i.e. such that the first principal component explains most of the data variability,
the second component contains the next most information and the last components provide the
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slightest information. If a sufficiently large proportion of total variance is covered by the first
k principal components, they prove to be sufficient to reproduce the data variability with little
loss of information. The remaining p− k components make only an insignificant contribution
to the overall variance and can therefore be neglected. The coordinate system spanned by the
k principal components allows a simplified depiction of the data structure or their covariance
matrix, respectively, in a k-dimensional space.
Consider now the vector X> = [X1, . . . , Xp] with covariance matrix Σ and eigenvalues
λ1 ≥ . . . ≥ λp > 0. Further, let A = (a1, . . . , an) be an orthogonal p×p matrix, i.e.A>A = Ip.
Then the principal components Y1, . . . , Yp are obtained by the transformation of X> → Y >
given by
Y1 = a1
>X = a11X1 + a12X2 + . . .+ a1pXp
Y2 = a2
>X = a21X1 + a22X2 + . . .+ a2pXp (3.1)
...
...
Yp = ap
>X = ap1X1 + ap2X2 + . . .+ appXp,
where a1> = (a11, . . . , a1p), . . . ,ap> = (ap1, . . . , app) are the vectors of weights. Since A is
orthogonal the transformation corresponds to a rotation of the n points in the p-dimensional
space.
The first principal component minimizes the sum of the Euclidean distances between the
projected data points and the original ones and maximizes the variance of the projections. Hence,
the variance of Y1 = a>1X must be maximized subject to a
>
1 a1 = 1. A method for the
optimization of a function subject to a constraint is the method of Lagrange multipliers. The
function L to be maximized is given by
L(a1, λ1) = a
>
1 Σ a1︸ ︷︷ ︸
fct. to max.
−λ1 (a>1 a1 − 1)︸ ︷︷ ︸
constraint
, (3.2)
where λ1 ∈ R denotes a Lagrange multiplier. The function in (3.2) is differentiated with respect
to a1 and λ1 and subsequently set equal to zero:
1) ∂L
∂λ1
= 1− a1>a1
2) ∂L
∂a1
= 2 Σ a1 − 2λ1 a1
 != 0. (3.3)
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The system of equations in (3.3) shows that the vector a1 has to satisfy a>1 a1 = 1 and
Σa1 = λ1 a1. The second term equals an eigenequation with the Langrange multiplier as
eigenvalue meaning that a1 is the normalized eigenvalue of the covariance matrix Σ with
eigenvalue λ1. Hereafter, let ei denote the eigenvector to eigenvalue i. The first principal
component is obtained by the projection ofX> onto e1 which is the eigenvector corresponding
to the largest eigenvalue λ1. The remaining principal components are constructed recursively
to the preceding ones such that the projections onto the kth principal component have maximal
variance and are orthogonal to the first k − 1 principal components, i.e. ai>ak = 0, 1 ≤ i < k.
Thus, the second principal component has to maximize
L(a1,a2, µ, λ2) = a2
>Σa2︸ ︷︷ ︸
fct. to max.
−µa2>a1︸ ︷︷ ︸
constraint
−λ2 (a2>a2 − 1)︸ ︷︷ ︸
constraint
, (3.4)
where µ ∈ R and λ2 ∈ R indicate the multipliers. Differentiating function (3.4) with respect to
all parameters and setting the partial derivatives equal to zero, delivers the second most important
linear combination e>2X which maximizes Var
(
e>2X
)
subject to the required constraints. The
remaining components are constructed analogously, i.e. the ith linear combination maximizes
Var
(
e>i X
)
with respect to both constraints, e>i ei = 1 and Cov
(
e>i X, e
>
kX
)
= 0 for k < i.
By induction, it can be shown that the first k principal components correspond to the first k
eigenvalues.
Replacing the coefficients ai, i = 1, . . . , p from equation (3.1) with the normalized and
orthogonal eigenvectors ei leads to the best i-dimensional approximations
Yi = ei
>X = ei1X1 + ei2X2 + . . .+ eipXp, i = 1, . . . , p
with the following properties
i) Var (Yi) = e>i Σ ei = λie
>
i ei = λi, i = 1, . . . , p
ii) Cov (Yi, Yk) = e>i Σ ek = 0, i, k = 1, . . . , p,
subject to the constraint e>i ei = 1.
The covariance matrix Σ can be rewritten as Σ = UΛU> by means of Spectral Decomposi-
tion (SD), where Λ is a diagonal matrix whose diagonal entries are the eigenvalues λ1, . . . , λp
and U = [e1, . . . , ep] is a orthogonal matrix whose columns are the eigenvectors of Σ. For a
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detailed description of the theory of SD, the reader is referred to Johnson and Wichern (1998).
The matrix U has the property: UU> = U>U = I .
The vectors e1, . . . , ep provide an orthogonal basis, i.e. U corresponds to the vector subspace
into which X> is projected: Y > = X>U . As a rotation is obtained by the multiplication of
a scalar with a orthogonal matrix, the transformation X> → Y > corresponds to the rotated
coordinate system.
The vector e>i = (ei1, . . . , eik, . . . , eip) can be interpreted as the score vector of the prin-
cipal component whose components eik, i, k = 1, . . . , p, indicate how good the kth variable
is approximated by the ith principal component. The first k principal components explain a
proportion of ∑k
i=1 λi∑p
j=1 λj
of the total variance.
The equation in (3.6) for the correlation of Yi und Xk can be justified by choosing a>k =
[0, . . . , 0, 1, 0, . . . , 0]︸ ︷︷ ︸
kthposition
such that
Xk = a
>
kX, Cov (Xk, Yi) = Cov
(
a>kX, e
>
i X
)
= a>k Σ ei = a
>
k λi ei = λi eik. (3.5)
The variance of Yi and Xk satisfy: Var (Yi) = λi and Var (Xk) = σk, respectively. It follows
ρYi,Xk =
Cov (Yi, Xk)√
Var (Yi)
√
Var (Xk)
=
λieik√
λi
√
σk
=
eik
√
λi√
σk
, i, k = 1, . . . , p. (3.6)
If the variables are not measured in the same scale unit, it is recommended to perform the PCA
on the basis of the correlation matrix rather than the covariance matrix, since the variables are
not comparable with each other. With respect to microarray analysis, standardization of the data
is not required as the variables representing the expression values are measured on the same scale
(log2). Usually, PCA is used as a prestep in a comprehensive analysis to obtain a first overview
of the data. Often, the first two components are sufficient to reveal features such as batches or
outliers.
24 3 Statistical methods
3.2 Heatmap
Heatmaps are a commonly used graphical method for the visualization of gene expression data
where rows and columns represent the genes of interest with respect to the analyzed arrays.
A heatmap compresses large amounts of information into a compact display area and, hence,
allows the visual detection of coherent patterns. A matrix containing the expression values of
genes is color encoded according to the values’ order of magnitude and displayed as color image.
Usually, heat colors are used for illustrating the data which is the reason for the name of the
heatmap. Many software systems such as the statistical software R use the heat colors as default.
Generally, different color schemes can be used to visualize the colormap. In the context of gene
expression data, it is useful to map the range of values to colors ranging from blue to red with
blue colors indicating low expression levels and red colors high expression values.
Coherent patterns of color are generated by hierarchical clustering. The rows and columns
of the data matrix are permuted such that objects with similar expression profiles are clustered
together. Cluster relationships are indicated by dendrograms generated for both axes. The
resulting patterns indicate functional relationships between the arrays and genes (Wilkinson
and Friendly, 2009). Heatmaps can be produced by using the R standard package stats (R
Core Team, 2015). It is up to the user to decide which agglomeration rule and metric should
be used for the cluster analysis. The complete linkage method is used by default to reorder the
dendrograms. Alternatively, both dendrograms can be reordered by a prescribed vector of values
or be completely omitted. By default, the Euclidean distance is used as distance measure for the
calculation of pairwise distances. The gplot package implements an extended version of the
standard R function which offers a number of additional features such as a color key illustrating
the range of values together with their distribution, or a side bar that may be used to classify the
objects with respect to any characteristics (Warnes et al., 2015).
Figure 3.1 shows an example for a heatmap, where rows represent genes and columns indicate
samples. For illustration purposes, gene expression data of human embryonic stem cells (hESCs)
after VPA (valproic acid) exposure was used. Originally, the cells were treated with eight
different concentrations (25-1000 µM with n=30) using three replicates (for more details on the
study see Section 2.4). For generating the exemplary heatmap only a subset of the measured
concentrations was used (150 µM, 550 µM, 800 µM, 1000 µM with n=12 samples). The absolute
gene expression levels (log2-scaling) of the ten transcripts with highest variance across the
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12 samples were color-coded for display. The samples have been classified with respect to
concentration level and replicate number. Up- and downregulation is indicated by blue and red
coloring.
Replicate
Concentration
1 3 2 4 5 6 7 9 8 10 12 11
MAB21L2
RSPO2
ARX
HAPLN1
MUC15
MUC15
SLC40A1
HAPLN1
SIX1
CR1L
4 6 8 10
Value
Color Key
Replicate
1
2
3
Concentration
150µM
550µM
800µM
1000µM
Figure 3.1: Example of a heatmap. Each row represents a gene, while each column stands for a
sample. Red color indicates up- and blue color downregulated genes as indicated by
the color key in the upper left. The rows and columns are reordered according to their
respective dendrograms which are generated by hierarchical clustering. The samples
have been classified according to concentration level and replicate number which are
indicated by the column side bar and the legends in the upper right and upper left.
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3.3 Limma: Linear Models for Microarray Data
Limma is an R/Bioconducter package which is used for the analysis of gene expression
data (Ritchie et al., 2015). The Limma t-test is a moderated t-test for detecting gene expression
changes which are associated with a particular treatment condition. The simple t-test is altered
in the sense that the information of the complete set of genes is used in the estimation of the
gene-wise variances in place of the ordinary variances. The basic idea of Limma is to shrink the
gene-wise residual sample variances towards a common value by an empirical Bayes approach.
The effect of sharing information has, especially in case of small sample sizes, the advantage of
more accurate estimators and therefore less unbiased test results.
Consider a microarray experiment with n arrays where yg> = (yg1, . . . , ygn) denotes the
response vector which contains the expression values of gene g. This means that the response
of gene g corresponds to the gth row of the expression matrix. LetX be the design matrix with
rows representing the arrays and αg the vector of coefficients. Let C denote the contrast matrix
whose rows correspond to the coefficients and whose columns contain the contrasts. In case that
only one contrast is of interest, a contrast vector is defined. The contrast matrix allows to adjust
for covariates, batch- or interaction effects. In terms of a linear model
E(yg) = Xαg.
The variance of the response vector yg is given by
var(yg) = W gσ2g ,
where Wg is a positive definite weight matrix which allows the incorporation of unequal
variances for more accurate test results, and σ2g indicates for gene g the residual variance
of the model with dg residual degrees of freedom. Samples can be individually weighted
according to their reliability (Smyth, 2005). The contrasts of interest are defined by βg =
C>αg. Given the expression- and design matrix the lmFit() function fits a linear model
to gene g. The same model is applied to the other genes of the microarray experiment. The
coefficient component contains the estimated coefficients for αg. Given the fitted model,
the contrast.fit() function estimates the coefficients and standard errors for βg. Unlike
the design matrix which has to be full-ranked, the contrast matrix is allowed to be linearly
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dependent. That means that the number of contrasts does not necessarily have to be the same as
that of the coefficients. It is quite possible that the contrasts correspond to a subset of the original
coefficients. As the coefficients themselves are usually of no further interest, but certain contrasts
of them, they are re-calculated together with their standard deviations and their covariance matrix
into the corresponding contrast objects. In the special case that the design matrix consists of a
single n-dimensional column of onesX> = (1, . . . 1), the Limma t-test equals a simple t-test
but adjusted for the gene-wise variance estimator which comprises both, the information of the
gene alone and the pooled one of all genes. The contrast matrix is redundant in that case and can
be omitted. The simplest experimental design is a microarray experiment with two treatment
groups comparing experiment and control RNA. If the entries in the gene expression matrix
correspond to the log2-fold changes, i.e. the differences in gene expression between experiment
and control, the coefficient vector αg consists only of one element αg. The coefficient estimator
corresponds to the mean log2-fold changes of the gth gene. In that special case, the coefficient αg
corresponds to the contrast of interest, namely the treatment effect.
As mentioned above, the coefficient estimator α̂g, the estimator s2g of the residual variance σ
2
g
and the estimated covariance matrix of α̂g: v̂ar(αˆg) = Wgs2g are re-calculated in terms of the
contrasts βˆg = C
>α̂g. Given the contrast matrix C and the weight matrixWg, the covariance
matrix of βg is estimated by
v̂ar(βˆg) = C
>W gC︸ ︷︷ ︸
Ug
s2g.
Unlike the responses yg, for which no distributional assumptions are made, the contrast estimators
are assumed to be at least approximately normally distributed with mean βg and covariance
matrix C>W gCσ2g . Let Ug = C
>W gC be the matrix whose diagonal entries correspond to
the unscaled variances of βˆg, then the j th diagonal entry ugj denotes the variance of βˆgj and the
ordinary t-statistics for the j th contrast is given by
tgj =
βˆgj
sg
√
ugj
, (3.7)
which is t-distributed with dg degrees of freedom.
Thus, the j th component of the estimated contrast vector βˆg satisfies
βˆgj
∣∣βgj, σ2g ∼ N (βgj, ugjσ2g)
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and
s2g
∣∣σ2g ∼ σ2gdg χ2dg ,
where s2g is approximately χ
2-distributed with dg degrees of freedom.
The empirical Bayes approach uses a hierarchical model to estimate the posterior residual
variances. The basic idea is to incorporate the common information provided by all genes
together into the gene-wise sample variance. The residual variance σ2g is assumed to be a priori
inverse χ2-distributed with d0 degrees of freedom
1
σ2g
∼ 1
d0s20
χ2d0 , (3.8)
where s20 is a further hyperparameter which is estimated from the data, similar to d0. It can be
shown that the χ2-distribution in (3.8) can be rewritten as gamma distribution:
d0s
2
0
σ2g
∼ χ2d0 ⇒
1
σ2g
∼ Γ
(
k =
d0
2
, θ =
2
d0s20
)
.
The estimators for both parameters, s20 and d0, are obtained from the observed sample variances
s2g. Hence, the inverse posterior estimator for the residual variance
1
s˜g
corresponds to the mean of
the gamma distribution which is the a posteriori distribution of 1
σ2g
(Rempel, 2015):
1
σ2g
∣∣∣∣(s20, d0, s2g) ∼ Γ(k = d0 + dg2 , θ = 2d0s20 + dgs2g
)
.
It follows
1
s˜2g
= E
(
1
σ2g
∣∣∣∣s20, d0, s2g) = d0 + dgd0s20 + dgs2g ⇒ s˜2g = d0s
2
0 + dgs
2
g
d0 + dg
.
For more details the reader is referred to Rempel (2015).
Substituting the prior standard deviation sg in the ordinary t-statistic, given in (3.7), by the
posterior standard deviation s˜g, results in the moderated t-statistic
t˜gj =
βˆgj
s˜g
√
ugj
,
which is t-distributed with (d0 + dg) degrees of freedom under the null hypothesis H0 : βgj = 0.
The degrees of freedom are augmented due to the additional information which is borrowed from
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the other genes to adjust the individual genes in terms of the global variance. In case of d0 = 0,
t˜gj = tgj holds (Ritchie et al., 2015).
3.4 Statistics for concentration-dependent analyses
In concentration-dependent gene expression studies a convincing concentration progression
is a criterion for data quality. Genes that are deregulated by a compound at a certain tested
concentration are usually also deregulated at the next higher concentration. Therefore, genes
with a deviating expression profile, i.e. genes with a non-monotonous concentration progression,
may be indicative of low-data quality and, hence, should be treated with caution. In order to
improve the data reliability, Grinberg et al. (2014) has introduced two indices for the progression
analysis of gene alterations over increasing concentration levels, the progression profile index
and the progression profile error indicator. Both statistics return exclusivity indices for the
comparison of adjacent concentrations. They are calculated for each compound and incubation
time point separately. Mathematically, the indices are defined as the probability of being not
deregulated at a certain concentration level subject to the condition of being deregulated at an
other concentration level.
Let C1 and C2 denote two concentration levels and GDiffC1 and G
Diff
C2
the events of being dif-
ferentially expressed at C1 and C2. The complement GDiffC1 indicates the event of being not
differentially expressed at C1. The conditional probability of GDiffC1 given G
Diff
C2
is then defined as
the ratio of the probability of the intersection of the events GDiffC1 and G
Diff
C2
, and the probability of
the event GDiffC2 :
P
(
GDiffC1 |GDiffC2
)
=
P
(
GDiffC1 ∩GDiffC2
)
P
(
GDiffC2
) . (3.9)
This quantity is estimated by replacing the events with the corresponding relative proportions of
genes that are deregulated.
3.4.1 Progression profile index
The progression profile index is defined as the ratio of two proportions, the proportion of genes
that are deregulated exclusively at the higher concentration C2, and the proportion of genes that
are deregulated in total at C2. In formula in (3.9) this corresponds to the situation C1 < C2.
Values close to zero indicate that only a few additional genes are deregulated at the next higher
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concentration, whereas values close to one indicate many additional genes deregulated at the
higher concentration.
3.4.2 Progression profile error indicator
The progression profile error indicator is defined vice versa to the progression profile index,
namely as the ratio of the proportion of genes that are deregulated exclusively at the lower
concentration, and the proportion of genes that are deregulated in total at the lower concentration.
In terms of formula (3.9), it holds C1 > C2. Values close to one indicate that a high fraction
of genes are deregulated exclusively at a lower but not at the respective higher concentration.
Values close to zero indicate the revers case. Compounds with values above 0.5 are considered
as indicative of an implausible concentration progression.
3.4.3 Modified progression profile error indicator
The modified progression profile error indicator is an adjustment of the progression profile error
indicator and has been introduced for the case that only a few genes are altered in total. As
a certain amount of false positive genes is to be expected, a tolerance limit, i.e. a minimum
amount of differentially expressed genes, should be set before including the respective genes
in the calculations of the progression profile error indicator. Therefore the number of genes
deregulated in total is incorporated in the calculation of that index. The progression profile error
indicator is altered in the sense if the value of the index is larger than 0.5 and the number of
genes deregulated at the respective lower concentration is below 20, the value of the index is set
to zero. The interpretation of the modified index is the same as for the progression profile error
indicator.
3.4.4 Selection value
To systematically analyze stereotypic versus compound-specific gene expression responses, the
selection value principle has been introduced in Grinberg et al. (2014). A stereotypic response
means that an expression alteration is induced by many compounds, while a specific expression
response is induced by individual compounds or small numbers of compounds. For a gene, the
selection value determines the number of compounds that induces a change in its expression.
Compounds are ranked gene-wise in order of magnitude, in case of upregulated genes compounds
are ranked from high to low fold changes and in case of downregulated genes from low to high
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values. The selection value x for a gene (Sv x) defines the rank of the compound, indicating that
the gene is induced by at least x compounds. The threshold for the critical change is pre-specified.
In case of small replicate numbers, it is recommended to consider higher thresholds to keep
the number of false positive genes as low as possible. The probability of false positive alerts
decreases with increasing fold change. The higher the selection value the less compound-specific
is the response. For a given fold change the so-called Sv 20 genes refer to those genes which
respond to at least 20 compounds reflecting a stereotypical response. By contrast, a compound-
specific response is here specified by Sv 3 genes, i.e. genes which are deregulated by at least
three compounds. Note, that genes of higher selection values always overlap with genes of lower
selection values, i.e. Sv 20 genes are a subset of Sv 3 genes.
Based on the selection value concept a consensus Sv x signature of genes comprises the Sv x
gene lists of all individual test conditions. That means, the consensus Sv x list includes all those
genes that show for at least one of the tested conditions a change in expression. Consensus genes
are often used for the comparison of different model organisms, test systems, or data sets.
3.4.5 Overlap ratio
The overlap ratio is introduced to approach the question whether the overlap of genes between
two test conditions, condition 1 and condition 2, corresponds to a randomly expected result. The
ratio quantifies to which degree genes in the overlap are overrepresented, whereby a value of
1.0 indicates a random overlap and values higher than 1.0 are indicative of an overlap which is
higher than expected by chance in case of independence. A ratio of 2.0, for example, indicates
that twofold more genes are in the overlap than randomly expected. The overlap ratio is defined
as follows:
Overlap ratio =
O · nGene universe
nCondition 1 · nCondition 2 ,
where nGene universe represents the total number of genes on the array (array =ˆ sample), nCondition 1
represents the total number of genes that are altered under the influence of test condition 1,
nCondition 2 indicates the total number of genes differentially expressed under test condition 2, and
O represents the number of genes in the overlap. Significance of overrepresentation is calculated
by the Fisher test. The basic idea of the overlap ratio was first presented in Shinde et al. (2017).
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3.5 Dose-response theory
To this date, differential expression analysis was only performed using the classical naïve
approach, where for each measured concentration separately it is tested if the critical effect
level is exceeded (Limma t-test). This procedure has the disadvantage that only measured
concentrations can be considered as potential candidates for alert concentrations . But in practice,
it is highly unlikely that such a deregulation is first triggered at exactly one of the measured
concentrations. To this end, a model-based method is introduced which allows arbitrary positive
values as alert levels.
Dose-response models are used in various application fields, such as pharmacology, pharma-
cokinetics, toxicology and clinical research. Typically, dose-response data exhibit a monotonic
relationship between dose and response which can be modeled by a parametric regression model.
Often, a sigmoidal dose-response trend is observed in the data which is characterized by S-shaped
curves. Besides, there are other curves which can describe the response dependency of a dose,
e.g. J-shaped or inverted U -shaped curves. These kind of curves are used for describing dose-
response dependencies with a so-called hormesis effect which is, in toxicology, associated with
low dosis effects and high dosis inhibitions. In the context of gene expression data, such curve
progressions might be a hint for the use of cytotoxic concentrations which trigger cell death as
response to compound exposure. However, this work addresses only the modeling of log-logistic
functions which are by far the most commonly used models for describing dose-response rela-
tionships of toxicological background. Besides the log-logistic model, which exists in different
parameterizations, there are other models, based for example on the log-normal- or Weibull
distribution, that can be equally used to describe sigmoidal dose-response dependencies (Ritz,
2010).
All methods introduced in this section are based on an application of the four-parameter
log-logistic model (4pLL). The 4pLL model is fitted to the data in order to estimate the Absolute
Lowest Effective Concentration (ALEC) for a fixed and pre-specified effect level which is the
concentration at which a pre-specified expression change is observed. The ALEC is derived
from the fitted average trend (Jiang, 2013). Due to the fact that the critical concentration (ALEC)
results from a simple point estimator, the uncertainty of the effect level is entirely neglected.
But as it is vital to provide confidence intervals, the method introduced by Jiang (2013) is
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enhanced by means of a thorough confidence interval estimator in this thesis. The hereby
resulting concentration value is defined as the Lowest Effective Concentration (LEC).
3.5.1 Four-parameter log-logistic model (4pLL)
Given the parameter vector φ =
(
φ(b), φ(c), φ(d), φ(e)
)>, the four-parameter log-logistic model
(4pLL) is given by
y = f(x,φ) = φ(c) +
φ(d) − φ(c)
1 + exp {φ(b) [log(x)− log(φ(e))]}
= φ(c) +
φ(d) − φ(c)
1 + (x/φ(e))φ(b)
,
(3.10)
where x denotes the concentration and y the response. Under the assumption that the response
dependency of the dose x can be described by a sigmoidal function, the 4pLL model is a suitable
model to describe such a trend. In contrast to experiments where the response is for instance of
physiological or biochemical nature or death (mortality rate), the studies used in the present work
were conducted to investigate gene expression alterations induced by several test compounds. In
terms of gene expression data the response y corresponds to the fold change (log2-scale), i.e. the
difference in gene expression between treatment and control. Another term used in that context
is effect level. Figure 3.2 shows an example of a 4pLL model for an increasing dose-response
curve.
The function f reflects the mean difference between treatment and control (fold change) in
relation to a concentration x. The parameters φ(c) and φ(d) specify the lower and upper horizontal
asymptotes. The slope of f is determined by the parameter φ(b), where a positive sign indicates a
decreasing curve and a negative one an increasing curve. Higher values of φ(b) are associated
with a steeper curve progression. In case of an increasing curve, the lower limit corresponds
to the average level of control values and the upper limit to the average level measured at
the highest tested concentration. In case of a decreasing curve the upper and lower limit are
interchanged. According to Ritz (2010) it is not recommended to scale continuous data to a range
of values between 0 and 1, unless there is a good reason to do so. The parameter φ(e) denotes
the effective concentration EC50 which is the concentration that induces 50% reduction of the
maximal effect. Different parameterizations can be used for the effective concentration φ(e). The
use of the logarithmized parameter φ(e) provides more accurate parameter estimates (Ritz, 2010).
The EC50 is then re-parameterized with the following relationship to the original parameter:
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Figure 3.2: Example of a four-parameter log-logistic (4pLL) model. The blue dashed lines indicate
the lower and upper limit, respectively. The dashed green line displays the EC50. The
negative sign of the slope indicates an increasing curve.
φ(e) = exp (φ(e)
∗
). In general, a dose-response model can be fitted by the R function drm which
is implemented in the drc package. The 4pLL model function with log (φ(e)) can be specified
by the argument fct = LL2.4() (Ritz and Streibig, 2005).
3.5.2 Re-parametrization of the EC50
The choice of the parameterization depends on the sample size and the parameters to estimate.
Due to the non-linearity of the function in (3.10), f is approximated according to the least
square method with the Gauss-Newton algorithm which assumes that the parameter estimates
are approximately normally distributed. However, for a small sample size (n < 20-30) the
normality assumption is questionable. The violation of the distributional assumptions can lead
to biased estimators. The use of another parameterization can circumvent this problem. By
definition, the parameter φ(e) is a concentration and therefore needs to be a positive value
which implicates a right skewed distribution of its estimate. The smaller the data set, the more
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pronounced is the skewness and the more difficult it is to approximate the distribution by a normal
distribution. Therefore, it is more appropriate to estimate the logarithm-transformed parameter
φ(e)
∗
= log
(
φ(e)
)
rather than the original parameter φ(e), since φ(e)∗ permits values on the entire
real axis which makes the normality assumption more plausible. The EC50 together with its
confidence interval is then obtained by back-transformation of the corresponding log-scaled
parameter estimators.
The following function has to be minimized:
RSS =
n∑
j=1
(yj − f(xj,φ))2,
with n indicating the number of data pairs (xj, yj). Note, that the algorithm used is an iterative
method for approximating the parameter estimators and therefore does not guarantee to find the
global minimum of the function, that means, depending on the starting values of the iteration
process, the algorithm can result in a local rather than global minimum. By default, the starting
values are estimated from a self starter function which is specified by the user. In case of the
four-parameter log-logistic model the function fct = LL2.4() determines the initial values
of the four parameters φ(b), φ(c), φ(d) and φ(e). The upper and lower limits φ(c) and φ(d) are set
to the minimum and maximum response value ± 0.001. The initial values of the parameters
φ(b) and φ(e) are set as follows: A critical value is defined by the average value of the upper and
lower limit. In a stepwise procedure, the mean response value of two neighboring concentration
levels is calculated and compared with the critical value. If the critical value lies between the two
response values, the search algorithm stops, otherwise the first concentration value is replaced by
the next higher concentration value and the calculations are repeated. The initial value of φ(e) is
then obtained by taking the average value of the two given concentration levels and the starting
value of φ(b) is calculated by subtracting the two given response values from each other (value
with a negative sign is taken).
Alternatively, an optional vector of starting values can be specified by the user. Moreover,
convergence problems can occur as a result of different parameterizations. For more details the
reader is referred to Ritz (2010).
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3.5.3 The ALEC and its confidence interval
For a parametric regression model function y = f(x,φ) the ALEC estimates the Absolute
Lowest Effective Concentration for a pre-specified critical effect level λ and is defined as the
inverse function of f :
f(ALEC,φ) = λ⇒ ALEC = f−1(λ,φ).
In the parameterization (3.10) the ALEC is defined as a function h(φ) for a given λ:
ALEC = h(φ) = φ(e)
(
φ(d) − λ
λ− φ(c)
)1/φ(b)
. (3.11)
The ALEC can only be estimated for an effect level λ which lies between the lower and upper
limit φ(c) and φ(d).
A confidence interval for the ALEC can be estimated by using the delta method to approximate
the variance of h(φ):
Var(h(φ)) ≈ ∇h(φ)T · Σ · ∇h(φ), (3.12)
where Σ corresponds to the variance-covariance matrix of the parameter vector φ and ∇h(φ) to
the gradient of h:
∇h(φ) =

∂h(φ)
∂φ(b)
∂h(φ)
∂φ(c)
∂h(φ)
∂φ(d)
∂h(φ)
∂φ(e)
∗

= h(φ)

− 1
φ(b)
2 log
(
φ(d)−λ
λ−φ(c)
)
1
φ(b)(λ−φ(c))
1
φ(b)(φ(d)−λ)
1

.
A detailed derivation of ∇h(φ) is provided in Section A.1 in the Appendix. Differentiating
term (3.11) with respect to the parameter vector φˆ =
(
φˆ(b), φˆ(c), φˆ(d), φˆ(e)
)T
and inserting the
estimated ALEC together with its estimated variance, into (3.13) results in the following (1− α)
confidence interval
ÂLEC± tν,(1−α/2)
√
v̂ar(ÂLEC), (3.13)
where tν,(1−α/2) is the (1− α/2) quantile of a t-distribution with ν = n− 4 degrees of freedom
for n observations. However, Jiang (2013) recommends to calculate the confidence interval for
the logarithmized ALEC estimator and then to back-transform the log-scaled confidence interval
3.5 Dose-response theory 37
to the original dose scale. That ensures positive estimators for the lower interval limit. To apply
this procedure, the expressions in (3.11), (3.12) and (3.13) are re-parameterized into the terms
in (3.14), (3.15) and (3.16), respectively:
log(ALEC) = log(h(φ)) = log(φ(e)) +
1
φ(b)
log
(
φ(d) − λ
λ− φ(c)
)
, (3.14)
Var(h(φ)) ≈ ∇ log(h(φ))T · Σ · ∇ log(h(φ)), (3.15)
exp(log(ÂLEC))± tν,(1−α/2)
√
v̂ar(log(ÂLEC)). (3.16)
Besides the delta method, there are other methods which can be used for the construction of
confidence intervals like the profile likelihood method which is based on a re-parameterization
of function (3.10) or the bootstrap method that is based on resampling techniques. For a detailed
description of the two methods see Jiang (2013).
3.5.4 The effect level and its confidence interval
Given formula (3.10), let the function f(·) define the effect level. The confidence interval for a
fixed effect level λ can then be computed analogously to the confidence interval of the ALEC.
Approximating the following term
Var(f(x,φ)) ≈ ∇f(x,φ)T · Σ · ∇f(x,φ) (3.17)
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with the delta method provides an estimator for the variance v̂ar(f̂(x,φ)). Differentiating the
function in (3.10) with respect to the parameter vector φ gives the gradient of f :
∇f(x,φ) =

∂f(x,φ)
∂φ(b)
∂f(x,φ)
∂φ(c)
∂f(x,φ)
∂φ(d)
∂f(x,φ)
∂φ(e)

=

−(
φ(d)−φ(c))
(
log
(
x
φ(e)
))(
x
φ(e)
)φ(b)
1+( x
φ(e)
)φ(b)2
1−
 1
1+
(
x
φ(e)
)φ(b)

1
1+
(
x
φ(e)
)φ(b)
φ(b)(φ(d)−φ(c))
(
x
φ(e)
)φ(b)
φ(e)
1+( x
φ(e)
)φ(b)2

. (3.18)
For a detailed derivation of ∇f(x,φ) the reader is referred to Section A.2 in the Appendix.
Inserting the estimated parameters φˆ(b), φˆ(c), φˆ(d) and φˆ(e) into the functions (3.10) and (3.18)
gives estimators for f and its first order derivatives∇f for a specific concentration x. Estimating
the variance-covariance matrix of the four parameters provides Σˆ. By applying (3.17) to the
estimated parameters, the (1− α) confidence interval for the effect level is obtained:
f̂(x,φ)± tν,(1−α/2)
√
v̂ar(f̂(x,φ)), (3.19)
where tν,(1−α/2) is the (1− α/2) quantile of a t-distribution with ν = n− 4 degrees of freedom
for n observations.
Figure 3.3 illustrates the ALEC estimator together with its 95%-confidence interval, with
respect to both concentration and response (fold change). The horizontal line visualizes the 95%-
confidence interval obtained by formula (3.13) and the vertical line results from the application
of formula (3.19). The red dashed line marks the critical effect level which is 1.5-fold in the
present case.
3.5.5 Test statistic for the effect level
Consider the 4pLL model function (3.10) with its parameter vector φ =
(
φ(b, φ(c), φ(d), φ(e)
)>.
Let v̂ar(f̂(x,φ)) denote the estimate of the variance of f(x,φ) which is approximated according
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to formula (3.17) and let λ be the effect level of interest. The test statistic for testing the
hypothesis H0 : f(x,φ) = λ is given by
t4pLL =
|f̂(x,φ)− λ|√
v̂ar(f̂(x,φ))
. (3.20)
H0 is rejected at level α if the observed value of t4pLL exceeds the (1 − α/2) quantile of a
t-distribution with ν degrees of freedom where ν = n− 4 and n is the number of observations.
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Figure 3.3: Illustration of the ALEC estimator and its corresponding 95%-confidence intervals, with
respect to concentration (horizontal line) and response (vertical line). Dashed lines
indicate estimators and solid lines confidence intervals.
3.5.6 Lowest Effective Concentration (LEC)
The LEC estimates the Lowest Effective Concentration at which a given fold change is exceeded
significantly. For estimating the LEC, a grid search within the permissable parameter space is
performed. The used algorithm is presented in pseudo-code in Algorithm 1. Let λ denote the
critical effect level and x the test concentration. In this case the t4pLL-test in (3.20) is used to test
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Algorithm 1 Search algorithm for the LEC estimator.
Require: ps = ev, start = ALEC, finish = 1000,  = 0.01
1: erg ← t.test4pLL(x = finish)
2: if erg is not significant then
3: Stop and
4: return "Maximal number of iterations is reached"
5: start← 1
6: else
7: lower ← start
8: upper ← finish
9: end if
10: repeat
11: new ← (lower + upper)/2
12: erg ← t.test4pLL(x = new)
13: if erg is significant then
14: upper ← new
15: else
16: lower ← new
17: end if
18: until |upper − lower| < 
19: return new
whether the fold change at the given concentration is different from the pre-specified effect level
λ. The null hypothesis is tested at each concentration separately. If the obtained statistic leads to
the rejection of H0 : f(x,φ) = λ and the critical effect level lies below (upregulation) the lower-
or above (downregulation) the upper confidence limit, then the tested concentration exceeds
the critical effect level at level α significantly. To avoid unnecessarily long computation times,
the test concentrations within the parameter space are well-chosen. The lower and upper limit
of the parameter space are defined by the ALEC and the highest test concentration which can
be specified by the user. The algorithm starts at the highest test concentration and iteratively
determines the next test concentration. If no significant result for the highest tested concentration
is obtained, the algorithm stops, otherwise the parameter space is halved. The center of the lower
and upper limit is chosen as the new test concentration. If the new test concentration exceeds
the critical effect level significantly, the parameter space within which the search takes place is
restricted to its lower half, otherwise to its upper half. The concentration search continues until
the algorithm converges which is the case if the difference between the lower and upper limit
is smaller than a given range specified by . In case of convergence, the algorithm returns an
estimator for the LEC, otherwise a warning message that the estimated value lies outside the
valid range. The ALEC and LEC estimator are visualized together with their 95%-confidence
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intervals in Figure 3.4. The ALEC defines the concentration at which the given fold change
(dashed red line) is reached exactly and the LEC refers to the concentration at which the given
threshold is exceeded significantly.
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Figure 3.4: Illustration of the ALEC estimator (in blue) and LEC estimator (in green). The ALEC
defines the concentration at which the 1.5-fold threshold is reached exactly (point esti-
mate) and the LEC refers to the concentration at which the given threshold is exceeded
significantly (CI-based estimate). For the LEC estimator a grid search is performed
within the respective limits.
3.5.7 Measures of toxicity
The 4pLL method introduced in Section 3.5.4 is an alternative to the classical naïve Limma
approach where for each measured concentration separately it is tested whether the given
threshold is exceeded significantly. In this case the Lowest Observed Effective Concentration
(LOEC), also referred to as CI-based estimate, indicates the lowest concentration at which the
average value of the fold change exceeds the critical effect level significantly. The Limma t-test
from Section 3.3 is used to test the hypothesis.
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By contrast, the Lowest Effective Concentration (LEC) refers to the lowest concentration
at which the fitted fold change exceeds the given threshold significantly (CI-based estimate).
Therefore, the LEC estimator is also defined by hypothesis testing, but this time the test procedure
is performed within a pre-specified concentration range by means of an iterative algorithm which
uses the t4pLL-test. The used algorithm is presented in pseudo-code in Algorithm 1 and the used
test statistic in (3.20).
The Absolute Lowest Observed Effective Concentration (ALOEC) defines the lowest concen-
tration at which the given fold change is exceeded by its average fold change value. In contrary
to the LOEC (point estimate), no significance testing is performed. Both estimators, the ALOEC
and LOEC, are restricted to measured concentration levels. This explains the letter "O" in the
names of the two Limma estimators. The "O" indicates that for these two alert concentrations
only measured values are potential candidates for estimates.
The estimates for the LEC and the ALEC can take any continuous value in the given concen-
tration range. The ALEC (point estimate) is defined as the concentration at which the critical
effect level is reached exactly by the fitted fold change value. Table 3.1 summarizes the four
parameters with respect to their estimation method.
Table 3.1: Methods for estimating alert concentrations from concentration - gene expression studies.
Rows indicate the cut-off criteria and columns the methods for estimating critical concen-
trations. An alert means either that a given fold change value is reached exactly (4pLL)
or exceeded by the average value (Limma) (FC) or that additionally the corresponding
p-value is below a given cutpoint (FC & p-value). The p-value results from the t-test from
the 4pLL model-based approach or from the Limma t-test.
4pLL Limma
ALEC ALOEC
(Absolute Lowest (Absolute Lowest ObservedFC
Effective Concentration) Effective Concentration)
LEC LOEC
(Lowest Effective (Lowest ObservedFC & p-value
Concentration) Effective Concentration)
Fitted fold change value Average fold change value
↪→ Allow arbitrary positive ↪→ Restricted to measuredCriteria
values concentration levels
4 Toxicogenomics directory of
chemically exposed human
hepatocytes
This chapter adresses the statistical challenges which arise from the task to analyze a large-scale
gene expression data set, in this case on the basis of the TG-GATEs data set (NIBIOHN, 2017).
The database is one of the largest toxicogenomic databases to date and was generated by treating
cultivated primary human and rat hepatocytes, as well as rat liver and kidney samples with
more than 150 compounds using different concentration and time points. However, despite
the advantages of such an extensive database, one of the main challenges of toxicogenomics
is to identify artifacts and to eliminate errors. To tackle this problem, several curation steps,
including batch correction, assessment of data reproducibility and exclusion of implausible data,
are applied. The curated database is then used to analyze the structure of the chemically induced
gene expression alterations . The results reported in this chapter have been published in Grinberg
et al. (2014). All calculations were performed with the statistical software R version 3.3.2 (R
Core Team, 2015).
4.1 Batch effects
Besides the curse of dimensionality, the greatest challenges while working with such large data
sets is to identify and remove substantial errors. Experimental errors occur inevitably but can
be controlled to a certain extent. In order to do so, various steps of a curation process must be
performed. In the first step, a principal component analysis (PCA) is carried out in order to
visualize the different gene expression alterations across all compounds and replicates. The PCA
is based on the 100 probe sets with highest fold change (absolute values) across all compounds.
The analysis is performed for all concentration and time sets separately. Figure 4.1 displays
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the data of the high concentration and 24h time set. The corresponding figures for all other test
conditions are shown in the Appendix (Figures C.1-C.3). Each point represents one experiment,
where the color coding indicates the controls (dark green) and the exposed samples (light green).
The percentages of the variances covered are indicated on the axes. Plotting of the first two
principal components reveals two main clusters. Non-exposed samples are located on the left side
of the PCA plot, while exposed samples move along the first principal component which explains
40.4% of the data variability. Controls are subdivided into two batches, but cluster at least within
the two batches closely together (Figure 4.1 A). In Figure 4.1 B replicate samples of the same
compounds are connected by lines to visualize the reproducibility between replicates. Most of
the replicate pairs are located next to each other indicating a high replicate reliability. Due to
the low technical variability, replicate values are averaged for further analyses (Figure 4.1 C).
As a next step, control-treatment samples are compared by connecting lines (Figure 4.1 D). The
resulting pattern reveals that the individual control-treatment pairs are located within the same
cluster. This gives reason to believe that the two batches arise from experimental discrepancies.
Subtracting controls from the corresponding compound exposed samples results in a pattern
without any clusters. The aforementioned batch effect is removed by simple control subtraction.
No further procedures are required to correct for batch effects (Figure 4.1 E).
4.2 Reproducibility
As the PCA provides only a visual overview of the technical variability between compound
specific replicates, the reproducibility between them is analyzed in more detail. For quantifying
the distance between replicate pairs, Euclidean distances are calculated and compared to the Eu-
clidean distances of control-treatment pairs. The results are visualized by histograms. Figure 4.2
illustrates the results for the 24h, high concentration subset. The histogram in the left-hand panel
shows the distances between the replicates tested at that condition. Except for some outliers,
the distribution is approximately normally distributed with mean 2.1 and standard deviation 0.5.
The 95%-quantile of the distribution, indicated by the red line in the histogram, determines the
threshold for the acceptable variability range. Distances of larger values are considered as outlier
candidates and are visualized with lines in the PCA plot on the right-hand side of the figure.
For the given subset, 14 compounds (9.5%) are identified as outliers. Comparing the distances
between replicate pairs with those between control-treatment sample pairs shows that even the
5% largest observed distances exhibit a relatively low degree of variability (in median 4.9-fold
4.2 Reproducibility 45
lll
l
ll
ll
l
l ll
ll
ll
ll
ll
ll
ll
l
ll
ll
ll
ll
ll
ll
l
ll
lll
l
l
l
lll l
l l
ll
ll
lll
ll
l
ll
ll
ll ll
llll
ll
ll
l
l
l
l
l
lll
l
l
ll
lll
ll
l
ll ll ll
ll ll
l ll
l
l
l
ll
ll
l
ll
ll
l
l
lll
lll
l
l
ll
ll
l
llll
l
ll
l
llll
l
l
ll
ll
lll
l
ll
l
ll
ll
ll
l lll
l
l
ll
l
ll
ll
ll
l
l
l
ll
ll
l l
ll
l
l
ll
ll
ll
l
ll
l
ll
ll
ll
ll
ll
ll
l
ll
l
−10 −5 0 5 10 15 20
−10
−5
0
5
10
15
PC1 (40.4 %)
PC
2 
(15
.3 
%)
A
l
lll
l
ll
ll
l
l ll
ll
ll
ll
ll
ll
ll
l
ll
ll
ll
ll
ll
ll
l
ll
lll
l
l
l
lll l
l l
ll
ll
lll
ll
l
ll
ll
ll ll
llll
ll
ll
l
l
l
l
l
lll
l
l
ll
lll
ll
l
ll ll ll
ll ll
l ll
l
l
l
ll
ll
l
ll
ll
l
l
lll
lll
l
l
ll
ll
l
llll
l
ll
l
llll
l
l
ll
ll
lll
l
ll
l
ll
ll
ll
l lll
l
l
ll
l
ll
ll
ll
l
l
l
ll
ll
l l
ll
l
l
ll
ll
ll
l
ll
l
ll
ll
ll
ll
ll
ll
l
ll
l
−10 −5 0 5 10 15 20
−10
−5
0
5
10
15
PC1 (40.4 %)
PC
2 
(15
.3 
%)
B
l
ll
l
l
l
l
l l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l ll
l
l
l
l
l
l
l l
ll
l
l
l
l
l
l
l
ll
l
l
l
l l
l
l l l
l l
l l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
ll
l
l
ll
ll
l
lll
l
ll
l
ll
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
−10 −5 0 5 10 15 20
−10
−5
0
5
10
15
PC1 (40.7 %)
PC
2 
(15
.4 
%)
C
ll
l
l
l
l
l l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l ll
l
l
l
l
l
l
l l
ll
l
l
l
l
l
l
l
ll
l
l
l
l l
l
l l l
l l
l l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
ll
l
l
ll
ll
l
lll
l
ll
l
ll
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
−10 −5 0 5 10 15 20
−10
−5
0
5
10
15
PC1 (40.7 %)
PC
2 
(15
.4 
%)
D
l
l
l l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l lll
l
l
ll
l
l
l
ll
l
l
l
l
l l
l
ll
l
l
l
l
l
l
l
l
l
ll l
l
l
l
l l
l
l
l
l
l
l
l
ll
l l
l l
l
l
l l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l l
l
l
l
ll
l
l
l
ll
−10 −5 0 5 10 15
−15
−10
−5
0
5
10
PC1 (47.3 %)
PC
2 
(10
 %
)
E
Figure 4.1: Principle component analysis of gene expression data obtained from human hepatocytes
after incubation with 148 chemicals (green symbols) and 7 cytokines (red symbols). Data
of the high concentration and 24h incubation is shown. A. Overview of all samples and
replicates. The dark and light green symbols illustrate the controls and exposed samples,
respectively. B. Connecting lines between replicates illustrates the degree of variability.
C. Mean values of the replicates. D. Connecting lines between controls (dark green) and
corresponding compound exposed samples (light green). E. Subtraction of the controls
from the corresponding compound exposed samples.
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lower) in relation to the much larger control-treatment effect. Similar results are obtained for the
other concentration and time sets (see Figures C.4-C.6). Distances between control-treatment
pairs are visualized in Figure C.7 in the Appendix.
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Figure 4.2: Reproducibility between replicates. The left panel shows the frequency distribution of
the Euclidean distance between all pairs of replicates. The red line indicates the 5%
largest observed distances between replicates. The right panel shows the PCA plot with
connecting lines between the 5% largest observed distances, representing 14 (9.5%) of
the compounds tested in the 24h, high concentration subset. The variability of the worst
replicates is still relatively small in relation to the much larger compound effects shown
by connecting lines in Figure 4.1 D.
4.3 Number of deregulated genes
As a next step, the number of deregulated genes is calculated for all concentration and time
sets. This is shown in Figure 4.3. The barplots list the number of genes with at least 1.5-, 2.0-
and 3.0-fold expression change, separately for each test condition. All results are presented
cumulated. The barplot in the lower right-panel for the 24h, high concentration subset reveals that
the compound cycloheximide (CHX) is responsible for most of the gene expression alterations.
After incubation of CHX, 887 genes show a change of at least threefold, 2547 and 5124 genes of
at least 2.0- and 1.5-fold, respectively. Similar numbers are observed for downregulated genes.
In contrast, triazolam (TZM) causes, under the same test conditions, a change of at least 1.5-fold
in only 37 genes (6 up and 31 down) and in only one gene of at least twofold. As a whole,
Figure 4.3 shows that the number of induced genes differs strongly between compounds.
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While most of the compounds cause only very few gene expression alterations, only a small
number of compounds induce high fold changes. The number of induced genes increases with
increasing concentration and time of incubation. 48 compounds have been tested at all nine
test conditions, 11 of them have been characterized as weak compounds due to the fact that
they deregulate (twofold up or down compared to control) less than 20 genes in total across all
concentration and time sets.
In addition, an exclusivity analysis is performed for the up- and downregulated genes, meaning
that the 100 top-ranking genes with the highest fold change across all 148 compounds have been
assigned to the compound with the most extreme fold change. The same 100 genes were used
for the PCA plots in Figure 4.1. The analysis is performed for the up- and downregulated genes
separately. Figure 4.4 visualizes the results for the strongest upregulated genes and Figure C.9
in the Appendix shows the results for the corresponding downregulated genes. The dark and
light green bars highlight the absolute number of genes deregulated by the compound and the
number of genes which are deregulated twofold up or down compared to control, respectively.
The exclusivity analysis reveals that only a small fraction of compounds contribute to the 100
strongest deregulated genes. In case of the 24h, high concentration subset, for example, only 32
of the 148 compounds tested, causes upregulations and even fewer compounds (n = 23) induce
downregulations. The results strengthen the assumption that the majority of the compounds
induces only weak expression changes.
4.4 Concentration progression
As mentioned earlier, experimental errors cannot be fully avoided, but can be identified and
curated to some extent. It requires some curation steps to improve the data quality, the removal
of batch effects is the first step of many and forms the basis for further analyses. The detection of
batch effects is important as otherwise relevant mode of actions might remain undetected due to
strong batch effects. In the second and third step the data reproducibility across replicates and the
increase of gene deregulations across concentration and time sets is assessed. The next step in the
curation procedure is the identification of compounds which exhibit an implausible concentration
progress. For this, two indices, the progression profile index and the progression profile error
indicator, are introduced for the comparison of adjacent concentrations (Section 3.4).
The progression profile error indicator value is calculated for each compound and specifies the
proportion of additional genes at the next lower dose, i.e. the error indicator indicates the fraction
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of genes deregulated exclusively at a lower compared to a respective higher concentration,
resulting here in the comparison of the low versus middle and middle versus high concentration
for each of the three exposure periods 2h, 8h and 24h. Compounds that have been tested with
only two concentrations were excluded from the calculations.
The progression profile index which indicates the proportion of genes that are deregulated
exclusively at the next higher compared to the respective lower concentration, serves as additional
information. Genes are considered as deregulated if they exhibit a change in gene expression
of at least twofold. For the progression profile index high values are desirable, while low
values are more desirable for the progression profile error indicator. If the latter is the case, a
monotonous concentration progression from the low to the middle and from the middle to the
high concentration can be assumed.
But as false positive genes are almost unavoidable, the total number of deregulated genes
should not be disregarded when calculating the error indicator. If a certain number of non-
monotonous genes falls below a pre-specified level, then they should not be included in the
calculations of the the error indicator. In the present study, the threshold is set to 20, meaning
that in case of less than 20 deregulated genes the respective error indicator value is automatically
set to zero. This results in the modified progression profile error indices (Section 3.4).
The principle is illutrated in Figure 4.5, exemplified by the four compounds valproic acid
(VPA), propranolol (PPL), triazolam (TZM) and allyl alcohol (AA). The compounds were chosen
to illustrate specific cases. Figure 4.5 shows the results of the 24h, high concentration subset.
The left panel shows the individual expression profiles of the four compounds at the low, middle
and high concentration. The corresponding Venn diagrams which count the genes that are
upregulated twofold by the indicated compound are provided in the middle panel. The right
panel shows the plots for the respective profilers with the four compounds highlighted in green.
Each symbol represents an individual compound. Color coding indicates if more (black) or less
(grey) than 20 genes are deregulated by the indicated compound. The triangles represent the
compounds that will be later excluded from the analysis.
VPA shows a monotonous concentration progression and therefore yields a relatively high
value for the progression profile index for both concentration comparisons, low versus middle
and middle versus high. This positions the compound in the upper right corner of the progression
profile index plot. Similar values are obtained for the compound AA which clusters closely to
VPA. TZM, in contrast, induces genes only at the low but not at the next higher concentrations.
This places TZM in the lower left corner of the progression profile index plot.
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Figure 4.5: Concentration progression analysis. Principles of the progression profile index and the
progression profile error indicator illustrated for the four compounds: Valproic acid
(VPA), propranolol (PPL), triazolam (TZM) and allyl alcohol (AA). Only the upregulated
genes after 24h exposure are shown here. The left panel shows the levels of the individual
upregulated genes at three concentrations. The panel in the middle summarizes the
upregulated genes by Venn diagrams. The right panel shows the resulting positions of
the four compounds in the respective profile plots indicated in green.
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The progression profile error indices for the four compounds reveal that VPA, PPL and AA
yield relatively low values for at least one pair of adjacent concentrations. All three compounds
are located on the left-hand side of the progression profile error indicator plot and move up
along the y-axis. An exception is TZM which is located in the lower right corner of the plot,
indicating that genes that are upregulated with the low concentration are not upregulated with
the middle concentration. After adjusting for the number of altered genes, the compound AA
moves from the upper left to the lower left corner in the plot of the modified progression profile
error indicator. The relocation of the compound’s position indicates that the compound induces
in less than 20 genes a twofold change at the middle concentration.
The progression profile indices for all compounds are depicted in Figure 4.6. Rows indicate
the exposure period and columns the direction of deregulation. The majority of the compounds
cluster to the upper right corner of the plot, independently from time point and direction (up
or down). This indicates that the number of additional genes that are induced by the indicated
compounds increase with increasing concentration. Those compounds that cluster in the upper
left or lower right corner exhibit a distinct progression only from the low to the middle or the
middle to the high concentration, respectively. Weak compounds which cause no expression
changes are located in the lower left corner of the plot.
Figure 4.7 shows the corresponding plots for the progression profile error indices. Compounds
deregulating more than 20 genes and yielding an error indicator value above 0.5 for at least one
concentration comparison are marked in red. Basically, two main clusters can be observed for all
incubation time points. The majority of the compounds cluster to the left-hand side of the plot
indicating a plausible concentration progression from the low to the middle concentration. The
other compounds cluster to the right-hand side of the plot. This reflects the situation where a
high fraction of genes is deregulated exclusively at the low but not at the middle concentration.
Compounds that cluster in the lower or upper half of the plot indicate a plausible or implausible
progression, respectively, in the comparison of the high versus middle concentration. After
applying the modified progression profile error indicator to the compounds, almost all cluster to
the lower left corner of the plot indicating a plausible concentration progression (Figure C.10).
On the basis of the modified progression profile error indices a progression error profile is
defined for each compound which documents a compound’s concentration progression for each
time period. A profile is created for the up- and downregulated genes separately. For a detailed
description of how the profile is defined the reader is referred to Grinberg et al. (2014).
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Figure 4.6: Progression profile indices for all compounds tested at three concentrations (low, middle,
high) after three exposure periods (2h, 8h and 24h). A high value means that a high
fraction of genes is deregulated exclusively at a higher concentration compared to a
respective lower concentration. These calculations were performed comparing the low
versus the middle (x-axis) and the middle versus the high (y-axis) concentration. Each
symbol represents an individual compound. The triangles represent the later excluded
compounds. Black or grey symbols indicate that more than or less than (or equal to) 20
genes, respectively, are deregulated in total.
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Figure 4.7: Progression profile error indicator. A high value means that a high fraction of genes
is deregulated exclusively at a lower compared to a respective higher concentration.
Each symbol represents an individual compound. The triangles represent the excluded
compounds. Grey symbols indicate that less than or equal to 20 genes are deregulated in
total. Black symbols indicate that more than 20 genes are deregulated in total and both
values are smaller than or equal to 0.5. Red symbols indicate that more than 20 genes are
deregulated in total and that at least one of the error indicator values is greater than 0.5.
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The individual progression error profiles are used as tools for the identification of compounds
with a non-monotonous concentration progression. The application of the profiles leads to
the exclusion of five compounds (carbon tetrachloride (CCL4), doxorubicin (DOX), triazolam
(TZM), tetracycline (TC), ticlopidine (TCP)). Comparisons across all concentration and time
sets have been considered in the exclusion procedure and the combination of all indices have
contributed to the exclusion decision. The curated database serves as basis for all further analyses.
In general, only a fraction of the test compounds exhibits strong expression responses, while
most of the compounds induce low fold changes. In case of the 24h, high concentration subset,
for example, the top 32 (up) and 23 (down) compounds which contribute to the strongest
up- and downregulated genes, respectively, yield on average error indicator values below 0.5,
independently from the given time period. High error indices are obtained mainly for compounds
with weak expression patterns.
4.5 Stereotypic versus compound-specific gene
expression responses
The selection value principle is introduced to differentiate between stereotypical and compound-
specific responses (Section 3.4). The selection value specifies for a gene the minimum number
of compounds that induce an expression change. Mathematically, the compounds are ranked
in order of fold change, from high to low fold change (upregulation) or from low to high fold
change (downregulation), respectively, and then the compound with rank x determines selection
value x (Sv x). The lower the selection value, the more compound-specific the response, and in
contrast, the higher the selection value, the more stereotypical the response. Figure 4.8 gives
an overview of the observed selection values (Sv 1 to Sv 50) for all concentration and time sets.
The selection values are determined for fold changes of at least 1.5-, 2.0- and 3.0-fold. The
barplots list for each test condition the number of genes which are upregulated by at least one
(Sv 1), two (Sv 2), three (Sv 3),..., and fifty (Sv 50) compounds. The corresponding results for
the downregulated genes are shown in Figure C.11 in the Appendix. The number of genes that
show a change of at least 1.5-, 2.0- and 3.0-fold for at least one or more compounds increases
with increasing time- and concentration progression. The same progression is observed for the
downregulated genes. Most of the compounds induce high or low fold changes, respectively,
when tested close to cytotoxic concentrations and long incubation periods.
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As mentioned above, both response types are of interest, a compound-specific expression
response as well as a stereotypical one. While a stereotypical gene expression response is
observed for many compounds, a more specific response is only induced by a single or just
few compounds. To analyze stereotypical responses, a consensus list is defined including genes
influenced by at least 20 compounds (> threefold). These genes are referred to as Sv 20 genes. 20
compounds are considered as sufficient to represent a stereotypical expression pattern as previous
results have shown that only 32 of the test compounds induced strong expression responses,
while the rest induced only weak reactions. Individual responses are analyzed with Sv 3 genes.
Even though Sv 1 genes are more intuitive for studying compound-specific responses, Sv 3
genes are more reliable with respect to higher data stability. Due to the low replicate number
(n = 2) Sv 3 genes have a lower probability of containing false positive genes than Sv 1 genes.
Therefore, Sv 3 genes represent a good compromise between individuality and reliability.
Figure 4.9 gives an overview of the number of genes that are deregulated by at least 1, 3, 5
and 20 compounds. The Venn diagrams summarize the results for the comparison of adjacent
selection value genes for the 24h, high concentration subset. Rows differentiate between up- and
downregulation. The Sv 20 list compromises 31 up- and 179 downregulated genes. The number
increases to 531, 1101 and 4135 for Sv 5, Sv 3 and Sv 1 in case of the upregulated genes and to
857, 1713 and 4479, respectively, in case of the downregulated genes.
Figure 4.9: Overview of the numbers of the selection value genes Sv 1, Sv 3, Sv 5 and Sv 20. Red
and green color indicate up- and downregulation. For example 31 genes are upregulated
(> threefold) by at least 20 compounds (Sv 20).
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4.6 Unstable baseline genes
Genes that are altered solely due to the process of isolation and cultivation stress of cells are
called unstable baseline genes. These gene expression alterations occur independently from
compound exposure, simply as response to stress, and represent therefore a pure in vitro artefact.
The unstable baseline genes result from the comparison of primary human hepatocytes cultivated
in collagen sandwich (CS) for 1, 2, 3, 5, 7, 10 and 14 days (n = 19) and freshly isolated primary
human hepatocytes (n = 3). Genes showing a change of at least threefold at one or more time
points are considered as unstable.
It is quite possible that a set of genes is influenced by both, compound exposure and isolation
and cultivation stress, as seen in Figure 4.10, which shows the overlaps between the unstable
baseline genes (CS) and the Sv 3 and Sv 20 genes, respectively, for the 24h, high concentration
subset. 10% to 15% of both response groups, the stereotypical (Sv 20) and compound-specific
(Sv 3) alterations, are induced under both, chemical and stress exposure. These genes might give
rise to false-positive findings or cloud true findings as a consequence of opposing effects.
4.7 Further analyses
Apart from the presented analyses some further analyses were performed which are not discussed
here in detail. To address the question if genes exposed to chemicals in vitro respond similarly
to in vivo exposure, the Sv 20 genes were analyzed with respect to liver disease associated
genes. Therefore, the overlap between Sv 20 genes and genes differentially expressed in
human liver diseases, such as cirrhosis, hepatocellular cancer or non-alcoholic fatty liver disease
was analyzed. The latter data results from a publicly genome-wide data set of human liver
tissue. Approximately 20% of the stereotypical stress response genes showed an overlap with
liver disease genes. Moreover, the compounds were clustered with respect to genotoxicity,
human hepatotoxicity and BSEP inhibiting capacity. Unsupervised clustering of the 24h, high
concentration subset compounds resulted in three clusters that could be assigned to biological
motifs: proliferation, cytochrome P450 (CYP) and stress response (see Figure C.12 in the
Appendix).
Furthermore, GO group analysis was performed for the 31 up- and 179 downregulated
Sv 20 genes. Upregulation of stereotypical stress response genes was most associated with
xenobiotic metabolism and downregulation with cell cycle progression. GO analysis for the more
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Figure 4.10: Overlap between unstable baseline genes (CS) and the Sv 20 (Sv 3) genes. Red and
green color indicate up- and downregulation. For example, 4 of the 31 Sv 20 genes
belong to the unstable baseline genes, meaning that their expression levels are altered
by the hepatocyte isolation and cultivation procedure.
compound-specific expression responses (Sv 3 genes) revealed a wide spectrum of biological
motifs including more specific mechanisms.
All in all, the results have been documented in a toxicotranscriptomics directory which is
publicly available under http://wiki.toxbank.net/toxicogenomics-map/. The directory provides
for each probe set from the HG-U133 Plus 2.0 chip the following information: (1) Is the gene
threefold up- or downregulated, and if so, by how many and which compounds? For this purpose,
the selection value principle was introduced to answer the question if the change corresponds to
a stereotypical gene expression response or rather to a more specific expression response. (2)
Is the gene also deregulated in human liver disease? (3) Does the gene belong to a group of
unstable baseline genes, i.e. does isolation process and cultivation stress alone cause expression
alterations? Moreover, GO group analysis identified about 2000 genes that could be associated
with biological functions.
The directory offers a basis for the choice of candidate genes for biomarker evaluation. A
long-term goal is to identify biomarkers in in vitro systems for the prediction of toxicity in vivo.
5 Consensus gene signature of rat
hepatocytes tested in in vitro and in
in vivo test systems
The previous chapter has shown one should differentiate between certain concentration ranges:
(1) range of tolerance with no expression alterations and range of deregulation (2) with cytotoxic
effects and (3) without cytotoxic effects. Cytotoxic concentrations induce cell death events in
addition to expression changes. With respect to biomarker detection, it is important to identify
the range of concentration in which deregulations are observable. However, expression alter-
ations rarely occur individually, but rather in sets of highly correlated genes. The concentration-
dependent analyses of the Open TG-GATEs data set of cultivated human hepatocytes showed a
stereotypical expression response in a subset of genes which was induced by many compounds.
However, the direct comparison of chemically-induced genes between cultivated human hepa-
tocytes and human liver samples in vivo is ethically not justifiable. To investigate whether in
vitro deregulated genes respond similarly under conditions of in vivo exposure, rat data is used
for analysis. The following study targets the identification of consensus genes, which show a
comparable stress response in rat hepatocytes. Compound-specific gene alterations are analyzed
with respect to similar patterns in in vivo and in in vitro experiments. For this purpose, the NRW
and the TG-GATEs database (Sections 2.4.1 and 2.4.3), comprising gene expression data of rat
hepatocytes cultured in vitro and rat livers exposed in vivo, are used. In this chapter a guideline
for the identification of consensus genes is developed, evaluated and discussed.
5.1 Data structure of the NRW database
The NRW database includes Affymetrix files of cultured rat hepatocytes incubated with 30
compounds that have been tested in cultured rat hepatocytes and rat liver cells in vivo. In vitro a
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24h exposure period was tested using three concentrations (Low, Middle, High) and in vivo four
time periods using one concentration level were analyzed (1 day, 3 days, 7 days and 14 days).
For more details on the data the reader is referred to Section 2.4. Tables B.5-B.6 in the Appendix
provide a compound-specific overview of the test compounds.
To display the transcriptome data structure across in vivo and in vitro samples a principle
component analysis for all concentration and time sets was performed, based on the 100 probe
sets with the highest variance across all samples. Figure 5.1 shows the corresponding plot of
the first two principal components which results in two main clusters. The two clusters are
separated by the first component - the in vitro samples cluster to the left and move along the
second principal component, and, the in vivo samples cluster to the right-hand side of the plot.
These results confirm the findings of Schug et al. (2013) who have shown that genes deregulated
by compound exposure in vitro respond differently under conditions of in vivo exposure.
Moreover, the PCA plot shows that the cluster of in vitro samples is subdivided into several
sub-clusters, the in vivo samples cluster closely together with the exposed samples to the right
of the controls. In contrast, the in vitro data shows no distinct separation between compound
exposed samples and controls. Merely, the samples at the beginning of the incubation period
(T0) cluster clearly apart from the samples that were tested after 24h of incubation. This
underlines that expression alterations already occur when hepatocytes are solely isolated and
cultivated (Grinberg et al., 2014).
To assess the data quality of the NRW database the two test systems were analyzed separately
with respect to batch effects, reproducibility across replicates and implausible concentration
progressions. For this, the pipeline introduced in Chapter 4 was applied to curate the NRW
database. To understand the data structure, a PCA analysis has been performed separately for
each concentration and time set. Figure 5.2 shows for the data of the in vitro experiments the
PCA plot for the low, middle and high concentration set. Figure 5.3 illustrates the structure of
the in vivo data for the time points 1 day, 3 days, 7 days and 14 days. Columns refer to the
individual test conditions and rows to the different analysis steps. Panel A provides an overview
of all samples tested at the indicated condition. Panel B illustrates the degree of variability
by connecting lines between triplicates. In vivo, the distances between sample triplicates is
relatively small in comparison to the distances between the corresponding sample triplicates
in vitro which exhibit a much higher variability. To quantify the data variability, the Euclidean
distances between all pairs of triplicates were calculated and illustrated in Figure 5.4. The
distances vary among the in vitro experiments much more than among the in vivo experiments.
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Figure 5.1: Principle component analysis of gene expression data obtained from cultured rat primary
hepatocytes (in vitro) and from rat liver samples (in vivo) after incubation with 29 (in
vitro) and 30 (in vivo) chemicals. The PCA plot is based on the 100 probe sets with
highest variance across all samples and was generated to display the transcriptome data
structure across in vivo and in vitro replicates. Each point represents one experiment. In
vitro hepatocytes were harvested at the beginning of the exposure period and 24h later
after exposure to the test compounds (exposed) or solvent (controls).
Compounds with distances outside the tolerated variability range, which is determined by the
95%-quantile of the distribution, have been classified as outlier candidates. In vitro, up to three
triplicate sample pairs exceed the cutoff of the 5% largest observed distances. In vivo, at each
incubation time point, two compound exposed triplicate pairs have been identified as outliers,
whereas all control triplicate-distances lie within the tolerance range.
For simplicity, mean values of the triplicates were calculated (Figures 5.2 C and 5.3 C,
respectively). Connecting lines between controls and corresponding compound exposed samples
(panel D) shows that the compound effects are larger in vivo than in vitro. In the last step,
controls were subtracted from the corresponding compound exposed samples (panel E). Panel E
shows that the above described clusters have been removed by this procedure. As shown before
(Chapter 4), simple control subtraction is sufficient to remove batch effects.
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Figure 5.2: NRW (in vitro): Data of the low, middle and high concentration and the incubation
time point 24h. A. Overview of all samples and replicates. The dark and light green
symbols illustrate the controls and exposed samples, respectively. B. Connecting lines
between replicates illustrates the degree of variability. C. Mean values of the replicates.
D. Connecting lines between controls (dark green) and corresponding compound exposed
samples (light green). E. Subtraction of the controls from the corresponding compound
exposed samples.
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Figure 5.3: NRW (in vivo): Data of the incubation time points 1 day, 3 days, 7 days and 14 days.
A. Overview of all samples and replicates. The dark and light orange symbols illustrate
the controls and exposed samples, respectively. B. Connecting lines between replicates
illustrates the degree of variability. C. Mean values of the replicates. D. Connecting
lines between controls (dark orange) and corresponding compound exposed samples
(light orange). E. Subtraction of the controls from the corresponding compound exposed
samples.
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In vitro, the experiments were organised in 6-well-dishes, i.e. 3-wells were incubated with
the test compound and 3-wells were used as controls. For this reason, 6-well dish-matched
controls were subtracted. In contrast, control subtraction in vivo proved to be more challenging.
As the treatment of animals was performed in different experimental series, this factor might
be, besides the factor exposure period, decisive in the context of batch removal. To decide how
to subtract controls, an analysis of variance (ANOVA) with two main effects was performed to
test whether the model parameters experimental series and exposure period have an influence
on gene expression. The analysis was performed gene-wise. The resulting p-values for the two
model parameters are shown in the frequency distribution in Figure C.13 in the Appendix. The
smaller the p-value, the stronger is the influence of the model parameter. Since most of the genes
yield p-values around zero, both parameters should be considered in the process of subtraction.
Therefore, experimental series- and exposure period-matched controls were subtracted from the
corresponding treated samples.
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Figure 5.4: Reproducibility between replicates. Boxplots of the Euclidean distance between all pairs
of triplicates for all test conditions. The grey and the green points illustrate the distances
between the control and compound replicate samples, respectively.
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The control-subtracted expression values (log2-fold changes) serve as base data for all further
analyses. To obtain an overview of the underlying compound effects, the number of gene dereg-
ulations induced by compounds was counted. Changes of at least 1.5-, 2.0- and 3.0-fold were
reported separately for each test system and condition. The barplots in Figure 5.5 and Figure 5.6
summarize the cumulated results for the in vitro test system and for the in vivo experiments,
respectively. The upper and lower panels of the figures refer to the up- and downregulated genes,
respectively. In vitro, the number of induced genes has increased concentration-dependent with
most of the genes being deregulated at the highest tested concentration. However, it should be
noted, that 8 of 29 compounds (27.5%) have induced only low fold changes (< 1.5-fold). Due to
weak expression changes, these compounds have been characterized as low profile compounds.
This group of compounds deregulates less than 30 genes in total. The exclusivity analysis in
Figure 5.7 confirms the aforementioned results. It has identified the 100 strongest deregulated
genes across all compounds (top-ranking genes with the highest/lowest fold change values)
and has assigned each of them to the compound with the most extreme fold change. These
compounds are match-winners per gene. Low profile compounds are scored with little to no
genes in the exclusivity analysis. In contrast, the in vivo data has shown no clear relationship
between exposure period and number of gene deregulations (Figure 5.6). Four of 30 compounds
(13.3%) have induced less than 15 genes in vivo (> 1.5 with adjusted p ≤ 0.01) and have been
consequently classified as low profile compounds. In the exclusivity analysis in Figure 5.8 these
compounds have scores not higher than one. Together, the in vitro and in vivo experiments
comprise 11 low profile compounds (AA, Aap, AfB1, CFX, DCB, ETH, MDA, Mcarb, Nif, Praz,
Prop). The cut-off criterion for being named low profile compound depends on the size of the
used chip, which includes in case of the in vitro experiments 31 099 probe sets and in case of the
liver samples 15 923 probe sets. The minimum number of deregulated genes, 30 in vitro and 15
in vivo, represents approximately 1% of the measured probe sets in total.
The results of the foregoing analyses have shown that the data reliability of the in vivo
experiments is much higher than the reliability of the in vitro experiments (Figures 5.2-5.4). For
this reason, the in vivo data are considered the gold standard to which the in vitro results are
compared to. But before a direct comparison of differentially expressed genes is performed
between the two test systems, the in vitro data is further analyzed under the particular aspect of
data plausibility. To do so, a concentration-dependent analysis of gene alterations is performed.
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The results are illustrated by Venn diagrams, which show the overlap between the low, middle
and high concentration. The concept is demonstrated for four examples in Figure 5.9. Genes
with a fold change of at least 1.5 and a false discovery rate (FDR) adjusted p-value smaller than
0.01 are considered differentially expressed. Orange and green colored Venn diagrams count
significantly up- and downregulated genes. 2-NF and CFX represent compounds with a plausible
concentration progression, where with each concentration step the number of additional genes
increases. The compound AIAI exemplifies another frequently observed constellation: For such
a compound, genes are only deregulated with the highest tested concentration. An implausible
concentration progression can be observed for DEHA, where genes are up- or downregulated
with the middle, but not with the low or high concentration. Such non-monotonous concentration
progressions may be indicative of experimental errors or sample mix-ups. Due to such limitations
imposed by the quality of the used data, the selection value principle, which assigns each gene the
number of compounds that up- or downregulate this gene after exposure, has been introduced in
Chapter 4. Therein, the use of selection value 3 genes (Sv 3) is recommended for the assessment
of compound-specific responses in order to ensure a higher data stability.
The Venn diagrams for all compounds are given in the Appendix. The Venn diagrams for
the concentration-dependent cultivation experiments are provided in Figure C.24. Those for
the time-dependent in vivo experiments are shown in Figure C.25. Since four time points were
measured in vivo, pairwise comparisons of adjacent time periods have been performed for the in
vivo experiments.
The selection value analysis in Figure 5.10 provides selection values in the range from 1 to 15
indicating that at most 15 compounds have induced gene alterations. 15 compounds represent
a relatively large fraction, because only 19 compounds belong to the group of high profile
compounds (deregulating more than 15 or 30 genes in vivo or in vitro, respectively). But the
number of deregulated genes decreases enormously from the selection value 6 on. The number
of Sv 3 genes varies between 200 and 500 genes for the two test systems.
5.2 Consensus signature
Since it is of high interest to figure out whether a gene chemically-induced in in vitro is also
induced in in vivo, a comparative analysis of genes differentially expressed in both test systems
is performed. For this purpose, the overlap between differentially expressed liver genes and
chemically deregulated genes in vitro is analyzed. To enable a direct comparison of genes
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Figure 5.9: Concentration dependency in the NRW in vitro database. Only representative examples
are shown (all compounds are shown in Figure C.24 in the Appendix). Orange colored
Venn diagrams show the overlap between genes that are upregulated at the low, middle
and high concentrations (> 1.5-fold with adjusted p≤ 0.01); green colored Venn diagrams
summarize the downregulated genes (< 23 -fold with adjusted p ≤ 0.01).
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Figure 5.10: Selection values for the up- and downregulated genes. The upper panel shows the
results for the in vitro experiments and the lower panel shows the results for the rat liver
samples. A selection value of e.g. three means that at least three compounds up- or
downregulate the indicated gene (> 1.5-fold with adjusted p ≤ 0.01).
between both test systems, which were analyzed on different chips, the analysis is restricted to
those genes that have been measured on the rae230a-GeneChip, which was used for the in vivo
experiments. This results in 10 044 genes for the NRW database. To improve the robustness of
the results, the analysis is performed on the basis of Sv 3 genes. First, a consensus signature of
Sv 3 genes is compiled for the in vitro and in vivo experiments. The consensus Sv 3 list combines
the Sv 3 gene lists of the individual test conditions which have been predefined for the in vitro
concentrations and in vivo time points. That means, the in vitro Sv 3 consensus list comprises the
genes that have been up- or downregulated by at least three compounds after exposure with a low,
middle or high concentration. The in vivo Sv 3 consensus list summerizes those genes that have
been deregulated by at least three compounds after 1 day, 3 days, 7 days or 14 days of exposure.
For generating the lists, the fold change cut-off was set to 1.5 and the p-value cut-off to 0.01 after
false discovery adjustment for multiple testing. This results in 369 up- and 1072 downregulated
consensus genes for the in vitro experiments and in 354 up- and 326 downregulated consensus
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genes for the in vivo experiments. The overlap covers 77 up- and 98 downregulated genes (see
Figure 5.11). The genes in overlap are further named consensus Sv 3 NRW genes. To quantify
to which degree genes in the in vitro-in vivo overlap are overrepresented, the overlap ratio is
calculated (see Section 3.4). The principle of the overlap ratio is illustrated in Figure 5.11 (upper
left panel). An overlap ratio of 1.0 corresponds to a randomly expected overlap. The overlap ratio
for the upregulated genes is 5.9 (p < 0.001) indicating that 5.9-fold more genes are in the overlap
than randomly expected. The downregulated genes yield an overlap ratio of 2.8 (p < 0.001).
The p-values result from the Fisher’s exact test. Even though the overlap is larger then expected
under stochastic independence, a relatively high fraction of genes is test system-specific.
Fig. 9
Key question Answer Formula
How strongly are in vitro genes (over)-
represented amongst in vivo genes? Overlap ratio
Is there a significant overlap of in vitro
and in vivo genes? Fischer’s exact test
*<0.05
**<0.01
***<0.001
O ∗ n(Gene universe)n(In vitro) ∗ n(In vivo)
5.921 = 77 ∗ 10044354 ∗ 369 2.817 = 98 ∗ 100441072 ∗ 326
Example of calculation of
Overlap ratio:
n(In vitro) n(In vivo)O
Remaining genesOverlap ratio
Figure 5.11: Overlap of genes deregulated by the same compounds in in vitro and in in vivo. The
Venn diagram in the upper left panel illustrates the principle of the overlap ratio. The
lower panels show the overlap between the in vitro and in vivo consensus Sv 3 genes
for the NRW data set. The overlap ratio is calculated by the formula given in the table
in the upper right panel.
Figure 5.12 illustrates for the 77 up- and 98 downregulated consensus Sv 3 NRW genes the
corresponding overall selection values (upper and lower panel). The overall selection value
provides for a gene the number of compounds that deregulate this gene under at least one of the
test conditions (repeatedly occurring compounds are counted only once).
5.2 Consensus signature 75
Aldh1a1
Ephx1
Akr7a3
Cdkn1a
Phlda3
Ugt2b1
Ccng1
Mdm2
Nqo1
Cyp1a1
Cyp3a23/3a1
Decr1
Gdf15
Nhej1
Acaa2
Acat1
Acot4
Atp6v1d
Cks2
Ech1
LOC100912446
Plk2
Pln
Skap2
Slc17a3
Stmn1
Acsl3
Aig1
Casp3
Crat
Cyp1a2
Cyp4a3
Ehhadh
Gclc
Gstp1
Ifrd1
Msmo1
Pex11a
Tfrc
Tmem120a
Tubb5
Angptl4
Asns
Elovl6
Fkbp11
G6pd
Gadd45a
Gpnmb
Ifitm1
Lgals3
Mcm6
Mgmt
Nr1d2
Odc1
Plin2
Psat1
Snrpa1
Timm9
Tubb6
Acat2
Ccl6
Cyp51
Fgf21
Gsta4
Hn1
Idi1
LOC100360017
Lyz2
Nr0b2
Nxt1
Pcna
Rpa2
Rsad2
Stk24
Tuba4a
Tyms
Uchl3
024681012141618202224262830
Number of Compounds
Co
ns
en
su
s 
Sv
 3
 g
en
es
Un
iq
ue
O
ve
rla
p
In
 v
ivo
In
 v
itr
o
Up
Gls2
RT1−S3
Aass
Cited2
Acss2
Dpyd
Rprm
Slc16a10
Cth
Cyp4f4
Cyp4v3
Dmgdh
Gnmt
Got1
Mlc1
Nrbp2
Ptger3
Ang
Anp32a
Apol9a
Ass1
Atrn
C1r
C1s
Car5a
Cbs
Ces1d
Cps1
Cyb5r3
Cyp2j3
Cyp4f1
Egr1
Eif4ebp3
Fga
Hacl1
Hal
Lgals9
Myo1d
Nr3c1
Phyh
Pkdcc
Rnase4
RT1−Da
Sepp1
Slc25a25
Slc37a4
Acly
Acmsd
Acy3
Adck3
Adora2b
Alcam
Angptl4
Bbox1
Bmf
Ceacam1
Clec4f
Col18a1
Egfr
F10
Fmo3
Gldc
Gpam
Hnrnpa2b1
Kng2
Lima1
LOC100910885
LOC100912411
Mafb
Nt5e
Papss2
Per2
Polg2
Ptprf
RGD1564614
Sdc1
Sgk1
Sult1a1
Xdh
Zfp189
Acaca
Apoc4
Clcn4
Cldn2
Cyp7a1
Dao
Dixdc1
Echdc3
Epb4.1
Kynu
LOC100912446
Ogt
Pc
Rcan2
Slc31a1
Smoc1
Tnfsf13
Ugp2
02468101214161820
G
en
es
Number of Compounds
Co
ns
en
su
s 
Sv
 3
 g
en
es
Un
iq
ue
O
ve
rla
p
In
 v
ivo
In
 v
itr
o
Down
Fi
gu
re
5.
12
:N
R
W
:O
ve
ra
ll
se
le
ct
io
n
va
lu
es
of
th
e
co
ns
en
su
s
Sv
3
N
R
W
ge
ne
s
(g
en
es
th
at
ar
e
de
re
gu
la
te
d
by
at
le
as
tt
hr
ee
co
m
po
un
ds
in
bo
th
te
st
sy
st
em
s,
in
vi
tr
o
an
d
in
vi
vo
,f
or
at
le
as
to
ne
te
st
co
nd
iti
on
).
C
om
po
un
ds
ar
e
co
un
te
d
on
ce
.T
he
up
pe
rp
an
el
sh
ow
s
th
e
ba
rp
lo
ts
fo
rt
he
77
up
re
gu
la
te
d
co
ns
en
su
s
ge
ne
s
an
d
th
e
lo
w
er
pa
ne
lt
he
co
rr
es
po
nd
in
g
on
es
fo
rt
he
98
do
w
nr
eg
ul
at
ed
co
ns
en
su
s
ge
ne
s.
Th
e
sh
ad
ed
ba
rp
lo
ts
in
di
ca
te
th
e
nu
m
be
r
of
in
di
vi
du
al
in
vi
tr
o
an
d
in
vi
vo
co
m
po
un
ds
an
d
th
e
fu
lly
co
lo
re
d
ba
rp
lo
ts
in
di
ca
te
th
e
nu
m
be
ro
fc
om
m
on
co
m
po
un
ds
.
76 5 Consensus gene signature of rat hepatocytes tested in in vitro and in in vivo test systems
Figure 5.12 shows both, the number of compounds common to both test systems and the
number of compounds specific for the two test systems. Genes are ordered by their relevance
with respect to their selection value in order to find a subset of as few genes as necessary to
depict a compound sensitivity as large as possible. Up to nine compounds could be identified
that induce common gene alterations in vitro and in vivo.
In contrast, Figure 5.13 represents the number of genes for the 30 test compounds that are
induced by these compounds under at least one of the test conditions, whereas the analysis is
restricted to the consensus Sv 3 NRW genes. If a gene is deregulated under several conditions, the
gene is counted only once. Both common and distinct gene deregulations are shown. Compounds
are listed alphabetically on the x-axis.
5.3 Data structure of the TG-GATEs database
To validate the results of the NRW database, another data set is analyzed, the TG-GATEs data
set which compiles Affymetrix files of rat liver cells tested in vivo and in vitro. For the in
vitro data, liver tissue was used to isolate and cultivate primary rat hepatocytes for 2h, 8h and
24h. The cultured rat hepatocytes were tested with several compounds (up to 145 compounds
depending on the test condition) using a low, middle and high concentration. For the in vivo data
rat liver samples were used and sacrificed after 3h, 6h, 24h, 4 days, 8 days, 15 days and 29 days
after exposure. Up to 155 compounds (depending on the test condition) were tested with three
different concentration levels. For the analysis only subsets of the test conditions are used (i.e.
particular combinations of concentration and time sets). In vitro, only the data of the low (145
compounds), middle (140 compounds) and high concentration (138 compounds) after 24h of
incubation is used, and, in vivo only the highest tested concentration after 24h of exposure is
investigated. All other test conditions are excluded from the analysis due to non-removable batch
effects.
The structure and quality of the data is assessed along the curation pipeline which was
introduced in Chapter 4. An overview of all cultivated hepatocytes is given in Figure C.14 and of
all hepatocytes in liver in Figure C.15 (Appendix). PCA analysis has been performed, based on
the 100 probe sets with highest variance across all compounds, to visualize the in vitro and in
vivo response to chemicals. Figures C.16-C.18 in the Appendix illustrate the number of altered
genes for the concentration-dependent in vitro experiments. Changes of at least 1.5-, 2.0- and
3.0-fold have been counted. Figure C.19 in the Appendix shows the corresponding barplots for
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the in vivo data. The analysis reveals that a relatively high fraction of compounds induce only
low fold changes. The exclusivity analysis shows that only a few compounds contribute to the
100 strongest genes, while most of the compounds have no effect (see Figures C.20-C.23 in
Appendix). The fact that the in vitro experiments were tested with only two replicates limits
the validity of statistical tests. Therefore genes are considered differentially expressed when
the mean difference to controls is at least threefold. The liver hepatocytes, on the contrary,
were tested with three replicates which enables the detection of gene alterations by means of
hypothesis testing. For this, the Limma t-test is applied. The p-values are adjusted for multiple
testing by controlling the false discovery rate (FDR) according to the Benjamini-Hochberg (BH)
procedure. Changes of at least threefold with adjusted p-value smaller than 0.01 are defined as
significantly deregulated. Selection values between 1 and 60 are observed for the in vitro and in
vivo subsets (see Figures C.26-C.27 in Appendix). In comparison to the reactions in vitro less
compound effects are seen in vivo.
Similar to the NRW data set, the selection value concept has been applied to the TG-GATEs
database to identify compound-specific gene inductions. For the aforementioned reasons (more
reliable results), a consensus signature consisting of Sv 3 genes is compiled for the in vitro
and in vivo comparisons. Figure 5.14 (upper panel) reveals that the consensus Sv 3 in vitro
list comprises 574 up- and 1210 downregulated genes (across all concentration subsets) and
the consensus Sv 3 in vivo list for the 24h, high concentration subset summarizes those genes
which have been induced by at least three compounds (513 up, 414 down). The overlap of the
consensus Sv 3 genes between the in vitro and in vivo test systems is 140 (up) and 186 (down),
respectively. Hereinafter these genes are referred to as consensus Sv 3 TGD genes. Figure C.28
in the Appendix summarizes the corresponding overall selection values for the consensus Sv 3
TGD genes, i.e. compound inductions across all test conditions are counted. For the compounds
studied in the TGD database, Figure C.29 (Appendix) provides an overview of the number of
consensus Sv 3 TGD genes which are altered by them.
Furthermore, the overlap between the NRW and TGD database is analyzed with respect to
similar expression patterns. The Venn diagrams in Figure 5.14 (lower panel) count 23 up- and 22
downregulated genes, respectively, in the overlap. This corresponds to 29.8% (22.4%) of the
consensus Sv 3 NRW genes. The corresponding overlap ratios indicate a relatively high degree of
consensus between the two databases, even though only five compounds are common in both
data sets.
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Figure 5.14: Overlap between the in vitro and in vivo consensus Sv 3 genes. Rows indicate the
data set and columns indicate the direction of deregulation. The upper panel shows the
overlap within the TGD data set and the lower panel shows the overlap between the
TGD and NRW data set. The left-hand panel demonstrates the Venn diagrams for the
upregulated genes (NRW: > 1.5-fold with adjusted p ≤ 0.01 and TGD: > threefold) and
the right-hand panel illustrates the Venn diagrams for the downregulated genes.
The consensus Sv 3 genes of the NRW-TGD overlap (Figure 5.14) is further used for the in
vivo biomarker identification. The particular goal is to identify the smallest possible number of
genes, which, in combination, respond to as many test compounds as possible. The in vitro-in
vivo overlap of these genes indicates that the involved mechanisms are not pure in vitro artifacts.
The consensus genes are ranked in order of selection value, i.e. the gene with the highest selection
value is ranked first. The following genes are determined recursively to the previous ones such
that as many as possible individual compounds are covered cumulatively by the selected genes.
If no new compounds are added with further genes, the curve of covered compounds is saturated.
Figure 5.15 demonstrates such a cumulative curve for the NRW data set (upper panel). The
x-axis lists the number of biomarker genes and the y-axis lists the absolute number of covered
compounds. Aldh1a1, for example, is upregulated by nine compounds. Including the gene Gdf15,
four further compounds are covered in addition to the current ones, resulting in 13 covered
compounds in total. Five consensus genes are required to reach the saturation point of the curve.
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Figure 5.15: Plot showing the cumulative percentage of covered compounds in the NRW (upper
panel) and the TGD (lower panel) data set. Indicated genes represent biomarker genes
which are induced in both, the in vitro and in vivo data set, by most of the compounds
(same compounds). Biomarkers result from ranking the consensus Sv 3 NRW or TGD
genes, respectively, in order of selection value. Orange and green color indicate the up-
and downregulated biomarker genes, respectively.
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The lower panel of Figure 5.15 shows the subset of up- and downregulated biomarkers that
cover, in combination, 29 and 10 compounds, respectively, which correspond to 17.5% and 6.1%
of the compounds studied in the TGD data set (n = 165). It can be noted, that from the fourth
biomarker on only one compound per gene is added to the ones covered already. In case of
the downregulated biomarker genes this single-wise compound increase can be observed from
the first gene onwards. At this point it is worth mentioning, that a relatively high fraction of
compounds, 151 of 165, induce no or only very few genes and are therefore classified as low
profile compounds.
In combination, the NRW and TGD data set comprise 189 compounds of which 160 (84.6%)
are low profile compounds. The curve showing the number of covered compounds in the
combined database is given in Figure 5.16. Saturation is achieved with 11 biomarker genes.
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Figure 5.16: Plot showing the cumulative percentage of covered compounds in both data sets com-
bined, the NRW and TGD data set. Indicated genes represent biomarker genes which
are induced in both the in vitro and in vivo combined data set by most of the compounds
(same compounds). Biomarkers result from ranking the consensus Sv 3 genes from
both data sets in order of selection value. Orange and green color indicate the up-and
downregulated biomarker genes, respectively.
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The first five upregulated genes (Cyp1a1, Ugt2b1, Ehhadh, Cdkn1a, Mdm2) cumulatively
contribute most to the covered compounds. They cover 39 of 189 compounds, i.e. 20.8% of all
compounds, while each of the next six genes adds only one new compound. A similar coverage
increase can be observed for the downregulated genes, where only the first four genes (Dpyd,
Cited2, Cyp4f4, Cth) add more than one new compound to the already existing compounds.
Cumulatively, the up- and downregulated biomarker genes cover 23.8% and 11.6% of the
compounds, respectively, such that 76.2% and 88.4% of the compounds remain uncovered, of
which 71.4% and 82.0%, respectively, belong to low profile compounds anyway. Considering
the fact that with the exception of five mutual compounds, predominantly different compounds
were tested in the NRW and TGD data set, the coverage of compounds is relatively high since
only 4.8% (up) and 6.4% (down) of the high profile compounds remain uncovered.
The overall design of the foregoing analysis is summarized in Figure 5.17. In summary, the
analysis targeted the question, if a set of genes can be identified which responds similarly in vitro
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Figure 5.17: Overview of the study design and the analytical procedure for the in vivo biomarker
identification.
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and in vivo after chemical induction. To approach this question, two independent data sets, the
NRW and TGD databases, were analyzed with respect to a consensus response of rat hepatocytes
exposed to 189 different compounds. Database-specific consensus gene lists for the in vitro-in
vivo comparison, based on the Sv 3 concept, were compiled and examined in terms of overlaps.
11 biomarker genes covering in combination 45 up- and 22 downregulating compounds were
identified.
6 Statistical analysis of
dose-expression data
In this chapter, in contrast to the two previous ones where a classical method was used for the
detection of alert concentrations, an alternative model-based approach is proposed. In Chapters 4
and 5 only few treatment conditions were tested, usually three concentrations or time points.
Due to the limited number of measurements, differential expression analysis was performed
condition-wise, such that the dose-response relationship across different concentration or time
points was completely neglected. That means in particular, that for each test condition separately,
it was tested if the critical effect level was exceeded. Then an overlap analysis of deregulated
genes between adjacent condition levels was performed. In this chapter a concentration or time
series with more than three measurements is considered. Given these conditions, a regression
approach for the modeling of gene expression data can be used. The model-based approach fits
parametric models for repeated treatment-dependent gene responses using fold changes as a
measure of the association. The model is then used to derive an estimate of the concentration
(effective dose) that corresponds to a pre-specified effect level (response). Uncertainties of
the estimates are indicated by 95%-confidence intervals. This chapter presents the results of
a comparative analysis of two estimation methods which are used for the detection of critical
compound concentrations. The analysis is performed on both simulated and real experimental
dose-response data. All analyses are based on the assumption that the data exhibits a sigmoidal
relationship between dose and response and, hence, the four parameter log-logistic (4pLL) model
is an adequate approximation of the data.
6.1 Simulation study and setup
The simulation study was performed to evaluate and compare the 4pLL model approach with the
classical naïve Limma approach with respect to their estimated alert concentrations. The data was
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simulated to estimate a) the Absolute Lowest (Observed) Effective Concentration (AL(O)EC)
at which the effect level of interest is reached exactly or exceeded by the average value and b)
the Lowest (Observed) Effective Concentration (L(O)EC) at which the effect level is exceeded
significantly. The two estimates in case a) result from a simple point estimator, while those in
case b) take the uncertainty of the respective effect levels into consideration (CI-based estimates).
In the following, the two point estimates (ALEC vs. ALOEC) and the two CI-based estimates
(LEC vs. LOEC) are compared with each other. The respective alert concentrations are estimated
according to the methods in the Sections 3.3 and 3.5. For an overview of the four estimates the
reader is referred to Table 3.1. The critical effect level λ was set to a fold change value of 1.5.
Simulation setup
The setup of the simulation study matches the experimental design of the real VPA chronic
dose-response study which was introduced in Section 2.4. The measured concentrations are
0, 25, 150, 350, 450, 550, 800 and 1000 µM where the concentration 0 refers to the control
values. For each concentration, three replicate experiments were performed.
Simulated dose-expression data was generated from the 4pLL model function (3.10) in
Section 3.5. Different gene expression profiles were simulated by fitting 4pLL models with
various parameter sets. From the set of possible gene expression patterns four patterns were
selected for the simulation study. The four expression profiles were chosen such that four
different scenarios were covered by the chosen curve progressions. In the simulation study only
increasing dose-response relations were considered, i.e. the lower limit φ(c) was set to zero in
all four scenarios. The results obtained for increasing curve progressions are transferable to
decreasing curve progressions by changing the sign of the log-fold change values from positive
to negative. Hence, increasing curve progressions represent upregulated gene expression profiles
and decreasing curves represent downregulated expression profiles. The following four scenarios
were analyzed:
Scenario I: The true parameters were set to φ(b) = −4, φ(c) = 0, φ(d) = 0.58, φ(e) = 200 such
that the fitted curve never exceeds the threshold log2(1.5) = 0.585. Since the given threshold is
not exceeded, the ALEC value cannot be calculated.
Scenario II: The true ALEC is equal to 500 µM. In this scenario the parameters were chosen
such that the fitted curve clearly exceeds the given threshold and the upper limit of the curve is
not reached. The parameters were set to φ(b) = −3, φ(c) = 0, φ(d) = 4, φ(e) = 900.
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Scenario III: The scenario represents the case where a saturated sigmoid curve is given and
the true ALEC value coincides with a measured concentration level, here 550 µM. The true
parameters were set to φ(b) = −5, φ(c) = 0, φ(d) = 1.5, φ(e) = 600.
Scenario IV: The scenario is characterized by a S-shaped curve with an upper asymptote
close to the given threshold. The ALEC is equal to 680 µM, which is between two measured
values. The scenario represents a compromise between the two curves fitted in Scenario I and II.
Thus, the parameter values were set to φ(b) = −5, φ(c) = 0, φ(d) = 0.9 and φ(e) = 600.
The four simulated scenarios are illustrated in Figure 6.1. The true parameters were used to
calculate the true ALEC value and to generate simulated data. For each concentration level k
response points were generated which were assumed to be normally distributed with a mean
equal to f(xi,φ) and a standard deviation equal to a given value σi, i = 1, . . . , 8, where i
indicates the ith-concentration. Let ysimij , i = 1, . . . , 8, and, j = 1, . . . , k, denote the simulated
expression value of concentration i and replicate j, then ysimij ∼ N (f(xi,φ), σ2i ), where f(xi,φ)
corresponds to the true 4pLL model which was determined by the pre-specified parameters
φ(b), φ(c), φ(d) and φ(e) of the given scenario. The standard deviations between the simulated
replicates were obtained from the respective standard deviations in the real data set. They were
calculated from the VPA chronic concentration study (real data example) gene-wise and for each
concentration separately, i.e. the values for σi, i = 1, . . . , 8, were chosen equal to the empirical
standard deviations of the eight triplicate pairs of the gene which was randomly selected from
the set of all measured genes (54 675 in total).
For each scenario 1000 expression profiles with k, k ∈ {3, 6, 10}, replicates per concentration
were generated. The Limma method used the information of all 1000 genes for the empirical
Bayes adjustment of the gene-wise variance estimates. The simulation study with k = 3 replicates
was carried out to reflect the realistic data example. To evaluate, if the sample size has an effect
on the model performance of the applied methods, the number of replicates per concentration
was increased from 3 to 6 to 10 replicates. The two methods were evaluated with respect to their
estimate accuracy. The estimated alert concentrations of the two methods were compared in
terms of their total number of alerts (n), median (Med), interquartile range (IQR) and standard
deviation (SD), as well as their deviation from the true alert concentration. Distributions of the
estimated alert concentrations are shown. In addition, 95%-confidence intervals (CIs) for the
ALEC estimators were calculated (according to formula (3.12) in Section 3.5.3) and compared
regarding their lengths and coverage probability. The term false positive alert is used in cases in
which the estimated concentration value is below the true ALEC value.
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Figure 6.1: Illustration of Scenarios I-IV: The green curves represent the true expression profiles
fitted from the 4pLL model. Dashed lines indicate the critical effect level λ (red) and its
true ALEC value (blue).
6.2 Results of the simulation study
6.2.1 Comparison of the distributions
Figure 6.2 shows the distributions of the estimated alert concentrations for the four simulated
scenarios. Rows indicate the scenario and columns the method of estimation. The histograms
in the left panel of the figure show the distributions of the estimated ALECs (4pLL). The
distributions of the ALOEC estimators (Limma) are displayed by the barplots in the right panel
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Figure 6.2: Distributions of the estimated alert concentrations for Scenarios I-IV with k = 3 repli-
cates. Rows indicate the scenario and columns the method of estimation. The left panel
shows the distributions of the ÂLECs (4pLL) and the right panel the distributions of the
̂ALOECs (Limma). The number of estimates ≤ 1000 µM is indicated by n. Grey colored
bars indicate the number of no alerts.
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of the figure. Note, that the estimated alerts shown in Figure 6.2 represent the lowest (observed)
concentration levels at which the critical effect level of 1.5-fold is reached exactly (ÂLEC) or
exceeded by the average value (ÂLOEC), i.e. without significance testing.
The number of successful simulations was lower than 1000 when the 4pLL model did not
converge successfully or when the respective ALEC estimator was larger than the highest
approved test concentration, which was 1000 µM in the simulation study. For Limma, rarely it
was observed that for one concentration the upper threshold (log2(1.5)) was exceeded and for
another concentration the estimated value fell below the lower threshold (− log2(1.5)). From
these few cases only ALOEC estimators were affected. The respective genes were excluded
from the analysis. Table 6.1 lists, for each scenario, the numbers of excluded genes.
Table 6.1: Total number of excluded genes in Scenarios I-IV. The given numbers indicate for how
many genes the Limma approach has noticed a crossing of the upper threshold (0.585) at
one concentration and a crossing of the lower threshold (-0.585) at another concentration.
Such genes were excluded from further analysis. Only ALOEC estimators were affected
from these cases.
Scenario I Scenario II Scenario III Scenario IV
k=3 5 12 6 14
k=6 0 3 0 0
k=10 0 0 0 0
Scenario I, in which the true dose-expression curve does not exceed the given threshold,
represents the most challenging situation of all four scenarios. Although, no alerts are expected,
both methods trigger alerts which are, in this case, interpreted as false positives. The 4pLL
method detects 543 alerts, in median at a concentration level of 406.6, and the Limma method
falsely identifies 847 alerts, in median at 450 µM. Thus, the number of false positive alerts
obtained with the Limma approach is clearly higher than the one observed for the ÂLECs.
In contrast to the other three scenarios, where the ÂLECs follow approximately a normal
distribution, the distribution of the ÂLECs in Scenario I is slightly right skewed.
In Scenario II, where the true expression curve exceeds the given fold change at 500 µM,
the median of the estimated ALECs is 502.2 µM. The distribution of the ÂLECs is, with a
standard deviation of 40.8, more concentrated than the distribution of the ÂLECs in Scenario I.
The distribution of the ̂ALOECs has a median of 550 µM and a standard deviation of 96.7 µM,
whereas the interquartile range is zero, meaning that the 25th- and 75th percentiles coincide.
In Scenario III, where the true ALEC value is equal to 550 µM (measured concentration), both
methods hit on average the true value. Nevertheless, Limma gives an alert at 800 µM almost
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as often as at 500 µM. In addition, the estimates of Limma vary more than those of the 4pLL
approach (SDLimma = 136.4 vs. SD4pLL = 43.1).
In Scenario IV, which reflects the situation in which the true ALEC value is 680 µM and lies
between two measured concentration levels, the largest differences between the two estimates
are visible. The 4pLL method is, on average, with a median of 666.6 µM, closer to the true
ALEC value than the Limma method with a median of 800 µM. Similar to the previous three
scenarios the distribution of the ALOEC estimates exhibits a higher standard deviation than
the distribution of the ALEC estimates (SDLimma = 131.3 vs. SD4pLL = 92.7). Table B.7 in the
Appendix summarizes the results of Figure 6.2.
Figure 6.3 shows the distributions of the estimated LECs (4pLL) and LOECs (Limma). Here,
the estimated alerts refer to the lowest (observed) concentration level at which the given fold
change is exceeded significantly (p ≤ 0.05). The p-values result from the respective t-tests
adjusted for the two estimation methods.
In all four scenarios the number of successfully converged LEC estimators is only a fraction
of the number of successfully converged point estimates (see Figure 6.2).
In Scenario I, Limma provides in 153 cases a false positive result, while the 4pLL method
triggers only in 36 cases a false positive alert.
In Scenario II, the 4pLL approach did not converge in 684 of 1000 cases. In this scenario,
where the true ALEC value is equal to 500 µM, all converged LEC estimators (n = 316), except
of one, take values in the range between 500 and 1000 µM. On average, an alert is given at
785.1 µM. Limma, however, provides a CI-based estimator for the LOEC in all cases but one.
This is due to the fact that the curve has not reached its saturation point at the highest tested
concentration and the uncertainty about the further path of the curve leads to large variance
estimates for the given fold change values. This results in wide confidence intervals, which
influence the estimation of the LECs. For this reason, the 4pLL method detects a significant
change in expression in only a fraction of the genes (Table 6.2). In contrast, the Limma method is
not affected by this problem as its estimation strategy does not depend on the curve progression.
Thus, Limma provides for all genes a LOEC estimator. The median 50% of the L̂OECs take
values of the two next higher levels measured after the true 500 µM (550 µM or 800 µM). The
median concentration coincides with the 75%-quantile which is 800 µM. In those cases, in which
an estimator is obtained, both methods overestimates the true ALEC value. The false positive
rate is below 1% for both methods.
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Figure 6.3: Distributions of the estimated alert concentrations for Scenarios I-IV with k = 3 repli-
cates. Rows indicate the scenario and columns the methods of estimation. The left panel
shows the distributions of the L̂ECs (4pLL) and the right panel the distribution of the
L̂OECs (Limma). The number of estimates ≤ 1000 µM is indicated by n. Grey colored
bars indicate the number of no alerts.
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In Scenario III, where a saturated sigmoid curve is given, the largest number of converged LEC
estimators is observed (n = 749), i.e. in 251 cases (25.1%) the 4pLL model failed to converge.
The Limma approach, in contrast, did not notice a significant alert in 12 of 1000 cases. Neglecting
the number of false positive alerts (n4pLL= 35 vs. nLimma= 4), the 4pLL method provides more
accurate estimates than the Limma approach. Even though the true ALEC value corresponds
to 550 µM, a measured concentration level, the model-based (4pLL) estimates are on average
closer to the true ALEC value than the classical estimates (Med4pLL = 632 vs. MedLimma = 800).
The L̂ECs take values predominantly in the upper concentration range, starting from the true
value of 550 µM. The LOEC estimates vary around 800 µM with a standard deviation of 91.3,
which is similar to the standard deviation of the L̂ECs (SD4pLL = 100.7), but with an interquartile
range of 0, which is much smaller than the interquartile range of the L̂ECs (IQR4pLL = 113.9).
Table 6.2: Summary statistics for the distributions of the estimated alert concentrations for Scenarios
I-IV. The following parameters are presented: The total number of alerts (n), the median
(Med), the interquartile range (IQR) and the standard deviation (SD). The method for
estimating the alerts is subscripted after the corresponding parameter. An alert was given
when the given fold change value of 1.5 was exceeded significantly (p ≤ 0.05). The table
refers to the Figures 6.3, C.31 and C.33.
n4pLL nLimma Med4pLL MedLimma IQR4pLL IQRLimma SD4pLL SDLimma
Scenario I
k=3 36 153 398.200 no alert 284.300 0 197.026 226.859
k=6 55 213 351.600 no alert 258.800 0 203.559 237.007
k=10 50 137 540.500 no alert 326.500 0 217.300 206.052
Scenario II
k=3 316 999 785.100 800 163.200 250 114.745 126.586
k=6 427 1000 780.300 550 162.100 250 105.958 125.794
k=10 495 1000 785.700 550 162.200 250 102.972 117.702
Scenario III
k=3 749 988 632.000 800 113.900 0 100.691 91.290
k=6 861 995 620.700 800 95.500 0 92.705 77.510
k=10 929 1000 609.200 800 69.000 0 80.034 69.939
Scenario IV
k=3 285 648 745.200 1000 175.100 400 115.488 164.588
k=6 419 833 779.600 800 153.700 200 105.302 150.982
k=10 570 910 772.200 800 135.800 200 97.921 130.159
In Scenario IV, where the true ALEC value is 680 µM, the algorithm of the 4pLL method
has successfully converged in 285 cases. The distribution of the successfully converged LEC
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estimates has a median of 745.2 µM and a standard deviation of 115.5. The Limma method, on
the other hand, notices a significant crossing of the threshold in 648 cases. Limma assumes to
find the true ALEC value predominantly at 800 µM and 1000 µM. The 648 LOEC estimates vary
around a median of 1000 µM with a standard deviation of 164.6. The 4pLL method provides
estimates in the range of 500 and 1000 µM in all 285 cases. Although Limma yields less false
positive alerts (n = 6), the method detects, on average, the true alert with a delay. The 4pLL
method, on the other hand, returns more false positive results, 84 in total, but is generally closer
to the truth. Nevertheless, it should be noted, that both methods missed the alert in a relatively
high fraction of genes. The 4pLL algorithm failed in 715 cases and Limma in 352 cases. The
reason for this might be that the given scenario is unfavourable for both methods. Although
the S-shaped curve reaches its saturation point within the given concentration range, most of
the estimated confidence intervals capture, however, the critical effect level λ due to the fact
that the distance between the upper asymptote of the curve (φ(d) = 0.9) and the threshold is
very small (≈ 0.3). Similar results are obtained with Limma, where the computed average fold
change values do not exceed the threshold significantly. To this end, this scenario allows the
estimation of an accurate point estimator, but as soon as the uncertainty of the estimates is taken
into consideration, the alert can only be proven in a fraction of genes. In Table 6.2 the results of
Figure 6.3 are summarized. Table 6.3 reports the total number of false positive results obtained
for both criteria, the less stringent criteria (FC≥ 1.5) and the more stringent criteria (FC≥ 1.5 &
p ≤ 0.05).
Both figures, Figure 6.2 and Figure 6.3, refer to the simulation study, in which k = 3 replicates
per concentration were generated. The corresponding distributions for k = 6 and k = 10
simulated replicates are presented in the Appendix (Figures C.30-C.33). Figures C.30 and C.32
refer to the situation, in which an alert was given when the given fold change value of 1.5 was
reached exactly (4pLL) or exceeded by the average value (Limma), both indicating the point
estimate, and Figures C.31 and C.33 refer to the situation, in which an alert was identified by
means of hypothesis testing (CI-based estimate).
The increase of sample size has a larger impact on the model-based estimates than on the
classical ones. The number of successfully converged ALEC/LEC estimators has increased with
the number of replicates. Similar to, but not quite as pronounced as for the 4pLL estimates, the
number of alerts missed by the classical method, has decreased. Notable improvements were
obtained for Scenario III (saturated sigmoid curve), where the number of successfully converged
LEC estimators has increased from 749 to 929. In general, increasing the sample size, affects the
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estimates from the hypothesis driven approach (L̂EC and L̂OEC) more than the point estimates
(ÂLEC and ÂLOEC). However, in comparison to the original replicate number of k = 3 the
distributions for k = 6 and k = 10 simulated replicates do not show large differences in median
(Med), interquartile range (IQR) or standard deviation (SD). Table 6.2 provides an overview of
the summary statistics for the CI-based estimates. The corresponding summary statistics for
the point estimates are given in Table B.7 in the Appendix. The only remarkable difference can
be observed in Scenario II and IV for the L̂OECs , where the increase of sample size results in
an earlier alert detection. The median of the L̂OECs has shifted to the left: The median alert
concentration has taken the value of the next lower concentration which is 550 µM in Scenario II
(true ALEC = 500 µM) and 800 µM in Scenario IV (true ALEC = 680 µM).
Table 6.3: Total number of false positive alerts. A false positive alert means that the indicated
method yields an estimate of a value below the true ALEC value. In case of Scenario I,
where no ALEC value was provided, a false positive alert has been noted, if any alert
was triggered. An alert was given when the given fold change value of 1.5 was reached
exactly (ÂLEC) or exceeded by the average value (ÂLOEC) (upper table) or exceeded
significantly (p ≤ 0.05) (lower table).
Scenario I Scenario II Scenario III Scenario IV
4pLL Limma 4pLL Limma 4pLL Limma 4pLL Limma
ÂLEC ÂLOEC ÂLEC ÂLOEC ÂLEC ÂLOEC ÂLEC ÂLOEC
k=3 543 847 476 140 523 45 520 71
k=6 503 886 507 93 505 16 498 29
k=10 519 815 484 41 520 6 526 12
Scenario I Scenario II Scenario III Scenario IV
4pLL Limma 4pLL Limma 4pLL Limma 4pLL Limma
L̂EC L̂OEC L̂EC L̂OEC L̂EC L̂OEC L̂EC L̂OEC
k=3 36 153 1 12 35 4 84 6
k=6 55 213 0 7 26 1 72 2
k=10 50 137 0 0 23 0 88 0
From the distributions of the estimates, it can be concluded that, firstly, the convergence
of the LEC estimates critically depends on the sample size. Secondly, the 4pLL method has
outperformed the Limma approach in Scenario I (no ALEC value provided) and Scenario III
(saturated sigmoid curve) in terms of less false positive alerts and more accurate estimates. In
Scenario II, where an unsaturated curve progression is given, the highest uncertainties for the
LEC estimates are observed. In Scenario IV, where the critical effect level is exceeded only
slightly, both methods yield biased estimates.
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6.2.2 Comparison of the quantile distributions
Figure 6.4 displays the distribution of the quantiles which were calculated from the distribution
of the ÂLECs representing the ̂ALOECs. Given the distribution of the ALEC estimators, it
can be calculated which quantiles of this distribution the ̂ALOECs correspond to. A detailed
description and derivation of the quantiles is given in Section A.3 in the Appendix.
0.0 0.2 0.4 0.6 0.8 1.0
0
5
10
15
20
25
Scenario I
γ
Fr
eq
ue
nc
y
n=543
0.0 0.2 0.4 0.6 0.8 1.0
0
100
200
300
400
Scenario II
γ
Fr
eq
ue
nc
y
n=988
0.0 0.2 0.4 0.6 0.8 1.0
0
100
200
300
400
Scenario III
γ
Fr
eq
ue
nc
y
n=991
0.0 0.2 0.4 0.6 0.8 1.0
0
50
100
150
200
250
300
350
Scenario IV
γ
Fr
eq
ue
nc
y
n=926
Figure 6.4: Distributions of the quantiles calculated from the distribution of the ÂLECs representing
the ̂ALOECs. The alert concentrations were estimated from the simulated data with
k = 3 replicates per concentration under the indicated scenario. Values close to zero
indicate that the Limma method detects alerts at lower concentrations than the 4pLL
method, values close to one indicate the reverse case.
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Values close to zero indicate that Limma detects alerts at lower concentration levels than the
4pLL method, while values close to one indicate the reversed case, namely that the 4pLL method
notices expression changes at lower concentrations than Limma. In Scenario I, 25% of the alerts
detected by both methods do not differ in terms of their estimated concentration values. In 50%
of the cases, the ÂLOEC values are slightly higher than the ÂLEC values.
In the Scenarios II-IV the distributions of the quantiles are left-skewed with median values
close to one. In none of the three scenarios the 25%-quantile falls below the value of 0.7
indicating that in 75% of the cases lower concentration levels are obtained for the ÂLECs than
for the ̂ALOECs .
Similar results can be observed for the distribution of the quantiles which were calculated
from the distribution of the L̂ECs representing the L̂OECs (calculated as above, but this time
the calculations refer to the distributions of the CI-based estimators). Figure 6.5 shows the
corresponding histograms for the Scenarios I-IV. In all four scenarios, except Scenario II, the
median of the observed values is close to one. In 75% of the cases, the quantiles take values
above 0.6. In Scenario III the smallest interquartile range of 0.08 can be observed indicating a
relatively low dispersion of the values. In agreement with Table 6.2, the histogram in Figure 6.5
shows that the lower values of the L̂ECs are closer to the true ALEC value than the values of
the L̂OECs. That means, that in this particular case the model-based approach outperforms the
classical procedure in terms of more accurate estimates. In Scenario II, however, the distribution
of the quantiles shows two peaks, one peak at zero and the other peak at one. Hence, the Limma
method detects an alert in half of the cases at much lower concentration levels than the 4pLL
method and in one sixth of the cases at much higher concentrations. Compared to the other three
scenarios, where a lower dispersion is observed, the quantiles obtained in that scenario vary the
most with an interquartile range of 0.85 and a median value of 0.02.
All in all, it can be said that in all scenarios, except Scenario II (unsaturated sigmoid curve),
where the reverse case is observed, the 4pLL approach generally indicates alerts at lower
concentrations than the Limma method.
6.2.3 Comparison of the deviations
Next, the differences between the estimated alert concentrations and the respective true ALECs
were calculated for both methods. Deviations were only computed for successfully converged
simulations. Due to the fact, that in Scenario I no ALEC value was provided, deviations from the
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Figure 6.5: Distribution of the quantiles calculated from the distribution of the L̂ECs representing
the L̂OECs. The alert concentrations were estimated from the simulated data with k = 3
replicates per concentration under the indicated scenario. Values close to zero indicate
that the Limma method detects alerts at lower concentrations than the 4pLL method,
values close to one indicate the reverse case.
ALEC value could not be computed. Therefore, Scenario I was excluded from this analysis.
In general, no alert solutions were omitted in the calculations. The results are illustrated by
boxplots in Figure 6.6. The boxplots in the upper panel show the deviations of the point estimates
from the true ALEC value, and, the boxplots in the lower panel those of the CI-based estimates.
The results refer to the simulation study with k = 3 replicates. The corresponding results for
k = 6 and k = 10 replicates are shown in the Appendix (Figures C.34-C.35).
98 6 Statistical analysis of dose-expression data
In Scenarios II-IV, both methods provide CI-based estimates of values higher than the respec-
tive true alert concentrations. The medians of the L̂OEC deviations take values between 250 µM
and 321 µM. The deviations of the L̂ECs, on the other hand, yield average values in the range of
66 µM-285 µM. In all three scenarios, Scenario II, III and IV, the mean deviations of the L̂ECs
are smaller and closer to zero than the deviations obtained for the L̂OECs. However, it should be
taken into account, that the total number of simulations, for which Limma has provided estimates
of measurable values, is in all scenarios higher than the total number of the corresponding LEC
estimators.
Tables B.8-B.9 in the Appendix provide summary statistics for the boxplots shown in Fig-
ure 6.6. The results for k = 6 and k = 10 replicates are documented in the tables as well.
The analysis has shown that the distributions of the ÂLECs have changed in terms of their
interquartile range, which is reduced by half for k = 10. The average ÂLECs deviate less from
the true ALEC value when the replicate number is high, other than the ̂ALOECs, for which the
increase of sample size does not reveal any noteworthy differences.
The reverse case can be observed for the CI-based estimates. In this present situation, the
increase of sample size shows an effect on the Limma results: In Scenario II and IV, the median
of the L̂OEC deviations has shifted from the upper to the lower quantile (see Figures C.34-C.35
in Appendix). Apart from these changes, no further noteworthy differences were observed,
neither for the LOEC nor the LEC estimators. For more details the reader is referred to the
Tables B.8-B.9 in the Appendix.
6.2.4 Direct comparison of the two estimates
In addition, the estimates of the 4pLL method were directly compared with those of the Limma
approach. Therefore, the ALEC and LEC estimates were analyzed with respect to their con-
cordant Limma estimates. The results are illustrated by boxplots in the Figures 6.7-6.10. The
distributions of the model-based estimates are split into subsets according to the discrete esti-
mates of the classical approach. Comparisons were made only for simulations for which the
4pLL models have successfully converged. The estimates of the 4pLL aprroach are depicted on
the y-axis, which is restricted to the values 0-1000 µM. Alert concentrations of higher values
(> 1000 µM) were not used for generating the boxplots, but were highlightened as extreme data
points at the top of the single boxes. The number of valid alerts is indicated by n at the bottom
of the boxplots. The estimates of the classical Limma approach are depicted on the x-axis with
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Figure 6.6: Boxplots illustrating the distributions of the differences between the estimated alert
concentrations and the respective true ALECs of the Scenarios II-IV (the difference is
indicated by ∆). Scenario I was excluded from the analysis since no deviations could
be computed (no ALEC value was provided). The upper panel shows the deviations of
the point estimates from the true ALECs and the lower panel shows the deviations of
the CI-based estimates (p ≤ 0.05). The alert concentrations were estimated from the
simulated data with k = 3 replicates per concentration under the indicated scenario.
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coordinate values equal to the measured concentration levels (0, 25, 150, 350, 450, 550, 800
and 1000 µM). No alert means that no expression change of at least 1.5-fold was noticed by
the indicated method. The black points within the single plots indicate the seven measured
concentrations. The uncertainties of the 4pLL point estimators were also taken into account
when comparing the two methods with each other. For this, the 95%-confidence intervals (CIs)
for the ÂLECs and L̂ECs were calculated and evaluated with respect to the ALOEC and LOEC
point estimators, respectively. The results of Scenarios I-IV are discussed individually. The
layout of the Figures 6.7-6.10 is the same for all four scenarios: The first row shows the boxplots
of the estimated ALECs (left panel) and of their estimated 95%-CIs (right panel) subdivided
with respect to the estimated ALOECs. The second row shows the same plots for the CI-based
estimates, the L̂ECs with respect to the L̂OECs. The alert concentrations were estimated from
the simulated data with k = 3 replicates per concentration under the condition of the indicated
scenario. Remember that the true expression profiles together with their true ALEC values for
λ = log2(1.5) are shown in Figure 6.1.
Scenario I. In Scenario I the true dose-expression curve falls slightly below the given threshold
and thus never meets the 1.5-fold threshold. Nevertheless, both methods sometimes trigger alerts.
Figure 6.7 shows that the median of all model-based estimates is below the respective Limma
estimates (left panel). This indicates earlier alerts with the model-based approach in more than
50% of the cases. The use of the 4pLL method for estimating the ALECs results, in Scenario I,
in the widest confidence intervals with median lengths of 500 µM.
The boxplots in the lower panel of Figure 6.7, showing the L̂ECs in direct comparison to the
LOEC estimators, show that the number of alerts decreases enormously when taking confidence
intervals into consideration (from 543 to 36 alerts). In 129 cases, the Limma approach detects
expression changes that do not show any significant change with the 4pLL method (false positive
alerts), while the 4pLL method triggers only in 12 other cases a false positive alert (which is
not noticed by Limma). Thus, in this regard, the 4pLL method outperforms the Limma method.
These results are in line with the aforementioned results (reported in Table 6.3).
Scenario II. Scenario II was set up to simulate the situation in which the true curve clearly
exceeds the given threshold at 500 µM. Figure 6.8 summarizes the results for this scenario. Most
of the ALOECs (n = 748) are estimated at 550 µM which is the next higher concentration level
measured after 500 µM. In contrary, for this subset of genes the 4pLL method provides ALEC
estimates of lower values which vary around the true ALEC value with a standard deviation
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Figure 6.7: Boxplots comparing the alert concentrations obtained with the 4pLL method with those
obtained with the Limma method. Rows indicate the cut-off criteria: The upper row
shows the ALEC estimators and their 95%-CIs with respect to the ̂ALOECs. The lower
row shows the same split for the LEC and LOEC estimators. The results of the 4pLL
method are depicted on the y-axis, the estimates of the Limma method on the x-axis.
Black points indicate equal values on the x- and y-axis. The alert concentrations were
estimated from the simulated data with k = 3 replicates per concentration under the
conditions of Scenario IV. The blue dashed line indicates the true ALEC value.
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Figure 6.8: Boxplots comparing the alert concentrations obtained with the 4pLL method with those
obtained with the Limma method. Rows indicate the cut-off criteria: The upper row
shows the ALEC estimators and their 95%-CIs with respect to the ̂ALOECs. The lower
row shows the same split for the LEC and LOEC estimators. The results of the 4pLL
method are depicted on the y-axis, the estimates of the Limma method on the x-axis.
Black points indicate equal values on the x- and y-axis. The alert concentrations were
estimated from the simulated data with k = 3 replicates per concentration under the
conditions of Scenario IV. The blue dashed line indicates the true ALEC value.
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of 25 µM. Moreover, for this subgroup of ALEC estimates the narrowest confidence intervals are
obtained (lengths ranging from 25 µM to 100 µM).
140 genes that have been deregulated at early concentrations (25 µM to 450 µM), according to
Limma, turn out to be false positive alerts, i.e. ̂ALOECs with values lower than 500 µM. For most
of these genes (n = 117) Limma notices a change at 450 µM, the next lower value measured
before the true 500 µM. For this group of genes the 4pLL approach notices expression changes
at much higher concentrations.
Considering both criteria, fold change and p-value, shows that a change in gene expression is
confirmed to be significant in 16.7% of the cases (lower panel in the figure). For all these genes,
except of one, Limma provides L̂OECs of 550 µM and 800 µM. The 4pLL method, in contrast,
provides estimators for the LEC, which are on average much higher than or equal to the L̂OECs
and, thus, deviate more from the true ALEC value (500 µM) than the L̂OECs. The corresponding
95%-CIs for the L̂ECs exhibit median lenghts of about 100 µM. In this respect, it should be noted
that in this scenario the 4pLL method fails in most of the cases due to inestimable confidence
intervals, while the Limma method provides satisfying results.
Scenario III. In Scenario III the true ALEC value coincides with the measured concentration
level of 550 µM. The boxplots in Figure 6.9 show the distributions of the alert concentrations in
relation to each other. 489 of the estimated ALOECs exhibit values equal to 550 µM and 456 of
those point estimates at 800 µM, the next higher concentration level after 550 µM. The ÂLECs,
on the other hand, vary closely around the true ALEC value (upper panel).
The boxplots for the CI-based estimates reveal that 45 genes with fold change values of at
least 1.5 at ÂLOEC values of 150 µM, 350 µM and 450 µM, respectively, do not exceed the
given threshold significantly due to the Limma t-test (i.e. p > 0.05). 749 of the previously
991 point estimates meet the criteria for significance (FC ≥ 1.5 & p ≤ 0.05). Most of the
significant upregulations are detected by Limma at 800 µM and by the model-based approach
at approximately 600 µM. The number of false positive alerts, i.e. estimates with values below
550 µM, reduces from 45 to 4 and from 523 to 35 in the case of Limma and the 4pLL approach,
respectively, when taking p-values into account (Table 6.3). The 95%-confidence intervals
obtained for the ÂLECs and L̂ECs are mostly small in this scenario.
Of all four scenarios, Scenario III provides the most preferable curve shape (saturated sigmoid
curve) for estimating the LECs with the 4pLL method. The results show that in this scenario the
LEC estimates clearly outperform the LOEC estimates.
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Figure 6.9: Boxplots comparing the alert concentrations obtained with the 4pLL method with those
obtained with the Limma method. The rows indicate the cut-off criteria: The upper row
shows the ALEC estimators and their 95%-CIs with respect to the ̂ALOECs. The lower
row shows the same split for the LEC and LOEC estimators. The results of the 4pLL
method are depicted on the y-axis, the estimates of the Limma method on the x-axis.
Black points indicate equal values on the x- and y-axis. The alert concentrations were
estimated from the simulated data with k = 3 replicates per concentration under the
conditions of Scenario III. The blue dashed line indicates the true ALEC value.
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Scenario IV. In Scenario IV the true ALEC value is 680 µM. The results are illustrated by
the boxplots in Figure 6.10. Due to Limma, most of the genes (n = 768) show a change in
gene expression at 800 µM, the next higher value measured after the true ALEC value (upper
panel). 748 of 926 ̂ALOECs meet, on average, the true ALEC value exactly. Restricting the
analysis to those genes for which the t4pLL-test yields p-values of less than 0.05 results in 285
estimators of which almost all take values of above 680 µM (lower panel). In addition, LEC
estimators are obtained for genes that show no significant change according to Limma (n = 41).
4pLL modeling of these expression profiles results in the widest L̂EC confidence intervals so far.
Similar lengths have only been observed for the point estimates in Scenario I.
All in all, Scenario IV is unfavorable for both methods since both approaches have difficulties
to provide accurate estimates.
In addition, it was counted how often the true ALEC value was captured by the 95%-confidence
intervals (CIs) of the ÂLECs. Therefore, the coverage probability (CP) which indicates the
proportion of covered cases was computed. In the calculations only CIs of lengths smaller than
1000 µM were considered. The corresponding numbers are provided in Table 6.4. In case of
Scenario I the coverage probability could not be computed since no ALEC value was provided.
The coverage probabilities were computed for k = 3, k = 6 and k = 10 replicates.
The number of successfully computed CIs (widths ≤ 1000 µM) has increased with increasing
sample size. The observed coverage probabilities are between 0.8 and 0.86 and, thus, in all cases
relatively small (Table 6.4).
Table 6.4: Coverage probabilities for the Scenarios II-IV. The coverage probability (CP) is defined
as the proportion of how often the 95%-confidence interval of the ÂLECs cover the true
ALEC value. In case of Scenario I the coverage probability could not be computed since
no ALEC value was provided. The total number of confidence intervals is denoted by n.
Only confidence intervals of lengths smaller than 1000 µM are considered.
Scenario II Scenario III Scenario IV
n CP n CP n CP
k=3 987 0.827 990 0.861 904 0.803
k=6 996 0.809 997 0.844 956 0.827
k=10 1000 0.818 996 0.830 963 0.849
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Figure 6.10: Boxplots comparing the alert concentrations obtained with the 4pLL method with those
obtained with the Limma method. The rows indicate the cut-off criteria: The upper row
shows the ALEC estimators and their 95%-CIs with respect to the ̂ALOECs. Lower
row shows the same split for the LEC and LOEC estimators. The results of the 4pLL
method are depicted on the y-axis, the estimates of the Limma method on the x-axis.
Black points indicate equal values on the x- and y-axis. The alert concentrations were
estimated from the simulated data with k = 3 replicates per concentration under the
conditions of Scenario IV. The blue dashed line indicates the true ALEC value.
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6.3 Results of a real data study
The VPA chronic study, which was introduced in Section 2.4, is used as real data example.
The study was conducted to investigate concentration-dependent gene expression changes in
response to chemical exposure. The cells were treated in vitro with valproic acid (VPA) using
eight different concentrations (25, 150, 350, 450, 550, 650, 800, 1000 µM) and three replicates
per concentration.
To obtain an overview of the data, principal component analysis (PCA) has been performed,
based on the 100 probe sets with highest variance across all replicates, to visualize the different
gene expression profiles of all experiments (Figure 6.11). Each point represents one experiment,
where the color indicates the concentration and the form indicates the replicate. The percentages
of the variances covered are plotted on the axes.
Plotting of the first two principal components shows that the three replicates for each concentra-
tion all cluster closely together, and the concentrations can be clearly distinguished. The treated
samples move in the direction of the first principal component, which explains almost 90% of
the data variability, and hence, represents a convincing concentration progression. Only the
concentration of 650 µM, which is in the range of beginning cytotoxicity, shows a high variability
between the three replicates (upper panel, purple color coding). Therefore, this concentration is
excluded from further analysis. The lower panel in Figure 6.11 thus shows that the data quality
could be improved by excluding the measurements with 650 µM.
The flowchart in Figure 6.12 illustrates the approach to analyze the data. The goal is to
detect concentrations with critical changes in gene expression. Analogously to the procedure in
the simulation study, the two methods for estimating critical concentrations, the 4pLL model
approach and the Limma method, are compared with each other.
On the one hand, the 4pLL model approach is applied to estimate the concentration at which
the fitted curve intersects the given threshold (ALEC). On the other hand, the Limma method
is used to obtain the lowest observed concentration at which the mean fold change exceeds the
threshold (ALOEC). The same analysis is performed to detect the lowest concentration at which
the critical effect level is exceeded significantly, i.e. by means of hypothesis testing (LEC and
LOEC). The t4pLL-test is used for estimating the LEC and the Limma t-test for specifying the
LOEC estimator. The critical effect level is set to 1.5-fold. The analysis is not performed on
the entire set of genes, which includes 54 675 probe sets from the HG-U133 GeneChip, but is
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Figure 6.11: Principal component analysis (PCA), based on the 100 probe sets with highest variance
across all replicates, was performed for the VPA chronic concentration study to visualize
the data structure across all concentrations and experimental replicates. The upper panel
shows the PCA plot for the complete VPA study (including 650 µM) and the lower
panel illustrates the concentration progression of the data after excluding experiments
with concentration 650 µM. Each point represents one experiment, where the color
indicates the concentration and the form indicates the replicate. The percentages of the
variances covered are plotted on the axes.
restricted to those genes that show a significant change in gene expression for at least one of the
concentration levels. For this, an analysis of variance (ANOVA) was performed in advance. The
9460 genes with a significant result (p < 0.001) were kept for the analysis. In the following, the
estimated alert concentrations are compared with respect to their distributions (Figure 6.13).
The left-hand histograms of Figure 6.13 show the distributions of the alert concentrations
detected with the 4pLL method and the barplots on the right-hand side of the figure show the
distributions of the classical estimates (Limma). In the upper row the distributions of the point
estimates are presented, while those of the CI-based estimates are displayed in the lower panel.
The number of successfully converged estimators (estimates ≤ 1000 µM) is denoted by n and
given in the upper right-hand corner of the respective distribution. No alerts and alerts of values
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Figure 6.12: Flowchart of the analytical procedure for the detection of critical changes in gene
expression.
higher than 1000 µM are not shown in the histograms. In the evaluation of the Limma results,
only estimates with unique solutions are considered, i.e. expression patterns exceeding both the
upper and lower limit were excluded before. In case of the ALOEC estimates 75 genes were
affected from the exclusion criteria and in case of the LOEC estimates 7 genes were excluded.
For 6756 (71.4%) expression profiles an ALEC estimator could be computed. For a few
more genes, 7191 (76.0%) in total, the Limma method has detected a 1.5-fold change in gene
expression. In more than 2000 cases both methods have not noticed an alert. According to
Limma, most of the genes (n = 2112) have been deregulated at 800 µM. 25% of the ̂ALOECs
have values below 450 µM. The middle 50% of the ̂ALOECs lie between 450 µM and 1000 µM,
while the ÂLECs vary around a median value of 520.5 µM with an interquartile range of 324.7
µM and a standard deviation of 220.8 µM. 75% of the ÂLECs exhibit values below 695.5 µM.
The lower panel in Figure 6.13 shows the results of the CI-based estimates. The number of no
alert signals has doubled for the Limma method (increase from nÂLOEC = 2194 to nL̂OEC = 4745)
and almost tripled for the 4pLL method (increase from nÂLEC = 2704 to nL̂EC = 7449), while
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the number of LEC and LOEC estimates has enormously decreased from 6756 to 2011 (4pLL)
and 7191 to 4708 (Limma) estimates, respectively. The median of the ̂ALOECs has shifted from
800 µM to no alert, by disregarding the no alert signals the median of the L̂OECs is still 800
µM. The median of the ALEC estimates has shifted slightly from 521 µM to 505 µM (L̂EC).
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Figure 6.13: Distributions of the estimated alert concentrations for the VPA chronic concentration
study. Rows indicate the cut-off criteria and columns the methods of estimation. The
left panel shows the distributions of the ALEC and LEC estimators (4pLL) and the
right panel shows the distributions of the ALOEC and LOEC estimators (Limma). The
number of estimates ≤ 1000 µM is indicated by n.
Figure 6.14 displays the distribution of the quantiles which were calculated from the distribu-
tion of the ÂLECs and L̂ECs representing the ̂ALOECs and L̂OECs, respectively. Remember,
that, given the distribution of the 4pLL estimates, it can be calculated which quantiles of that
distribution the Limma estimates correspond to. The histogram in the left panel illustrates the
results for the point estimators and the histogram in the right panel shows the results for the
significant alert concentrations. The calculation of the quantiles is based only on the successfully
converged ALEC and LEC estimators, respectively (i.e. estimates ≤ 1000 µM). The left-hand
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histogram exhibits a peak at one, and thus, indicates that most of the ̂ALOECs take values which
are higher than the values of the L̂OECs. The histogram on the right-hand side of the figure
shows the distribution with one pronounced peak at one and one smaller peak at zero. That
indicates, that, in comparison to the Limma approach, the 4pLL method has detected a change in
gene expression in 705 cases at lower concentrations and in 167 cases at higher concentrations.
The other 1139 quantile values are distributed uniformly within the interval (0, 1).
It can be stated, that for both cut-off criteria, the stringent (FC ≥ 1.5 & p ≤ 0.05) and the less
stringent one (FC≥ 1.5), the case study shows a tendency towards lower L̂EC values than L̂OEC
values. That means, that the 4pLL method generally indicates alerts at lower concentrations
when compared with the alerts of the classical Limma approach.
0.0 0.2 0.4 0.6 0.8 1.0
0
500
1000
1500
2000
γALEC
Fr
eq
ue
nc
y
n=6756
0.0 0.2 0.4 0.6 0.8 1.0
0
100
200
300
400
500
600
700
γLEC
Fr
eq
ue
nc
y
n=2011
Figure 6.14: Distributions of the quantiles calculated from the distribution of the ÂLECs and L̂ECs
representing the ̂ALOECs (left panel) and L̂OECs (right panel), respectively. The alert
concentrations were estimated from the VPA chronic concentration study. Values close
to zero indicate that the Limma method detects alerts at lower concentrations than the
4pLL method, values close to one indicate the reverse case.
The boxplots in Figure 6.15 show the model-based estimates in direct comparison to the
classical estimates. The estimates obtained with the 4pLL approach are depicted on the y-axis,
while the estimates of the Limma approach are displayed on the x-axis. The estimated ALECs
and LECs, and their 95%-confidence intervals, are subdivided with respect to the estimated
ALOECs and LOECs, respectively. Boxplots have only been generated for estimates for which
the 4pLL model has successfully converged (estimates ≤ 1000 µM). No alert detections as well
as confidence interval lengths of above 1000 µM are highlightened as extreme data points at the
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top of the single boxplots. Similar to the figure setups before, the plots in the upper row refer to
the distributions of the point estimators and the plots in the lower panel compare the distributions
of the CI-based estimates.
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Figure 6.15: Boxplots comparing the alert concentrations obtained with the 4pLL method with those
ones obtained with the Limma method. Rows indicate the cut-off criteria: Upper row
shows the ALEC estimators and their 95%-CIs with respect to the ̂ALOECs. Lower
row shows the same split but for the LEC and LOEC estimators. The results of the
4pLL method are depicted on the y-axis, the estimates of the Limma method on x-axis.
The alert concentrations were estimated from the VPA chronic concentration study.
The boxplots in the upper left-hand corner reveal that for almost all observed concentrations
the respective boxes are below the indicated black points, indicating that 75% of the ÂLECs
exhibit values below the values of the respective classical estimates ( ̂ALOECs). The only
exception is the lowest measured concentration (25 µM) where the entire boxplot lies above the
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value of 25 µM. That means, that this group of genes (n = 16) exhibits, according to Limma,
expression changes at much lower concentrations than according to the 4pLL method, which has
first noticed changes at levels between 30 µM and 550 µM. However, the widths of the respective
95%-confidence intervals are broader than those obtained for the higher concentrations (> 25 µM).
This gives reason to assume a high insecurity in the estimation of the ALECs. A similar degree
of uncertainty can be observed for the ALEC estimates that show no alert according to Limma.
Those ALEC estimates (n = 19) exhibit confidence intervals of similar large interquartile ranges
(300 µM-700 µM). In contrast, the ÂLECs observed for the concentrations 150, 350, 450, 550,
800 and 1000 µM yield confidence intervals of lower widths (on average 100 µM-200 µM).
When considering the LEC estimates (lower panel of Figure 6.15), it is important to mention,
that the model-based approach fails in most of the cases in terms of convergence. For the few
cases, in which the 4pLL model has converged (21.3%), the boxplots in the lower left-hand
corner show, that the relation between the L̂ECs and L̂OECs remains largely the same, except
for some minor shifts in the distribution of the CI-based estimates. Early alerts (alerts at 25 µM)
are not proved to be significant, but the Limma method provides more no alert signals than
before (for the ̂ALOECs). In 75% of the cases the model-based approach yields concentrations
of lower values than the Limma method. The uncertainties in the parameter estimates increase
with increasing concentrations. Thus, the widest confidence intervals are obtained for high
concentration levels (≥ 550 µM).
Note, that if the four-parameter-log-logistic (4pLL) model is misspecified, i.e. if the parametric
assumptions do not hold and the chosen model cannot capture the structure in the data, the
estimates might be biased. Hence, the results should be interpreted with caution.
7 Summary
The present work focused on the following three topics that often arise in the context of gene
expression analysis: Firstly, the identification and characterization of different modes of action
associated with certain expression changes, secondly, the identification of in vitro biomarkers for
the prediction of toxicity in vivo and thirdly, the identification of critical concentrations at which
pre-defined effect levels are exceeded.
For identifying molecular changes on a genome-wide scale as a response to chemical exposure
within the same species and between in vitro and in vivo systems the open-source Toxicogenomics
Project-Genomics Assisted Toxicity Evaluation system (TG-GATEs) was used. The database
covers more than 150 compounds and compiles Affymetrix files of rat liver samples and in vitro
cultivated human and rat hepatocytes. The cells were treated with each compound using different
concentrations, most of them at three distinct concentrations, and for different time periods.
Regarding the first thesis topic, the main task was to identify general principles of the toxico-
transcriptome in human hepatocytes. At first, the database had to be curated. This is a crucial and
necessary step to reduce errors in the detection process, such as false positives, false negatives or
undetected effects. In the context of concentration-dependent gene expression analysis, batch
effects, limited numbers of replicates and implausible concentration progressions can cause
such misleading results. A principal component analysis of the investigated data, based on the
100 strongest deregulated genes across all compounds, revealed several clusters which could be
removed by simple control subtraction (compound-matched). The results suggest that the batch
effects occurred as a consequence of experimental variability. The reproducibility between repli-
cates was assessed by the comparison of the distances between replicates and control-treatment
pairs. The analysis has shown that the distances between replicates was small in relation to the
much larger compound induced distances. Compounds with implausible concentration progres-
sions, i.e. with a high fraction of genes deregulated at a lower but not at the respective higher
concentration, were excluded from the analysis. For this curation step the progression profile
error indicator was defined to detect deviations from monotonous concentration progressions.
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This curation procedure was summarized into a guideline which is now recommended as a neces-
sary step before analyzing high-dimensional toxicogenomic data. The curated data was used to
categorize genes according to the following key features: (1) Stereotypical vs. compound-specific
stress response: To differentiate between these two kinds of responses, the selection value (Sv)
was introduced, which specifies for a gene the minimum number of compounds that induces an
expression change. Since it was observed that only 32 of 148 compounds have induced marked
effects and a single compound can lead to false positive results, genes that were deregulated by
at least three and at most 19 compounds, were used to describe compound-specific responses
(Sv 3), while genes altered by 20 or more compounds were categorized as stereotypical genes
(Sv 20). Conversely, this means that Sv 20 genes are always a subset of the Sv 3 genes. (2) Liver
disease-associated genes: It could be shown that the reported stereotypical stress response genes
overlapped with genes deregulated in human liver diseases, such as steatohepatitis, liver cirrhosis
and hepatocellular cancer. (3) Unstable baseline genes: A group of unstable baseline genes was
identified which were deregulated not by a compound but simply due to the procedure of isolating
and cultivating. (4) Biological function: More than 2000 genes were associated with biological
functions. The results of this analysis were stored in a toxicotranscriptomics directory that is
now publicly available under http://wiki.toxbank.net/toxicogenomics-map/.
It can be employed by toxicologists to obtain basic information of chemically-induced expression
responses in human hepatocytes.
Regarding the second thesis topic, detecting biomarkers in in vitro systems for the prediction
of in vivo toxicity, the next step should be to validate the aforementioned results in terms of
comparable responses in in vivo systems. The latter includes the step to investigate whether the
genes that are chemically induced in cultivated hepatocytes are also deregulated in human liver
tissue. Since the data investigated stems from human hepatocytes, such an analysis cannot be
performed, for obvious ethical reasons. To remedy this problem, a comparative analysis between
cultivated rat hepatocytes and rat liver samples was performed to assess the relevance of in vitro
responses for the in vivo situation. To this end, two databases, the NRW and TG-GATEs data
sets, comprising in vivo and in vitro gene expression data of rat hepatocytes for a total number of
189 different compounds, were used, of which only 5 compounds were present in both data sets.
The data curation pipeline introduced in this work was applied to both data sets. Data variability
among the in vitro experiments was observed to be much higher compared to the in vivo data.
Due to the heterogeneous data structure in in vitro data, the in vivo data was considered the
gold standard to which the in vitro results were compared. Concentration progression analysis
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revealed inconsistencies in parts of both data sets. To ensure reliable results in the detection of
mutual gene deregulations, the Sv 3 concept was applied to generate a consensus signature of
commonly regulated genes. To this end, consensus Sv 3 lists were generated to analyze the in
vivo-in vitro response within and between the two databases.
Consensus analysis of the NRW and TG-GATEs database, revealed an in vitro-in vivo overlap
which was more than random. Despite the significant overlap, a large fraction of genes was still
in the non-overlapping region inidcating in vivo and in vitro specific responses. Considering this
aspect, a direct deduction from in vitro to in vivo systems is difficult to accomplish. This is in
line with the findings of previous studies which revealed substantial differences between the two
test systems (Schug et al., 2013).
However, the comparison of the two data sets showed a relatively high degree of similarity,
considering the fact that only five mutual compounds were tested. The consensus genes of the
NRW-TG-GATEs overlap were further analyzed with respect to their response to different test
compounds. They were ordered with respect to the selection value in order to find a subset of as
few genes as necessary to depict a compound sensitivity as large as possible. This resulted in 11
up- and downregulated biomarker genes covering most of the high profile compounds. These
genes allow for a prediction of toxicity in in vivo experiments.
Hence, differential expression analysis was only performed using the classical naïve approach,
where for each measured concentration separately it was tested if the critical effect level was
exceeded. This procedure has an inherent fundamental flaw in the sense that it is highly unlikely
that such a deregulation is first triggered at exactly one of the measured concentrations. To this
end, a model-based method was introduced in this thesis.
Based on the assumption that the response dependency of the dose can be described by a
sigmoidal function, Jiang (2013) fitted a four-parameter log-logistic (4pLL) model to dose-
response data to estimate the Absolute Lowest Effective Concentration (ALEC) for a fixed and
pre-specified effect level. But since the ALEC results solely from a simple point estimator, the
uncertainty of the effect level is entirely neglected. However, for obvious statistical reasons,
it is vital to provide confidence intervals. Thus, in this thesis, the method was enhanced by
means of a thorough confidence interval estimator. The critical effect level (fold change) is
exceeded significantly if the entire confidence interval lies above the predefined threshold of
a given fold change. The hereby resulting concentration value was introduced as the Lowest
Effective Concentration (LEC). For significance testing a specific test statistic, the t4pLL-test
statistic, derived from the 4pLL model, was proposed.
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In order to validate the 4pLL method and assess the general feasibility of model-based
test methods, various gene expression profiles were simulated. In the first case the critical
fold change was never met. In this case, the proposed approach (LEC) performed better than
the classical approaches (ALOEC and LOEC) as well as the point estimator based method
(ALEC), i.e. less false positive signals were triggered. In cases in which the expression pattern
followed a pronounced sigmoidal shape distinctly crossing the threshold, the new method clearly
outperformed the others. However, if the threshold was only slightly exceeded, both methods,
the model-based and the classical one, had difficulties to provide accurate estimates. In cases of
unsaturated curve progressions, the classical approach yielded satisfying results, while the model-
based approach failed in most of the cases due to inestimable confidence intervals. By applying
the method to actual experimental data, the general trend was observed that the model-based
approaches yield alerts at lower concentrations than the classical approach.
The use of the 4pLL approach is recommended under the circumstances that the expression
profile can be justifiably assumed to obey a saturated sigmoidal path. Given this prerequisite,
the proposed method is preferential for many reasons. Firstly, the model-based approach
benefits from its independence of observed measurements allowing arbitrary positive values
as alert levels. Secondly, both estimates, the point and CI-based estimate, can be estimated
in the case of incomplete dose-response curves due to the fact that the critical effect-level is
defined independently from the lower and upper asymptote of the curve. Thirdly, the modeling
of continuous gene expression profiles allows the calculation of confidence intervals for the
estimated alert concentrations. In addition, the model-based approach incorporates the entire
information about the dose-response relationship which is neglected by the classical procedure.
On the other hand, the new method provides biased estimates if the given prerequisites do not
apply to the data. In order to obtain reasonable estimates, it is recommended to test explicitly for
sigmoidal functions, more precisely for deviations from sigmoidal curve progressions (Schmoyer,
1984). As the model choice is decisive for the assessment of estimation uncertainty, the search
for appropriate model candidates is worth further examination. The proposed method can be
extended and applied to other parametric dose-response models, such as the Log-normal- or
Weibull model. Fitting different parametric models to the data is one way, another is to fit non-
parametric models. The latter procedure has proven to be beneficial in case the parametric form
of the dose-response curve cannot be specified. Commonly used non-parametric methods include
kernel regression (Müller and Schmitt (1988) and Staniswalis and Cooper (1988)) or local linear
regression (Kelly and Rice (1990) and Zhang et al. (2013)). On the one hand, non-parametric
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methods can capture structure in the data that a misspecified parametric model cannot, but on the
other hand non-parametric techniques often result in estimates with high variance.
Thus, both methods, parametric and non-parametric methods, have their advantages and
disadvantages. When the parametric assumption holds, the parametric model yields the highest
possible efficiency but when the assumption is violated, the corresponding parameter estimates
will be biased with increased variances. Non-parametric models are more robust compared
with parametric models but less efficient. As a compromise, a semi-parametric approach can
be taken inheriting both efficiency and robustness from the two methods. The idea of a mixture
model is to use a linear combination of the two fits to retain the advantages of parametric and
non-parametric models. Yuan and Yin (2011) propose an estimator of a dose-response curve
which is a weighted average of the parametric and non-parametric curve estimates. The weight
is chosen by minimizing the mean integrated square error (MISE) such that a higher weight
is given to the estimate that fits the data better. In case of a correctly specified parametric
model, the semi-parametric estimate assigns more weight to the parametric estimate, in case of
a misspecification a higher weight is given to the non-parametric estimate. Furthermore, they
distinguish between a global and a local semi-parametric estimate. The global method assigns a
constant weight to the parametric estimate according to the global fit of the parametric model,
while the local method allows the weight to vary according to the local fit of the two models.
Nottingham and Birch (2000) linearly combine a logistic regression (parametric method)
with a local linear regression (non-parametric method) by using a mixture parameter. The
proposed method, known as model-robust quantal regression (MRQR), stabilizes the fit of an
inadequate parametric model by incorporating useful information from the non-parametric model.
Alternative model-robust procedures are presented in Olkin and Spiegelman (1987), Mays et al.
(2000) and Pickle et al. (2008), among others. Robinson et al. (2010) presents a semi-parametric
approach for the case when no replication is available. The proposed techniques all base on a
convex combination of a parametric and a non-parametric model.
Moreover, Rahman et al. (1997) and Wooldridge (1992) have suggested test procedures for
testing a functional form against non-parametric alternatives. Further tests on semi-parametric
models have been discussed in Davidson and MacKinnon (1981), Yatchew (1992) and Eubank
and Spiegelman (1990). To date, no unified approaches or guidelines have been developed in the
gene expression context that address the issue of model selection. Along with this, the reported
results have reinforced the general aspect of giving model insecurity in estimation processes
much more importance in the future.
Bibliography
Affymetrix (2017): Biology for a better world. URL http://images.slideplayer.
com/15/4665315/slides/slide_17.jpg. Retrieved March 28, 2017.
BK101 (2017): Basic Knowledge 101. URL http://www.basicknowledge101.com/
categories/dna.html. Retrieved March 28,2017.
Chang, K.-M., Harbron, C., and South, M. (2016): RefPlus: A function set for the Extrapolation
Strategy (RMA+) and Extrapolation Averaging (RMA++) methods.. R package version 1.44.0.
Davidson, R. and MacKinnon, J. (1981): Several tests for model specification in the presence of
alternative hypotheses. Econometrica, 49 (3), 781–793.
Ellinger-Ziegelbauer, H., Gmuender, H., Bandenburg, A., and Ahr, H. (2008): Prediction of a
carcinogenic potential of rat hepatocarcinogens using toxicogenomics analysis of short-term
in vivo studies. Mutation Research, 637 (1-2), 23–39.
Eubank, R. L. and Spiegelman, C. H. (1990): Testing the goodness of fit of a linear model
via nonparametric regression techniques. Journal of the American Statistical Association,
85 (410), 387–392.
Grinberg, M., Stöber, R., Edlund, K., Rempel, E., Godoy, P., Reif, R., Widera, A., Madjar, K.,
Schmidt-Heck, W., Marchan, R., Sachinidis, A., Spitkovsky, D., Hescheler, J., Carmo, H.,
Arbo, M., van de Water, B., Wink, S., Vinken, M., Rogiers, V., Escher, S., Hardy, B., Mitic,
D., Myatt, G., Waldmann, T., Mardinoglu, A., Damm, G., Seehofer, D., Nüssler, A., Weiss, T.,
Oberemm, A., Lampen, A., Schaap, M., Luijten, M., van Steeg, H., Thasler, W., Kleinjans,
J. S., Stierum, R., Leist, M., Rahnenführer, J., and Hengstler, J. (2014): Toxicogenomics
directory of chemically exposed human hepatocytes. Archives of Toxicology, 88, 2261–2287.
Harbron, C., Chang, K.-M., and South, M. (2007): Refplus: an r package extending the rma
algorithm. Bioinformatics, 23 (18), 2493–2494.
Irizarry, R., Bolstad, B., F., C., Cope, L., Hobbs, B., and Speed, T. (2003a): Summaries of
affymetrix genechip probe level data. Nucleic Acids Research, 31 (4), 1–8.
Irizarry, R., Hobbs, B., Collin, F., Beazer-Barclay, Y., Antonellis, K., Scherf, U., and Speed, T.
(2003b): Exploration, normalization, and summaries of high density oligonucleotide array
probe level data. Biostatistics, 4 (2), 249–264.
Jiang, X. (2013): Estimation of effective concentrations from in vitro dose-response data using the
log-logistic model. Ph.D. thesis, Medical Faculty of Ruprecht-Karls-University in Heidelberg.
Johnson, R. A. and Wichern, D. W. (1998): Applied Multivariate Statistical Analysis. Upper
Saddle River, New Jersey: Prentice Hall, 4th edition.
Kelly, C. and Rice, J. (1990): Monotone smoothing with application to dose-response curves and
the assessment of synergism. Biometrics, 46, 1071–1085.
120 Bibliography
Krug, A., Kolde, R., Gaspar, J., Rempel, E., Balmer, N., Meganathan, K., Vojnits, K., Baquiet’,
M., Waldmann, T., Ensenat-Waser, R., Jagtap, S., Evans, R., Julien, S., Peterson, H., Zagoura,
D., Kadereit, S., Gerhard, D., Sotiriadou, I., Heke, M., Natarajan, K., Henry, M., Winkler,
J., Marchan, R., Stoppini, L., Bosgra, S., Westerhout, J., Verwei, M., Vilo, J., Kortenkamp,
A., Hescheler, J., Hothorn, L., Bremer, S., van Thriel, C., Krause, K.-H., Hengstler, J., Rah-
nenführer, J., Leist, M., and Sachinidis, A. (2013): Human embryonic stem cell-derived test
systems for developmental neurotoxicity: a transcriptomics approach. Archives of Toxicology,
87, 123–143.
Lobanov, A., Turanov, A., Hatfield, D., and Gladyshev, V. (2010): Dual functions of codons in
the genetic code. Critical Reviews in Biochemistry and Molecular Biology, 45 (4), 257–265.
Mays, J., Birch, J., and Einsporn, R. (2000): An overview of model-robust regression. Journal
of Statistical Computation and Simulation, 66 (1), 79–100.
Müller, H. G. and Schmitt, T. (1988): Kernel and probit estimates in quantal bioassay. Journal
of the American Statistical Association, 83, 750–759.
NIBIO (2017): National Institute of Biomedical Innovation. URL https://www.nibiohn.
go.jp/english/index.html.
NIBIOHN (2017): National Institutes of Biomedical Innovation, Health and Nutrition. URL
http://toxico.nibiohn.go.jp/english/index.html.
NIHS (2017): National Institute of Health Sciences. URL http://www.nihs.go.jp/
english/index.html.
Nottingham, Q. J. and Birch, J. B. (2000): A semiparametric approach to analysing doseU˝re-
sponse data. Statistics in Medicine, 19, 389–404.
oerpub/epubjs-demo book (2017): Enhanced eBooks in the browser. URL http://oerpub.
github.io/epubjs-demo-book/content/m46032.xhtml. Retrieved March 28,
2017.
Olkin, I. and Spiegelman, C. H. (1987): A semiparametric approach to density estimation.
Journal of the American Statistical Association, 82 (399), 858–865.
PBworks (2016): Online Team Collaboration. URL http://compbio.pbworks.com/w/
page/16252906/Microarray%20Normalization%20and%20Expression%
20Index. Retrieved March 28, 2017.
Pickle, S. M., Robinson, T. J., Birch, J. B., and Anderson-Cook, C. (2008): A semi-parametric
approach to robust parameter design. Journal of Statistical Planning and Inference, 138,
114–131.
R Core Team (2015): R: A Language and Environment for Statistical Computing. R Foundation
for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/.
Rahman, M., Gokhale, D., and Ullah, A. (1997): A note on combining parametric and nonpara-
metric regression. Communications in Statistics-Simulation and Computation, 26, 519–529.
Rempel, E. (2015): Analyse der hochdimensionalen toxikologischen Expressionsdaten. Ph.D.
thesis, Faculty of Statistics of the Technical University of Dortmund.
Bibliography 121
Ritchie, M., Phipson, B., Wu, D., Hu, Y., Law, C., Shi, W., and Smyth, G. (2015): limma powers
differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids
Research, 43.
Ritz, C. (2010): Toward a unified approach to dose-response modeling in ecotoxicology. Envi-
ronmental Toxicology and Chemistry, 29 (1), 220–229.
Ritz, C. and Streibig, J. C. (2005): Bioassay analysis using r. Journal of Statistical Software,
12 (5). URL http://www.bioassay.dk.
Robinson, T. J., B., B. J., and Starnes, A. (2010): A semi-parametric approach to dual modeling
when no replication exists. Journal of Statistical Planning and Inference, 140, 2860–2869.
Schmoyer, R. L. (1984): Sigmoidally constrained maximum likelihood estimation in quantal
bioassay. Journal of the American Statistical Association, 79, 448–453.
Schug, M. (2011): Entwicklung eines in vitro Systems zur Untersuchung von substanzinduzierten
Genexpressionsänderungen bei primären Hepatozyten der Ratte. Ph.D. thesis, Faculty of
Chemistry of the Technical University of Dortmund.
Schug, M., Stöber, R., Heise, T., Mielke, H., Gundert-Remy, U., Godoy, P., Reif, R., Blaszkewicz,
M., Ellinger-Ziegelbauer, H., Ahr, H., Selinski, S., Günther, G., Marchan, R., Blaszkewicz,
M., Sachinidis, A., Nüssler, A., Oberemm, A., and Hengstler, J. (2013): Pharmacokinetics
explain in vivo/in vitro discrepancies of carcinogen-induced gene expression alterations in rat
liver and cultivated hepatocytes. Archives of Toxicology, 87 (2).
Shinde, V., Hoelting, L., Srinivasan, S., Meisig, J., Meganathan, K., Jagtap, S., Grinberg, M.,
Liebing, J., Bluethgen, N., Rahnenführer, J., Rempel, E., Stoeber, R., Schildknecht, S., Förster,
S., Godoy, P., van Thriel, C., Gaspar, J., Hescheler, J., Waldmann, T., Hengstler, J., Leist,
M., and Sachinidis, A. (2017): Definition of transcriptome-based indices for quantitative
characterization of chemically disturbed stem cell development: introduction of the stop-tox
ukn and stop-tox ukk tests. Archives of Toxicology, 91, 839–864.
Smyth, G. (2005): Limma: Linear models for microarray data. In: Bioinformatics and Computa-
tional Biology Solutions Using R and Bioconductor, Gentleman, R. and Carey, V. and Dudoit,
S. and Irizarry, R. and Huber, W (eds.), Springer, New York, 179–184.
Staniswalis, J. and Cooper, V. (1988): Kernel estimates of dose response. Biometrics, 44,
1103–1119.
Warnes, G., Bolker, B., Bonebakker, L., Gentleman, R., Liaw, W., Lumley, T., Maechler, M.,
Magnusson, A., Moeller, S., Schwartz, M., and Venables, W. (2015): gplots: Various R Pro-
gramming Tools for Plotting Data. URL http://CRAN.R-project.org/package=
gplots. R package version 2.17.0.
Wilkinson, L. and Friendly, M. (2009): The history of the cluster heat map. The American
Statistician, 63 (2), 179–184.
Wooldridge, M. (1992): A test for functional form against nonparametric alternatives. Econo-
metric theory, 8, 452–475.
Yatchew, A. (1992): Non-parametric regression tests based on least square. Econometric Theory,
8, 435–451.
122 Bibliography
Yuan, Y. and Yin, G. (2011): Dose-response curve estimation: A semiparametric mixture
approach. Biometrics, 67, 1543–1554.
Zhang, H., Holden-Wiltse, J., Wang, J., and Liang, H. (2013): A strategy to model nonmonotonic
dose-response curve and estimate ic50. PLoS ONE, 8 (8).
List of Figures
2.1 Illustration of the DNA and RNA structure. . . . . . . . . . . . . . . . . . . . 5
2.2 The genetic code. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
2.3 From DNA to protein. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
2.4 GeneChip expression array design. . . . . . . . . . . . . . . . . . . . . . . . . 9
2.5 Affymetrix microarrays. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
2.6 Illustration of the RMA and RMA+ algorithm. . . . . . . . . . . . . . . . . . . 12
2.7 Overview of the UKN1 test system’s treatment protocol. . . . . . . . . . . . . 18
3.1 Illustrative example of a heatmap. . . . . . . . . . . . . . . . . . . . . . . . . 25
3.2 Example of a four-parameter log-logistic (4pLL) model. . . . . . . . . . . . . 34
3.3 Illustration of the ALEC estimator and its 95%-confidence intervals. . . . . . . 39
3.4 Illustration of the ALEC estimator and LEC estimator. . . . . . . . . . . . . . 41
4.1 Principle component analysis of gene expression data obtained from human
hepatocytes after incubation with 148 chemicals and 7 cytokines. . . . . . . . . 45
4.2 Reproducibility between replicates in human hepatocytes. . . . . . . . . . . . . 46
4.3 Number of genes significantly upregulated in human hepatocytes. . . . . . . . 47
4.4 Exclusivity analysis of the genes upregulated in human hepatocytes. . . . . . . 49
4.5 Concentration progression analysis: Principles of the progression profile index
and the progression profile error indicator illustrated for four compounds. . . . 51
4.6 Progression profile indices for all compounds tested at three concentrations after
three exposure periods. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
4.7 Progression profile error indicator applied to genes deregulated in human hepa-
tocytes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
4.8 Selection values for genes upregulated in human hepatocytes. . . . . . . . . . . 56
4.9 Overview of the numbers of Sv 1, Sv 3, Sv 5 and Sv 20 genes. . . . . . . . . . 57
4.10 Overlap between unstable baseline genes (CS) and Sv 20 (Sv 3) genes. . . . . . 59
5.1 Principle component analysis of gene expression data obtained from cultured
rat primary hepatocytes (in vitro) and from rat liver samples (in vivo) after
incubation with 29 (in vitro) and 30 (in vivo) chemicals. . . . . . . . . . . . . . 62
5.2 Principle component analysis of gene expression data obtained from cultured rat
primary hepatocytes (in vitro) after incubation with 29 compounds. . . . . . . . 63
5.3 Principle component analysis of gene expression data obtained from rat liver
samples (in vivo) after incubation with 30 compounds. . . . . . . . . . . . . . 64
5.4 Reproducibility between replicates in the NRW database. . . . . . . . . . . . . 65
5.5 Number of genes significantly deregulated in the NRW in vitro database. . . . . 67
5.6 Number of genes significantly deregulated in the NRW in vitro database. . . . . 68
5.7 Exclusivity analysis of the genes up- and downregulated in the NRW in vitro
database. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
5.8 Exclusivity analysis of the genes up- and downregulated in the NRW in vivo
database. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
2 List of Figures
5.9 Concentration dependency in the NRW in vitro database. . . . . . . . . . . . . 72
5.10 Selection values for the genes up- and downregulated in the NRW database. . . 73
5.11 Overlap of genes deregulated by the same compounds in in vitro and in in vivo. 74
5.12 Overall selection values of the consensus Sv 3 NRW genes. . . . . . . . . . . . 75
5.13 Number of consensus Sv 3 NRW genes that are deregulated by the indicated
compounds in in vitro and in in vivo for at least one test condition. . . . . . . . 77
5.14 Overlap between the in vitro and in vivo consensus Sv 3 genes. . . . . . . . . . 79
5.15 Plot showing the cumulative percentage of covered compounds in the NRW and
TGD data set. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
5.16 Plot showing the cumulative percentage of covered compounds in the combined
NRW and TGD data set. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
5.17 Overview of the study design and the analytical procedure for the in vivo
biomarker identification. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
6.1 Illustration of the simulated Scenarios I-IV. . . . . . . . . . . . . . . . . . . . 87
6.2 Distributions of the estimated alert concentrations (point estimates) for Scenarios
I-IV with k = 3 replicates. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
6.3 Distributions of the estimated alert concentrations (CI-based estimates) for
Scenarios I-IV with k = 3 replicates. . . . . . . . . . . . . . . . . . . . . . . . 91
6.4 Distributions of the quantiles calculated from the distribution of the ̂ALECs
representing the ̂ALOECs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
6.5 Distributions of the quantiles calculated from the distribution of the L̂ECs repre-
senting the ̂LOECs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
6.6 Boxplots illustrating the distributions of the differences between the estimated
alert concentrations and the respective true ALECs of the Scenarios II-IV. . . . 99
6.7 Boxplots comparing the alert concentrations obtained with the 4pLL method
with those obtained with the Limma method in Scenario I. . . . . . . . . . . . 101
6.8 Boxplots comparing the alert concentrations obtained with the 4pLL method
with those obtained with the Limma method in Scenario II. . . . . . . . . . . . 102
6.9 Boxplots comparing the alert concentrations obtained with the 4pLL method
with those obtained with the Limma method in Scenario III. . . . . . . . . . . . 104
6.10 Boxplots comparing the alert concentrations obtained with the 4pLL method
with those obtained with the Limma method in Scenario IV. . . . . . . . . . . . 106
6.11 Principal component analysis of gene expression data obtained from human em-
bryonic stem cells after incubation of valproic acid (VPA chronic concentration
study). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
6.12 Flowchart of the analytical procedure for the detection of critical changes in
gene expression. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
6.13 Distributions of the estimated alert concentrations for the VPA chronic concen-
tration study. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
6.14 Distributions of the quantiles calculated from the distribution of the 4pLL es-
timates representing the Limma estimates in the VPA chronic concentration
study. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
6.15 Boxplots comparing the alert concentrations obtained with the 4pLL method
with the ones obtained with the Limma method in the VPA chronic concentration
study. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
List of Figures 3
C.1 Principle component analysis of gene expression data obtained from cultured
human hepatocytes: Data of the low concentration and the incubation time points
2h, 8h and 24h. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
C.2 Principle component analysis of gene expression data obtained from cultured
human hepatocytes: Data of the middle concentration and the incubation time
points 2h, 8h and 24h. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
C.3 Principle component analysis of gene expression data obtained from cultured
human hepatocytes: Data of the high concentration and the incubation time
points 2h, 8h and 24h. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
C.4 Reproducibility between replicates in the low TG-GATEs concentration set. . . 39
C.5 Reproducibility between replicates in the middle TG-GATEs concentration set. 40
C.6 Reproducibility between replicates in the high TG-GATEs concentration set. . . 41
C.7 Boxplots of the Euclidean distances between replicate and treatment-control
pairs in the TG-GATEs data set. . . . . . . . . . . . . . . . . . . . . . . . . . 42
C.8 Number of genes significantly downregulated in human hepatocytes. . . . . . . 43
C.9 Exclusivity analysis of the genes downregulated in human hepatocytes. . . . . . 44
C.10 Modified progression profile error indicator applied to the genes deregulated in
human hepatocytes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
C.11 Selection values for the genes downregulated in human hepatocytes. . . . . . . 46
C.12 Heatmap of the 100 most deregulated genes across all 148 compounds tested at
the highest concentration for 24h of incubation in human hepatocytes. . . . . . 47
C.13 P -values of ANOVA (analysis of variance) for the in vivo NRW experiments
resulting from testing the hypothesis whether the model parameters experimental
series and exposure period have an influence on gene expression. . . . . . . . . 48
C.14 Principal component analysis of gene expression data obtained from cultured
rat hepatocytes (TGD): Data of the low, middle and high concentration and the
incubation time point 24h. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
C.15 Principal component analysis of gene expression data obtained from rat liver
cells (TGD): Data of the high concentration and the incubation time point 24h. 50
C.16 Number of genes significantly deregulated at the low concentration after 24h
exposure in the TGD in vitro database. . . . . . . . . . . . . . . . . . . . . . . 51
C.17 Number of genes significantly deregulated at the middle concentration after 24h
exposure in the TGD in vitro database. . . . . . . . . . . . . . . . . . . . . . . 52
C.18 Number of genes significantly deregulated at the high concentration after 24h
exposure in the TGD in vitro database. . . . . . . . . . . . . . . . . . . . . . . 53
C.19 Number of genes significantly deregulated at the high concentration after 24h
exposure in the TGD in vivo database. . . . . . . . . . . . . . . . . . . . . . . 54
C.20 Exclusivity analysis of the genes up- and downregulated at the low concentration
after 24h exposure in the TGD in vitro database. . . . . . . . . . . . . . . . . . 55
C.21 Exclusivity analysis of the genes up- and downregulated at the middle concen-
tration after 24h exposure in the TGD in vitro database. . . . . . . . . . . . . . 56
C.22 Exclusivity analysis of the genes up- and downregulated at the high concentration
after 24h exposure in the TGD in vitro database. . . . . . . . . . . . . . . . . . 57
C.23 Exclusivity analysis of the genes up- and downregulated at the high concentration
after 24h exposure in the TGD in vivo database. . . . . . . . . . . . . . . . . . 58
C.24 Concentration dependency in the NRW in vitro database. . . . . . . . . . . . . 62
C.25 Concentration dependency in the NRW in vivo database. . . . . . . . . . . . . 71
C.26 Selection values for the up- and downregulated genes in the TGD in vitro database. 72
C.27 Selection values for the up- and downregulated genes in the TGD in vivo database. 73
4 List of Figures
C.28 Overall selection values of the consensus Sv 3 TGD genes. . . . . . . . . . . . 74
C.29 Number of consensus Sv 3 TGD genes that are deregulated by the indicated
compounds in in vitro and in in vivo for at least one test condition. . . . . . . . 75
C.30 Distributions of the estimated alert concentrations (point estimates) for Scenarios
I-IV with k = 6 replicates. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
C.31 Distributions of the estimated alert concentrations (CI-based estimates) for
Scenarios I-IV with k = 6 replicates. . . . . . . . . . . . . . . . . . . . . . . . 77
C.32 Distributions of the estimated alert concentrations (point estimates) for Scenarios
I-IV with k = 10 replicates. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
C.33 Distributions of the estimated alert concentrations (CI-based estimates) for
Scenarios I-IV with k = 10 replicates. . . . . . . . . . . . . . . . . . . . . . . 79
C.34 Boxplots illustrating the distributions of the differences between the estimated
alert concentrations and the respective true ALECs of the Scenarios II-IV (k = 6
replicates). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
C.35 Boxplots illustrating the distributions of the differences between the estimated
alert concentrations and the respective true ALECs of the Scenarios II-IV (k = 10
replicates). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
List of Tables
2.1 Overview of all data sets used within the framework of this work . . . . . . . . 14
2.2 Number of compounds tested in primary human hepatocytes (TG-GATEs). . . 15
2.3 Number of compounds tested in vitro in primary rat hepatocytes (TG-GATEs). . 16
2.4 Number of compounds tested in vivo in rat liver cells (TG-GATEs). . . . . . . 16
2.5 Overview of the number of replicates used in the VPA chronic concentration study. 18
3.1 Overview of the methods used for estimating alert concentrations from concentration-
dependent gene expression studies. . . . . . . . . . . . . . . . . . . . . . . . . 42
6.1 Total number of excluded genes in Scenarios I-IV. . . . . . . . . . . . . . . . . 89
6.2 Summary statistics for the distributions of the estimated alert concentrations
(CI-based estimates) for Scenarios I-IV. . . . . . . . . . . . . . . . . . . . . . 92
6.3 Total number of false positive alerts in Scenarios I-IV. . . . . . . . . . . . . . . 94
6.4 Coverage probabilities for capturing the true ALEC value in the Scenarios II-IV. 105
B.1 Compound-specific summary for the primary human hepatocytes in the TG-
GATEs data set. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
B.2 Compound-specific summary for the rat hepatocytes in the TG-GATEs (in vitro)
data set (TGD). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
B.3 Compound-specific summary for the rat liver cells in the TG-GATEs (in vivo)
data set (TGD, incubation for hours). . . . . . . . . . . . . . . . . . . . . . . . 20
B.4 Compound-specific summary for the rat liver cells in the TG-GATEs (in vivo)
data set (TGD, incubation for days). . . . . . . . . . . . . . . . . . . . . . . . 25
B.5 Compound-specific summary for the rat liver cells in the NRW data set. . . . . 30
B.6 Compound-specific summary for the rat hypotocytes in the NRW data set. . . . 31
B.7 Summary statistics for the distributions of the estimated alert concentrations
(point estimates) for Scenarios I-IV. . . . . . . . . . . . . . . . . . . . . . . . 32
B.8 Summary statistics for the distributions of the differences between the estimated
alert concentrations (point estimates) and the respective true ALECs of the
Scenarios II-IV. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
B.9 Summary statistics for the distributions of the differences between the estimated
alert concentrations (CI-based estimates) and the respective true ALECs of the
Scenarios II-IV. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
A Derivation
A.1 Derivation of∇h(φ)
Let h(·) denote the inverse function of f(·), the four-parameter log-logistic model in (3.10)
h(φ) = f−1(λ,φ).
The ALEC for a pre-specified effect level λ is then given by
ALEC = h(φ) = φ(e)
(
φ(d) − λ
λ− φ(c)
)1/φ(b)
, (A.1)
where φ(e) = exp (φ(e)∗) and φ(e)∗ denotes the logarithmized half-maximal effective concentra-
tion. The function in (A.1) can be rewritten:
h(φ) = exp {log(h(φ))} = exp
 1φb log
(
φ(d) − λ
λ− φ(c))
)
+ log
(
φ(e)
)︸ ︷︷ ︸
=φ(e)
∗
 . (A.2)
The gradient of ∇h(φ) is calculated by using the chain rule that states for two functions g1
and g2:
∇h(φ) = ∇g2(g1(φ)) · ∇g1(h(φ)), (A.3)
where g2 = exp{·} and g1 = log(·). Thus, g2 is a function of g1, which is a function of h, which
is itself a function of the parameter vector φ. As the exponential function is its own derivative,
the equation in (A.3) can be simplified as follows:
∇h(φ) = h(φ) · ∇ log (h(φ))︸ ︷︷ ︸
g1
. (A.4)
The function h(φ) can be considered as prefactor which is placed out the vector of first order
derivatives. Hence, it is sufficient to calculate the partial derivatives of the inner function g1
in (A.2), which is g1 = 1φb log
(
φ(d)−λ
λ−φ(c)
)
+ φ(e)
∗ . Differentiating g1 subject to the four parameters
φ(b), φ(c), φ(d) and φ(e)∗ yields
∂h(φ)
∂φ(b)
= − 1
φ(b)2
log
(
φ(d) − λ
λ− φ(c))
)
,
∂h(φ)
∂φ(c)
=
1
φ(b)
· λ− φ
(c)
φ(d) − λ · (−1) ·
φ(d) − λ
(λ− φ(c))2 · (−1) =
1
φ(b)(λ− φ(c)) , (A.5)
∂h(φ)
∂φ(d)
=
1
φ(b)
· λ− φ
(c)
φ(d) − λ ·
1
λ− φ(c) =
1
φ(b)(φ(d) − λ) ,
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∂h(φ)
∂φ(e)∗
= 1.
The gradient ∇g1 is the vector of the first order derivatives in (A.5). Setting ∇g1 into
formula (A.4), gives
∇h(φ) =

∂h(φ)
∂φ(b)
∂h(φ)
∂φ(c)
∂h(φ)
∂φ(d)
∂h(φ)
∂φ(e)
∗
 = h(φ)

− 1
φ(b)
2 log
(
φ(d)−λ
λ−φ(c)
)
1
φ(b)(λ−φ(c))
1
φ(b)(φ(d)−λ)
1
 .
A.2 Derivation of∇f(x, φ)
Let f(·) denote the four-parameter log-logistic model for a dose-response data (x, y):
f(x,φ) = φ(c) +
φ(d) − φ(c)
1 + exp {φ(b) [log(x)− log(φ(e))]}
= φ(c) + (φ(d) − φ(c)) · [1 + exp{φ(b) [log(x)− log(φ(e))]}︸ ︷︷ ︸(
x
φ(e)
)φ(b)
]−1 (A.6)
The 4pLL model function in (A.6) is differentiated with respect to φ(b), φ(c), φ(d) and φ(e):
∂h(φ)
∂φ(b)
= −(φ
(d) − φ(c)) · [log(x)− log(φ(e))] · exp{φ(b) [log(x)− log(φ(e))]}
[1 + exp {φ(b) [log(x)− log(φ(e))]}]2
= −
(φ(d) − φ(c)) · [log(x)− log(φ(e))] ·
(
x
φ(e)
)φ(b)
[
1 +
(
x
φ(e)
)φ(b)]2
∂h(φ)
∂φ(c)
= 1−
[
1
1 + exp {φ(b) [log(x)− log(φ(e))]}
]
= 1−
 1
1 +
(
x
φ(e)
)φ(b)

∂h(φ)
∂φ(d)
=
1
1 + exp {φ(b) [log(x)− log(φ(e))]} =
1
1 +
(
x
φ(e)
)φ(b)
∂h(φ)
∂φ(e)
=
−(φ(d) − φ(c)) · exp{φ(b) [log(x)− log(φ(e))]} · (−φ(b))
φ(e) · [1 + exp {φ(b) [log(x)− log(φ(e))]}]2
=
φ(b) · (φ(d) − φ(c)) ·
(
x
φ(e)
)φ(b)
φ(e)
[
1 +
(
x
φ(e)
)φ(b)]2 .
(A.7)
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The gradient∇f containing the partial derivatives from the calculations in (A.7) is then given
by
∇f(x,φ) =

∂f(x,φ)
∂φ(b)
∂f(x,φ)
∂φ(c)
∂f(x,φ)
∂φ(d)
∂f(x,φ)
∂φ(e)

=

−(
φ(d)−φ(c))
(
log
(
x
φ(e)
))(
x
φ(e)
)φ(b)
1+( x
φ(e)
)φ(b)2
1−
 1
1+
(
x
φ(e)
)φ(b)

1
1+
(
x
φ(e)
)φ(b)
φ(b)(φ(d)−φ(c))
(
x
φ(e)
)φ(b)
φ(e)
1+( x
φ(e)
)φ(b)2

.
A.3 Derivation of γ = F(tν)
Let L̂EC and L̂OEC be the estimated alert concentrations obtained from the 4pLL and Limma
model approach, respectively. According to section 3.5.4 a confidence interval for the LEC can
be constructed as follows
L̂EC± tν,γ
√
v̂ar(L̂EC), (A.8)
where tν,γ corresponds to the γ-quantile of a t-distribution with ν = n− 4 degrees of freedom
for n observations.
Given the distribution of the L̂ECs, it can be calculated which quantiles of this distribution
the L̂OECs correspond to. For this, the formula in (A.9) must be transformed with respect to γ.
The LOEC estimator is set equal to the upper confidence limit which is calculated according to
formula (A.8) and γ is then obtained with the following equivalent transformation
L̂OEC = L̂EC + tν,γ
√
v̂ar(L̂EC)
⇔ tν,γ = L̂OEC− L̂EC√
v̂ar(L̂EC)
⇔ γ = F(tν) = F
 L̂OEC− L̂EC√
v̂ar(L̂EC)
 ,
(A.9)
where F indicates the distribution function of the t-distribution with ν degrees of freedom.
Analogously, the ̂ALOECs are re-calculated in terms of the respective quantiles which result
from the distribution of the ÂLECs.
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32 B Tables
Table B.7: Summary statistics for the distributions of the estimated alert concentrations for Scenarios
I-IV. The following parameters are presented: The total number of alerts (n), the median
(Med), the interquartile range (IQR) and the standard deviation (SD). The method for
estimating the alerts is subscripted after the corresponding parameter. An alert was given
when the given fold change value of 1.5 was reached exactly (4pLL) or exceeded by
the average value (Limma) (point estimate). The table refers to the Figures 6.2, C.30
and C.32.
n4pLL nLimma Med4pLL MedLimma IQR4pLL IQRLimma SD4pLL SDLimma
Scenario I
k=3 543 847 406.600 450 229.000 450 177.856 307.333
k=6 503 886 431.300 450 221.400 350 171.852 275.917
k=10 519 815 462.800 550 209.500 550 169.098 307.119
Scenario II
k=3 988 988 502.200 550 40.100 0 40.789 96.717
k=6 996 997 499.600 550 30.400 0 31.084 69.232
k=10 1000 1000 500.400 550 22.200 0 22.251 53.692
Scenario III
k=3 991 994 548.200 550 40.800 250 43.118 136.465
k=6 997 1000 549.600 550 31.100 250 32.698 128.133
k=10 996 1000 549.200 550 25.000 250 25.010 126.099
Scenario IV
k=3 926 960 666.600 800 107.400 0 92.728 131.259
k=6 969 987 676.600 800 76.600 0 73.027 86.586
k=10 966 993 674.700 800 62.000 0 55.499 57.018
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Table B.8: Summary statistics for the distributions of the differences between the estimated alert
concentrations and the respective true ALECs of the Scenarios II-IV. Scenario I was
excluded from the analysis since no deviations could be computed (no ALEC value was
provided). The following parameters are presented: The total number of alerts (n), the
median (Med), the interquartile range (IQR) and the standard deviation (SD). The method
for estimating the alerts is subscripted and indicated after the corresponding parameter.
An alert was given when the given fold change value of 1.5 was reached exactly (4pLL)
or exceeded by the average value (Limma) (point estimate). The table refers to the upper
panels of the Figures 6.6, C.34 and C.35.
n4pLL nLimma Med4pLL MedLimma IQR4pLL IQRLimma SD4pLL SDLimma
Scenario I
No ALEC
Scenario II
k=3 988 988 2.383 50.170 40.070 0.000 40.789 96.717
k=6 996 997 -0.257 50.170 30.410 0.000 31.084 69.232
k=10 1000 1000 0.531 50.170 22.180 0.000 22.251 53.692
Scenario III
k=3 991 994 -0.482 1.358 40.810 250.042 43.118 136.465
k=6 997 1000 0.937 1.358 31.120 250.042 32.698 128.133
k=10 996 1000 0.537 1.358 24.930 250.042 25.010 126.099
Scenario IV
k=3 926 960 -12.480 120.900 107.450 0.000 92.728 115.675
k=6 969 987 -2.445 120.900 76.530 0.000 73.027 74.730
k=10 966 993 -4.340 120.900 62.030 0.000 55.499 46.622
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Table B.9: Summary statistics for the distributions of the differences between the estimated alert
concentrations and the respective true ALECs of the Scenarios II-IV. Scenario I was
excluded from the analysis since no deviations could be computed (no ALEC value was
provided). The following parameters are presented: The total number of alerts (n), the
median (Med), the interquartile range (IQR) and the standard deviation (SD). The method
for estimating the alerts is subscripted and indicated after the corresponding parameter.
An alert was given when the given fold change value of 1.5 was exceeded significantly
(p ≤ 0.05). The table refers to the lower panels of the Figures 6.6, C.34 and C.35
n4pLL nLimma Med4pLL MedLimma IQR4pLL IQRLimma SD4pLL SDLimma
Scenario I
No ALEC
Scenario II
k=3 316 999 285.200 300.200 163.200 250.030 114.745 125.684
k=6 427 1000 280.500 50.170 162.200 250.030 105.958 125.794
k=10 495 1000 285.900 50.170 162.300 250.030 102.972 117.702
Scenario III
k=3 749 988 83.350 251.400 113.870 0.000 100.691 80.644
k=6 861 995 72.020 251.400 95.490 0.000 92.705 71.981
k=10 929 1000 60.580 251.400 69.050 0.000 80.034 69.939
Scenario IV
k=3 285 648 66.150 320.900 175.080 200.000 115.488 113.294
k=6 419 833 100.500 120.900 153.710 200.000 105.302 98.027
k=10 570 910 93.140 120.900 135.780 200.000 97.921 87.823
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Figure C.1: Corresponding data to Figure 4.1. Data of the low concentration and the incubation time
points 2h, 8h and 24h. A. Overview of all samples and replicates. The dark and light
green symbols illustrate the controls and exposed samples, respectively. B. Connecting
lines between replicates illustrates the degree of variability. C. Mean values of the repli-
cates. D. Connecting lines between controls (dark green) and corresponding compound
exposed samples (light green). E. Subtraction of the controls from the corresponding
compound exposed samples.
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Figure C.2: Corresponding data to Figure 4.1. Data of the middle concentration and the incubation
time points 2h, 8h and 24h. A. Overview of all samples and replicates. The dark and light
green symbols illustrate the controls and exposed samples, respectively. B. Connecting
lines between replicates illustrates the degree of variability. C. Mean values of the repli-
cates. D. Connecting lines between controls (dark green) and corresponding compound
exposed samples (light green). E. Subtraction of the controls from the corresponding
compound exposed samples.
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Figure C.3: Corresponding data to Figure 4.1. Data of the high concentration and the incubation
time points 2h, 8h and 24h. A. Overview of all samples and replicates. The dark
and light green symbols illustrates the controls and exposed samples, respectively.
B. Connecting lines between replicates illustrate the degree of variability. C. Mean values
of the replicates. D. Connecting lines between controls (dark green) and corresponding
compound exposed samples (light green). E. Subtraction of the controls from the
corresponding compound exposed samples.
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Figure C.4: Reproducibility between replicates (low concentration). Left panel shows the frequency
distribution of the Euclidean distance between all pairs of replicates. The red line
indicates the 5% largest observed distances between replicates. The right panel shows
the PCA plot with connecting lines between the 5% largest observed distances.
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Figure C.5: Reproducibility between replicates (middle concentration). Left panel shows the fre-
quency distribution of the Euclidean distance between all pairs of replicates. The red line
indicates the 5% largest observed distances between replicates. The right panel shows
the PCA plot with connecting lines between the 5% largest observed distances.
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Figure C.6: Reproducibility between replicates (high concentration). Left panel shows the frequency
distribution of the Euclidean distance between all pairs of replicates. The red line
indicates the 5% largest observed distances between replicates. The right panel shows
the PCA plot with connecting lines between the 5% largest observed distances.
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Figure C.7: Reproducibility between replicates. Boxplots of the Euclidean distances between all
pairs of replicates for all test conditions. The grey and green points in each left boxplot
illustrate the distances between the control and exposed replicates; those in each right
boxplot show the distances between control-treatment pairs (matched pairs).
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Figure C.10: Modified progression profile error indicator. The progression profile error indicator
values have been modified such that the values were set to zero if they were greater
than 0.5 but the indicated compound has deregulated less than (or equal to) 20 genes at
the respective lower concentration. A high value means that a high fraction of genes
is deregulated exclusively at a lower compared to a respective higher concentration.
Each symbol represents an individual compound. The triangles present the excluded
compounds. Grey symbols: less than or equal to 20 genes are deregulated in total;
black symbols: more than 20 genes are deregulated in total and both values are smaller
than or equal to 0.5; red symbols: more than 20 genes are deregulated in total and at
least one of the error indicator values is greater than 0.5.
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Figure C.12: Unsupervised clustering of the 100 most deregulated genes across all compounds
tested at the highest concentration for 24h of incubation. The lines represent the
compounds, while each column stands for a gene. Red color indicates up and blue
color downregulated genes as indicated by the code in the upper left. Moreover, the
compounds have been classified with respect to their genotoxicity, human hepatotoxicity,
and BSEP inhibiting capacity. These properties are indicated in the columns left of the
heatmap. Unsupervised clustering results in three clusters that can be associated with
biological motifs, proliferation, cytochrome P450 (CYP), and stress response.
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Figure C.13: P -values of ANOVA (analysis of variance): The analysis was performed for the in
vivo NRW experiments to test whether the model parameters experimental series and
exposure period have an influence on gene expression. The analysis was performed
gene-wise. The left panel shows the results for the factor experimental series and
the right panel shows the results for the factor exposure period. Small p-values are
indicative of strong parameter influence.
49
l
l
l
l
l
l
ll
l
l
l
l
llll
l ll
ll
l
ll
l l
l l
l l
ll
l
ll
ll l l
l ll l
l l
l
l l
ll
ll
l
l
l
ll l
ll
l l
ll
l
l
l l
l
l
l l
l
l
l
ll
ll
l
l l
ll
l
l
l
ll
l
l
l l
l l
ll l l
l
l
l
ll
ll
l l ll
ll
l
l
ll
l
l
l l
ll
l
ll
ll
l l
l l
ll
ll
ll
ll
l
l
ll l
l
l
l
l
l
l l
l ll
l l
l
l
l l
l
ll ll
ll
ll
ll ll
ll l l
l
l l
ll
l
l l
lll
l
ll
l
l l
l
ll
l
l
l
l
ll
ll l
l
l
l l l
ll
l
l
ll
ll
l l
l
l
l
ll
lll
l
ll
ll
l l
l
ll
l
l
ll
ll
l
l
l
l
l
l
l l
ll
l l
l l
ll
ll
l
−10 −5 0 5 10
−
10
−
5
0
5
10
A
PC1 (25.2 %)
PC
2 
(13
.2 
%)
Low concentration, 24h
l
l
l
l
l
l
l
ll
l
l
l
l
llll
l ll
ll
l
ll
l l
l l
l l
ll
l
ll
ll l l
l ll l
l l
l
l l
ll
ll
l
l
l
ll l
ll
l l
ll
l
l
l l
l
l
l l
l
l
l
ll
ll
l
l l
ll
l
l
l
ll
l
l
l l
l l
ll l l
l
l
l
ll
ll
l l ll
ll
l
l
ll
l
l
l l
ll
l
ll
ll
l l
l l
ll
ll
ll
ll
l
l
ll l
l
l
l
l
l
l l
l ll
l l
l
l
l l
l
ll ll
ll
ll
ll ll
ll l l
l
l l
ll
l
l l
lll
l
ll
l
l l
l
ll
l
l
l
l
ll
ll l
l
l
l l l
ll
l
l
ll
ll
l l
l
l
l
ll
lll
l
ll
ll
l l
l
ll
l
l
ll
ll
l
l
l
l
l
l
l l
ll
l l
l l
ll
ll
l
−10 −5 0 5 10
−
10
−
5
0
5
10
B
PC1 (25.2 %)
PC
2 
(13
.2 
%)
l
l
l
l
l
l
l
ll
l
l l
l
l
l
l
lll
l l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l l
l l
l
l
l
l
l
l
l
l
l l
l
l l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
−10 −5 0 5 10
−
10
−
5
0
5
10
C
PC1 (25.3 %)
PC
2 
(13
.3 
%)
l
l
l
l
l
l
ll
l
l l
l
l
l
l
lll
l l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l l
l l
l
l
l
l
l
l
l
l
l l
l
l l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
−10 −5 0 5 10
−
10
−
5
0
5
10
D
PC1 (25.3 %)
PC
2 
(13
.3 
%)
l
l
l
l
l
l
ll
l
ll
l
ll l
l
l
l ll
ll
l
ll
l
ll
ll ll
ll
l
ll
l
l
l
ll
l
l l
l
l
l
l
ll
ll
l
l
l
l
ll
l
l
ll
l l
ll
l
l
l
ll
l
l
l
l
ll
l
l
l
−20 −15 −10 −5 0 5
−
10
−
5
0
5
10E
PC1 (51.6 %)
PC
2 
(8.
7 %
)
l
l
l
l
l
l
l
ll
l l
l
ll
l l
l
l
l
lll
l
l
l
ll ll
ll
l
l
l ll
ll
ll
lll
l
ll
l
l ll
l
l
ll
l
ll
l
l
ll
ll
ll
l
ll
l
l
l
lll
ll
ll
ll
ll
ll
l
ll
l
l
llll
ll ll
l
l ll
l
l
l
l
l
l
lll
l
ll
ll
l
ll l
ll
ll
ll
l l l
ll l
l
ll l
ll
l l
ll
ll
l
l
l
l
llll
ll
l
l
l
l
llll
l
ll
l l
ll
lll
l
ll
l
ll
ll
l
l
ll
ll l
l
l l
l
l l l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
ll
l
ll
ll
l
l
ll
ll
llll
ll
ll
l
l
l
ll l l
ll
ll
llll
l
l
−10 −5 0 5 10
−
10
−
5
0
5
10
PC1 (24.3 %)
PC
2 
(13
.4 
%)
Middle concentration, 24h
l
l
l
l
l
l
ll
l l
l
ll
l l
l
l
l
lll
l
l
l
ll ll
ll
l
l
l ll
ll
ll
lll
l
ll
l
l ll
l
l
ll
l
ll
l
l
ll
ll
ll
l
ll
l
l
l
lll
ll
ll
ll
ll
ll
l
ll
l
l
llll
ll ll
l
l ll
l
l
l
l
l
l
lll
l
ll
ll
l
ll l
ll
ll
ll
l l l
ll l
l
ll l
ll
l l
ll
ll
l
l
l
l
llll
ll
l
l
l
l
llll
l
ll
l l
ll
lll
l
ll
l
ll
ll
l
l
ll
ll l
l
l l
l
l l l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
ll
l
ll
ll
l
l
ll
ll
llll
ll
ll
l
l
l
ll l l
ll
ll
llll
l
l
−10 −5 0 5 10
−
10
−
5
0
5
10
PC1 (24.3 %)
PC
2 
(13
.4 
%)
l
l
l
l
l
l
l
l
l
ll
l
ll l
lll
l l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l
l
ll
ll
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l l
l
l
ll
l
−10 −5 0 5 10
−
10
−
5
0
5
10
PC1 (24.5 %)
PC
2 
(13
.5 
%)
l
l
l
l
l
l
l
l
l
ll
l
ll l
lll
l l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l
l
ll
ll
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l l
l
l
ll
l
−10 −5 0 5 10
−
10
−
5
0
5
10
PC1 (24.5 %)
PC
2 
(13
.5 
%)
l
l
l l
l
l
l
l
l
l l
l
l ll
l
l
l
l
ll l
l
l
l
l
ll lll llll
l
l
l ll
l
l
l
l
l
l
ll l
l
l
l
l
l ll
l ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
−20 −10 0 10
−
15
−
5
0
5
10
15
PC1 (45.5 %)
PC
2 
(8.
7 %
)
ll
l
l
l
ll
ll
ll
l
ll
ll
ll
l
l
ll
l ll
ll
lll
ll
ll
l
l
ll
l
l
ll
lll
l
l
l
l
ll
ll
l
ll
l
l
ll
l l
l
l
ll
ll
l
ll
l
l
l
l
l
l
ll
ll
l
l
l
l
l
ll
l
ll
ll
l l
lll
ll
l
l
l
l
lll
l
l
l l
l
l
l
ll
ll
l
l
ll
l
l ll
l
l
l l l
ll
ll
ll
l
l
l
l
ll
l l
lll
l
l
l
ll
l
ll
l
ll
l
l ll
l
l
l l
l
ll
ll
l
l
ll
l
l
ll
l
l
l l
ll
l
ll l
l
l ll
ll
l
l
l
l
l
l
l
l l
ll
l
l
l
ll
ll
l
l
l
l
ll
l
l
l
l ll
ll l
l
ll
ll l
ll
lll
l
ll
ll
−15 −10 −5 0 5 10 15
−
10
−
5
0
5
10
15
PC1 (27.2 %)
PC
2 
(12
.2 
%)
High concentration, 24h
ll
l
l
l
ll
ll
ll
l
ll
ll
ll
l
l
ll
l ll
ll
lll
ll
ll
l
l
ll
l
l
ll
lll
l
l
l
l
ll
ll
l
ll
l
l
ll
l l
l
l
ll
ll
l
ll
l
l
l
l
l
l
ll
ll
l
l
l
l
l
ll
l
ll
ll
l l
lll
ll
l
l
l
l
lll
l
l
l l
l
l
l
ll
ll
l
l
ll
l
l ll
l
l
l l l
ll
ll
ll
l
l
l
l
ll
l l
lll
l
l
l
ll
l
ll
l
ll
l
l ll
l
l
l l
l
ll
ll
l
l
ll
l
l
ll
l
l
l l
ll
l
ll l
l
l ll
ll
l
l
l
l
l
l
l
l l
ll
l
l
l
ll
ll
l
l
l
l
ll
l
l
l
l ll
ll l
l
ll
ll l
ll
lll
l
ll
ll
−15 −10 −5 0 5 10 15
−
10
−
5
0
5
10
15
PC1 (27.2 %)
PC
2 
(12
.2 
%)
ll
l
l
l
l
l
l
l
l
l
l
l l
l ll
l
l
l
l
l
l
l
ll
l l
l
l
l
l
l
l l
l
l
ll
l
l
l
l
l l
l
l
l
l
l
l
ll
l l
l
ll
l
l
l
l
l
l
l
l
l l
l
l l l
l
l l
l
l
l
l
l
l
l
l
l
l
ll l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l l
l
ll
l l
l
ll
l
l
−15 −10 −5 0 5 10 15
−
15
−
10
−
5
0
5
10
PC1 (27.3 %)
PC
2 
(12
.3 
%)
ll
l
l
l
l
l
l
l
l
l
l
l l
l ll
l
l
l
l
l
l
l
ll
l l
l
l
l
l
l
l l
l
l
ll
l
l
l
l
l l
l
l
l
l
l
l
ll
l l
l
ll
l
l
l
l
l
l
l
l
l l
l
l l l
l
l l
l
l
l
l
l
l
l
l
l
l
ll l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l l
l
ll
l l
l
ll
l
l
−15 −10 −5 0 5 10 15
−
15
−
10
−
5
0
5
10
PC1 (27.3 %)
PC
2 
(12
.3 
%)
l
ll
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
ll
ll l
ll
l
l
l
l
l
l
l
l
l
l
l l
lll
l l
ll
ll
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
ll
ll
l
l l
l
l
l
l
l
lll
l
ll
l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
−15 −10 −5 0 5 10
−
15
−
10
−
5
0
5
10
PC1 (45.4 %)
PC
2 
(11
 %
)
Figure C.14: TGD (in vitro): Data of the low, middle and high concentration and the incubation
time point 24h. A. Overview of all samples and replicates. The dark and light green
symbols illustrate the controls and exposed samples, respectively. B. Connecting
lines between replicates illustrates the degree of variability. C. Mean values of the
replicates. D. Connecting lines between controls (dark green) and corresponding
compound exposed samples (light green). E. Subtraction of the controls from the
corresponding compound exposed samples.
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Figure C.15: TGD (in vivo): Data of the high concentration and the incubation time point 24h.
A. Overview of all samples and replicates. The dark and light green symbols illustrate
the controls and exposed samples, respectively. B. Connecting lines between replicates
illustrates the degree of variability. C. Mean values of the replicates. D. Connecting
lines between controls (dark green) and corresponding compound exposed samples
(light green). E. Subtraction of the controls from the corresponding compound exposed
samples.
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Figure C.24: Concentration dependency in the NRW in vitro database. Corresponding Venn diagrams
to Figure 5.9 summarizing the concentration progressions of all further compounds
besides 2-NF, CFX, AlAl, DEHA which are already shown in Figure 5.9. Orange
colored Venn diagrams show the overlap between genes that are upregulated at the low,
middle and high concentration (> 1.5-fold with adjusted p ≤ 0.01); green colored Venn
diagrams summarize the downregulated genes (< 32 -fold with adjusted p ≤ 0.01).
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71
Figure C.25: Concentration dependency in the NRW in vivo database. Venn diagrams summarizing
the concentration progressions of all compounds tested in the NRW in vivo data set.
Orange colored Venn diagrams show the overlap between genes that are upregulated at
adjacent time periods (> 1.5-fold with adjusted p≤ 0.01); green colored Venn diagrams
summarize the downregulated genes (< 32 -fold with adjusted p ≤ 0.01). Due to the lack
of space in Figure C.24 the concentration progression of the compound Wy tested in
vitro at the low, middle and high concentration is shown at the end of this figure.
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Figure C.30: Distributions of the estimated alert concentrations for Scenarios I-IV with k = 6
replicates. Rows indicate the scenario and columns the methods of estimation. The left
panel shows the distributions of the ÂLECs (4pLL) and the right panel the distribution
of the ̂ALOECs (Limma). The number of estimates ≤ 1000 is indicated by n. Grey
colored bars indicate the number of no alerts.
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Figure C.31: Distributions of the estimated alert concentrations for Scenarios I-IV with k = 6. Rows
indicate the scenario and columns the methods of estimation. The left panel shows
the distributions of the L̂ECs (4pLL) and the right panel the distribution of the L̂OECs
(Limma). The number of estimates ≤ 1000 µM is indicated by n. Grey colored bars
indicate the number of no alerts.
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Figure C.32: Distributions of the estimated alert concentrations for Scenarios I-IV with k = 10
replicates. Rows indicate the scenario and columns the methods of estimation. The left
panel shows the distributions of the ÂLECs (4pLL) and the right panel the distribution
of the ̂ALOECs (Limma). The number of estimates ≤ 1000 µM is indicated by n. Grey
colored bars indicate the number of no alerts.
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Figure C.33: Distributions of the estimated alert concentrations for Scenarios I-IV with k = 10
replicates. Rows indicate the scenario and columns the methods of estimation. The left
panel shows the distributions of the L̂ECs (4pLL) and the right panel the distribution
of the L̂OECs (Limma). The number of estimates ≤ 1000 µM is indicated by n. Grey
colored bars indicate the number of no alerts.
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Figure C.34: Boxplots illustrating the distributions of the differences between the estimated alert
concentrations and the respective true ALECs of the Scenarios II-IV (the difference is
indicated by ∆). Scenario I was excluded from the analysis since no deviations could
be computed (no ALEC value was provided). The upper panel shows the deviations of
the point estimates from the true ALECs and the lower panel shows the deviations of
the CI-based estimates (p ≤ 0.05). The alert concentrations were estimated from the
simulated data with k = 6 replicates per concentration under the indicated scenario.
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Figure C.35: Boxplots illustrating the distributions of the differences between the estimated alert
concentrations and the respective true ALECs of the Scenarios II-IV (difference is
indicated by ∆). Scenario I was excluded from the analysis since no deviations could be
computed (no ALEC value was provided). The upper panel shows the deviations of the
point estimates from the true ALECs and the lower panel the deviations of the CI-based
estimates (p ≤ 0.05). The alert concentrations were estimated from the simulated data
with k = 10 replicates per concentration under the indicated scenario.
